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ABSTRACT  
  
Background 
 
Systemic therapy is the mainstay of treatment for stage IV colorectal cancer (CRC) and provides 
meaningful survival benefit. Currently, there is very low quality evidence available regarding 
benefit of primary tumor resection in patients with metastatic CRC. In spite of uncertain survival 
benefit, high rates of surgical resection have been reported in patients with unresectable metastatic 
disease. There is a lack of randomized clinical trial to address this important question in patients 
with stage IV CRC. Although several observational studies have suggested potential survival 
benefit of primary tumor resection, lack of randomization and failure to control important 
prognostic variables such as performance status, are major critiques to the findings of the 
observational studies. We have undertaken this large population-based cohort study to determine 
the survival benefit of primary tumor resection in stage IV CRC by minimizing various biases 
reported in the literature.  
 
Hypothesis 
 
We hypothesized that primary tumor resection in patients with stage IV CRC improves survival 
independent of chemotherapy and other known prognostic variables. 
 
Objectives  
 
 To systematically review the published literature and synthesize the data in relation to 
primary tumor resection in stage IV CRC.  
 To compare survival of patients with stage IV CRC who underwent primary tumor 
resection with the patients who did not have surgery and to determine the prognostic 
importance of surgery of the primary tumor in stage IV CRC.  
 To determine survival advantage of primary tumor resection in patients with stage IV CRC 
and minimally symptomatic or asymptomatic primary tumor.  
 To determine survival advantage of primary tumor resection in patients with stage IV CRC 
during the period of modern chemotherapy.  
 
Methods 
 
The study was conducted in two phases. During the first phase, a systematic review of published 
literature was performed using the Medline, EMBASE and CENTRAL databases.  Studies were 
selected by using pre-specified eligibility criteria with restriction to publication dates from 1980 
onward, English language, and human studies. Articles that met the inclusion criteria were 
assessed for quality by using the Ottawa-Newcastle score & GRADE. Data was collected and 
synthesized as per the PRISMA guideline. In the second phase, population-based retrospective 
cohort studies were performed. The study population was comprised of patients with stage IV CRC 
diagnosed during the period of January 1992 to December 2010 in the province of Saskatchewan, 
Canada. The prognostic significance of primary tumor resection was initially evaluated in patients’ 
cohort with stage IV CRC diagnosed during 1992-2005 period. The results were validated in a 
iii 
 
second patients cohort diagnosed during 2006-2010. Survival was calculated using the Kaplan-
Meier method. Survival distributions of different groups were compared by the log-rank tests. Cox 
proportional multivariate regression analyses were performed to determine survival benefit of 
primary tumor resection by controlling the other prognostic variables.  
 
Results 
 
Systematic review: Of total of 3379 reports, 15 retrospective observational studies were selected. 
Of total 12456 patients, 8620 (69%) underwent primary tumor resection.   Median overall survival 
of the resection group was 15.2 months (range: 10-30.7) compared with 11.4 months (range: 3-22) 
in the non-resection group. Hazard ratio (HR) for survival was 0.69 (95% CI: 0.61-0.79), which 
favors surgical resection. Mean postoperative mortality and nonfatal complications rates were 
4.9% (95% CI: 0-9.7) and 25.9% (95% CI: 20.1-31.6), respectively.  
 
Cohort Studies: A total 1378 eligible patients were identified during the period of 1992-2005. Nine 
hundred and forty-four (68.5%) underwent primary tumor resection. Among 1378 patients, 42.3% 
received chemotherapy. Cox proportional analyses revealed that use of chemotherapy (HR 0.47, 
95% CI: 0.41-0.54), primary tumor resection (HR 0.49, 95% CI: 0.41-0.58), second-line 
chemotherapy (0.47, 95% CI: 0.45-0.64), and metastasectomy (HR 0.54, 95% CI: 0.45-0.64) were 
correlated with superior survival.  In a subcohort of 834 patients with asymptomatic or minimally 
symptomatic disease, primary tumor resection was correlated with better survival (HR 0.47; 0.39-
0.57). Test for interaction between ≥1 metastatic sites and surgery was significant suggesting a 
larger benefit of surgery in patients with stage IVa disease. 
 
These findings were validated in a cohort of 569 patients with stage IV CRC diagnosed during the 
period of 2006-2010. Fifty seven percent patients received chemotherapy and 91.4% received 
modern chemotherapy. Median overall survival of patients who received all active agents and 
underwent primary tumor resection was 39 months (95% CI: 25.1-52.9). In multivariate analysis, 
primary tumor resection, hazard ratio (HR):0.44 (95% CI: 0.35-0.56), was correlated with superior 
survival.  
 
Conclusions 
 
Our study supports primary tumor resection in patients with stage IV CRC. It correlates with better 
survival independent of known prognostic variables such as chemotherapy, metastasectomy, 
performance status and comorbid illness. In a subgroup of asymptomatic or minimally 
symptomatic patients or who were treated with modern chemotherapy and biologics, primary 
tumor resection was correlated with better survival.  
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Summaries of Companion Studies 
 
1. Predictive factors of use of systemic therapy in stage IV colorectal cancer  
 
Although in a clinical trial setting, strict eligibility criteria are used for chemotherapy, little 
is known about the use of chemotherapy in the general population. The study aims to assess 
clinicopathological variables that correlate with the use of chemotherapy in patients with 
stage IV CRC. A total of 1,237 eligible patients were identified. A multivariate logistic 
regression analysis revealed that age <65 year (odd ratio [OR] 3.82, 95% CI:2.59-5.63), 
metastasectomy (OR 3.60, 95% CI:1.82-7.10), normal albumin (OR 3.26, 95%CI:2.44-
4.36), absence of  comorbid illness (OR 2.87, 95% CI:1.34-6.16), ECOG performance 
status of <2 (OR 2.72, 95% CI:1.94-3.82), normal blood urea nitrogen (OR 2.24, 95% 
CI:1.40-3.59), palliative radiation (OR 2.03, 95% CI:1.38-2.99), primary tumor resection 
(OR 2.00, 95% CI:1.47-2.73), and the time period (OR 1.85, 95% CI:1.41-2.42) were 
significantly correlated with the use of chemotherapy. 
 
2. Regional Lymph Nodes Status in Stage IV Colorectal Cancer 
 
Lymph nodes status and the ratio of metastatic to examined lymph node (LNR) are 
important prognostic factor in early-stage colorectal cancer (CRC); however, their 
significance in patients who have already developed distant metastases remains unknown. 
The study aims to determine prognostic importance of nodal status and the LNR in patients 
with stage IV CRC who underwent primary tumor resection. Among 1109 eligible patients 
who underwent primary tumor resection, no chemotherapy, HR: 2.36 (95% CI:2.0-2.79); 
not having metastasectomy, HR: 1.94 (95% CI:1.63-2.32); ratio of metastatic to examined 
lymph node ≥0.36, HR: 1.59 (95% CI:1.38-1.84); nodal status, HR 1.34 (95% CI:1.14-
1.59); and T status, 1.23 (95% CI:1.07-1.40) were correlated with survival. 
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CHAPTER 1 - INTRODUCTION 
 
1.1 Background 
 
1.1.1 Epidemiology of Colorectal Cancer  
 
Colorectal Cancer (CRC) is a major cause of morbidity and mortality (1-4). Every year at least 
600,000 people die of this kind of cancer. It is the third most common cancer and the fourth most 
common cause of cancer death worldwide. In 2012 approximately 1.4 million people were 
diagnosed with CRC, which accounts for over 9% of global cancer incidence (1).  The incidence 
of CRC varies about 15-fold across various geographic regions in the world. Approximately one 
in 20 people in developed countries will develop CRC in their life time; the case fatality from 
this disease is 33%. In North America, CRC is the third most common cancer diagnosis among 
men and women and is the second leading cause of cancer-related death (2-5).  
 
Each year more than 20,000 Canadians are diagnosed with CRC, and approximately 9,000 die 
from the cancer (5). One in 14 men and one in 15 women will develop CRC during their lifetime. 
In 2015, this translated into 14,000 new cases in men and 11,100 new cases in women in 
Canada.  The case fatality for men is one in 27 and for women one in 31. CRC is the second 
leading type of cancer incidence in men (14%) and the third one in women (12%). (5)   
 
Advances in screening and diagnostic methods have contributed to early detection and better 
staging.  Despite the advent of CRC screening program approximately 20 to 25% of patients with 
CRC are diagnosed with synchronous metastatic CRC (4). Whereas surgery is the primary 
treatment for early stage CRC and chemotherapy with or without radiation is used in high risk 
disease to reduce the risk of recurrence (3-5), systemic therapy is the mainstay of treatment for 
Stage IV CRC (6-9) [Figure 1.1]. 
 
1.1.2 Treatment of Stage IV Colorectal Cancer 
 
There are several known and unknown factors that may affect survival of patients with newly 
diagnosed CRC (Figure 1.2). Although for the majority of patients with stage IV CRC there are 
no curative options, a significant improvement in survival can be achieved with systemic 
treatment. The median overall survival (OS) of patients with stage IV CRC with best supportive 
care alone is only about 6 months (10). Systemic therapy, comprising chemotherapy and targeted 
therapy, provides meaningful improvements in median survival and progression-free survival (11-
29). The last fifteen years have seen remarkable improvements in the survival of patients with 
stage IV CRC, which is primarily attributed to the availability of several novel agents, 
metastasectomy and other liver-directed therapies in selected patients. For many years, 5-
fluorouracil (5-FU) was 
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the only active agent available in the management of patients with stage IV CRC (11, 12). Access 
to several novel agents has significantly improved the survival of patients with Stage IV CRC. 
These agents include two cytotoxic agents (irinotecan and oxaliplatin) and three humanized 
monoclonal antibodies (e.g., bevacizumab and cetuximab and panitumumab) that target vascular 
endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR). More 
recently regorafenib, an orally active inhibitor of angiogenic/stromal/oncogenic receptor 
tyrosine kinases, and aflibercept a recombinant fusion protein that interferes with VEGF binding, 
have also improved survival in this particular patient population (13-28). 
 
Overall, with the judicious use of active agents in the management of CRC, the median OS of 
patients with advanced CRC has increased to about 30 months (29) [Figure 1.3]. Survival is 
improved when patients are exposed to all available cytotoxic drugs during the course of their 
disease (30). The five-year OS for patients who are diagnosed with distant metastases ranges from 
5-20 %.( 31-33). However, only a small percentage of patients with advanced CRC achieve long-
term remission. 
 
1.1.3 Surgical Management of Stage IV CRC 
 
The role of surgery in stage IV CRC has evolved over the past decade. For example, surgery is 
performed with a curative intention by removing the metastatic lesions and primary tumor or it is 
contemplated for the palliation of symptoms via removal of the primary tumor (4, 6, 8, 34-38). 
Among patients presenting with synchronous distant metastases, approximately 15 - 20% have 
metastases that are resectable for cure. Complete resection of the primary tumor with metastatic 
lesions in these patients has been associated with durable remission in approximately 30-40% cases 
(34-39). Nevertheless, only a subset of patients with limited liver and or lung metastases can be 
cured with multimodality therapy. The optimal surgical management of Stage IV CRC that is not 
amenable to curative resection is unknown.  Although administration of systemic therapy in 
patients with metastatic CRC may convert unresectable into resectable disease, for most patients 
the principal goal of treatment is to prolong survival and only about 10-15% patients are alive at 5 
years. Primary tumor resection in patients with incurable metastatic disease is usually 
recommended for palliative purposes to manage obstruction, perforation, or bleeding. In spite of 
the uncertain survival benefit, a high rate of surgical resection has been reported in patients with 
unresectable metastatic disease.   
 
For instance, two population-based studies that were designed to examine patterns of surgical 
practice in patients with advanced CRC reported primary tumor resection rates of 66-72% (40, 
41). Both studies utilized data obtained during the period of monotherapy with 5-FU and the 
current rate of resection of primary tumor with the introduction of new generation treatment is not 
known. Nevertheless, a recent retrospective cohort study using data from the 
National Cancer Institute's Surveillance, Epidemiology, and End Results CRC registry suggested 
a trend toward fewer primary tumor resections during the period of modern chemotherapy (42). 
Of 64,157 patients, diagnosed with stage IV CRC, 67.4% had undergone primary tumor resection. 
The annual rate of primary tumor resection decreased significantly from 74.5% in 1988 to 57.4% 
in 2010. 
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1.2 Rationale for the Study 
 
The benefit of primary tumor resection in patients with synchronous unresectable metastases is not 
known. Even though enormous progress has been made in the treatment of patients with CRC 
within the past three decades, the optimal management of patients with metastatic disease not 
amenable to curative therapy, who present without severe primary tumor- related symptoms, is 
remained controversial. Primary tumor resection in patients with stage IV cancer is often 
performed to deal with presenting primary tumor symptoms and/or to prevent future primary tumor 
complications. Palliative primary tumor resection in patients with advanced solid cancers may 
prevent local tumor complications and improve disease control by reducing the tumor bulk. In 
advanced ovarian and renal cell cancer, surgical resection of the primary tumor has shown 
significant survival benefit (43, 44). The primary tumor may secrete cytokines that promote tumor 
growth and reduce response to cytotoxic agents (45).  
 
1.2.1 Arguments for Surgery 
 
Potential advantages of primary tumor resection in stage IV CRC are prevention of obstruction 
and major bleeding, better pain control, and potential reduction in serious adverse effects related 
to novel targeted therapy such as bleeding and perforation. The primary tumor complication rates 
including obstruction, perforation, and hemorrhage have been reported to be as high as 63% (40). 
Stillwell and others have demonstrated that patients who were treated with upfront chemotherapy 
were 7.3 times more likely to have a complication from the primary tumor. Furthermore, when 
these patients were operated for the primary tumor-related complications, they were more likely 
to have a poor postoperative outcome (46). Hence, surgical resection of primary tumor may 
facilitate treatment tolerance with better response and potentially improve survival.   
 
Removal of the primary tumor results in reduction in the disease burden. This may result in 
alteration in the host immune response and a better outcome. 
 
1.2.2 Arguments Against Surgery 
 
Conversely, the newer generation chemotherapy in combination with targeted therapy has been 
associated with response rate of 40-60% (29, 47). Complications following primary tumor 
resection in patients with advanced CRC can delay or prevent initiation of systemic therapy and 
thereby precludes benefit associated with it. There is no evidence that primary tumor response 
rates are inferior to those of metastases. Systemic therapy not only reduces the size of metastatic 
lesions but also shrinks the primary tumor, thereby potentially decreases local complications 
related to an intact primary tumor such as bowel obstruction (48, 49). For example, Karoui and 
others have demonstrated that 70% of patients with stage IV CRC had major histological responses 
in the primary tumor following preoperative chemotherapy, which suggests that treatment with 
chemotherapy can be effective in the majority of patients (50). Three retrospective studies 
specifically investigated the risk of primary tumor complication in patients with non-resection 
management (51-54).  Muratore and others demonstrated that only one out of 35 patients who were 
treated with oxaliplatin-based chemotherapy developed major complications related to the primary 
tumor (51). Sarlea and others reported an obstruction rate of 17% with the use of single agent 5FU. 
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In their study 12% patients required surgery for worsening pain (52). In the study by Clement and 
others, 3 of 37 patients developed obstruction during palliative chemotherapy and were managed 
with defunctioning stoma and stent (53). 
 
There remains a risk of perforation when combining anti-VEGF therapy with cytotoxic agents in 
patients with intact primary tumors (54). A retrospective study evaluated the frequency of 
interventions necessary to palliate the intact primary tumor in patients with synchronous, stage IV 
CRC who received up-front modern combination chemotherapy. Of 233 patients, 7% required 
emergent surgery for primary tumor obstruction or perforation, 4% required non-operative 
interventions (i.e. stent or radiotherapy), and 89% never required any direct symptomatic 
management for their intact primary tumor. The authors concluded that most patients with 
synchronous, advanced CRC who receive up-front systemic therapy never require palliative 
surgery for their primary tumors, and that systemic therapy can be administered safely to these 
patients. Nevertheless, the median overall survival of these patients was only 13 months, while 
median overall survival of 20-24 months has consistently been reported for patients with stage IV 
CRC in phase III trials (55). The National Surgical Adjuvant Breast and Bowel Project 
subsequently conducted a phase II trial (NSABP C-10) using FOLFOX (5-FU, leucovorin and 
oxaliplatin) and bevacizumab combination in 85 patients with synchronous Stage IV CRC. Overall 
14% patients developed major complications including obstruction, perforation, bleeding, or death 
related to an intact primary tumor. Median overall survival for the treated cohort was 19.9 months. 
The author concluded that combining bevacizumab with chemotherapy did not result in 
unacceptable complication rates related to an intact primary tumor and that these patients can be 
spared initial non-curative resection of the primary colon tumor (56).  
 
While the benefit of metastasectomy is well established in the setting of oligometastases, surgical 
removal of the primary tumor in patients with unresectable metastases remains controversial. 
There is still considerable uncertainty as to whether patients with advanced CRC with few or no 
symptoms related to the primary tumor should undergo surgery prior to systemic therapy and 
whether elective surgery in patients with advanced colorectal cancer will have a survival advantage 
independent of the use of systemic therapy. Currently, there is very low quality evidence available 
regarding survival benefit of primary tumor resection, in patients with Stage IV CRC and otherwise 
unresectable metastatic lesions. No randomized trials are available to guide the management of the 
primary tumor in patients with unresectable metastatic CRC. Most are single institutional small 
retrospective studies conducted during the period of mono therapy with a fluoropyrimidine 
compound. While some have advocated for surgery (57-66), other have failed to demonstrate 
survival benefit with the resection of primary tumor in patients with advanced CRC (67-71). 
Furthermore, it is not known if a similar benefit can be achieved during the period of second- and 
third-generation anti-cancer agents which are associated with a higher response rate and a better 
overall survival in patients with advanced CRC.     
 
We propose a large population-based cohort study to analyze the role of primary tumor resection 
in metastatic colon cancer.  In the absence of randomized controlled trials and well-designed large 
population-based studies, this study is undertaken, to investigate the optimal surgical management 
of patients diagnosed with synchronous stage IV CRC cancer by controlling for various known 
confounding factors including age, comorbid illness, performance status and other important 
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prognostic variables. Furthermore, this study also investigates prognostic significance of various 
patients- and tumor-related factors and other interventions in stage IV CRC.  
 
Chemotherapy is known to be one of the most important prognostic variables in patients with stage 
IV CRC. In a companion study we evaluated prevalence of use of chemotherapy in patients with 
stage IV CRC and its correlation with several clinicopathological factors.  
 
Given the fact that little is known about the prognostic significance of nodal involvement in stage 
IV CRC, in a second companion study, we examined the relationship between regional nodal status 
and other tumor-related factors and survival in patients with stage IV CRC. 
 
1.3 Hypothesis 
 
We hypothesize that surgical resection of the primary tumor, in patients with synchronous stage 
IV colorectal cancer, improves survival independent of the use of systemic therapy and other 
known prognostic variables. 
 
1.4 Objectives 
 
 To systematically review the published literature and synthesize the data in relation to 
primary tumor resection in stage IV CRC.  
 To compare survival of patients with stage IV CRC who underwent primary tumor 
resection with the patients who did not have surgery and to determine the prognostic 
importance of surgery of the primary tumor in stage IV CRC.  
 To determine survival advantage of primary tumor resection in patients with stage IV CRC 
and minimally symptomatic or asymptomatic primary tumor.  
 To determine survival advantage of primary tumor resection in patients with stage IV CRC 
during the period of modern chemotherapy.  
 
1.5 Objectives of Companion Studies 
 
 To examine various patients and tumor-related characteristics and co-interventions that are 
associated with the use of chemotherapy in patients with stage IV CRC. 
 To determine the prognostic significance of primary tumor-related factors in patients who 
underwent surgical resection of the primary tumor. 
 
6 
 
1.6 References  
 
1. World Cancer Research Fund International. http://www.wcrf.org/int/cancer-facts-figures/data-
specific-cancers/colorectal-cancer-statistics (accessed on Aug 22 2015). 
2. Hagger FA, Boushey R. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and 
Risk Factors. Clin Colon Rectal Surg. 2009; 22:191–197. 
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11. 
4. Ahmed S, Johnson K, Ahmed O, et al. Advances in the management of colorectal cancer: from 
biology to treatment. Int J Colorectal Dis. 2014; 29:1031-42.  
5. Cancer Statistics: http://www.cancer.ca/Canada (accessed on Aug 24 2015).  
6. Kanthan R, Senger JL, Ahmed S, et al. Recent Advances in the Management of Stage IV Colon 
Cancer. J Cancer Ther. 2012;3:1104-1118. 
7. Saskatchewan Cancer Agency Provincial Colorectal Cancer Treatment Guidelines. 
http://www.saskcancer.ca/Colorectal%20CPGs (accessed on Aug 24 2015). 
8. National Cancer Comprehensive Network Clinical Practice Guidelines in Oncology 
http://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp#site(accessed on 
Aug 22 2015). 
9. Ahmed S, Bathe O, Berry S, et al. Consensus statement: the 16th Annual Western Canadian 
Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 
2014. Curr Oncol. 2015;22:e113-23. 
10. Scheithauer W, Rosen H, Kornek GV, et al. Randomized comparison of combination 
chemotherapy plus supportive care with supportive care alone in patients with metastatic 
colorectal cancer. BMJ. 1993;306:752-55. 
11. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous 
fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal 
cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-92. 
12. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and 
meta-analysis. Colorectal Cancer Collaborative Group. BMJ. 2000;321:531-5. 
13. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared 
with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre 
randomized trial. Lancet. 2000;355:1041-7. 
14. Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional 
fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal 
cancer: European Organization for Research and Treatment of Cancer Gastrointestinal Group 
Study 40986. J Clin Oncol. 2005;23:4856-65. 
15. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin 
added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic 
colorectal cancer. J Clin Oncol. 2000;18:136-47. 
16. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse 
sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 
22:229-37. 
17. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus 
FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo 
Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23:4866-75. 
7 
 
18. Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line 
treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J 
Cancer. 2006;94:969-75. 
19. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens 
in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011; 103:21-30. 
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and 
leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. 
21. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, 
bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated 
results from the BICC-C study. J Clin Oncol. 2008;26:689-90. 
22. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus 
irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351:337-
45. 
23. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal 
cancer.N Engl J Med. 2007;357:2040-48. 
24. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for 
metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17. 
25. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best 
supportive care compared with best supportive care alone in patients with chemotherapy-
refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-64. 
26. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with 
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as 
first-line treatment in patients with previously untreated metastatic colorectal cancer: the 
PRIME study. J Clin Oncol. 2010;28:4697-4705. 
27. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated 
metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-
controlled, phase 3 trial. Lancet. 2013;381:303-12. 
28. Van Cutsem E, Tabernero J, Lakomy R, et al.  Addition of aflibercept to fluorouracil, 
leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with 
metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin 
Oncol. 2012;30:3499-506. 
29. Lenz H, Niedzwiecki D, Innocenti F, et al. CALGB/SWOG 80405: PHASE III trial of 
irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with 
bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated 
metastatic adenocarcinoma of the colon or rectum (MCRC). European Society of Medical 
Oncology 2014 Annual meeting, Madrid, Spain, Abstract 5010. 
30. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates 
with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or 
single-agent therapy is used first line. J Clin Oncol. 2005;20:9441-42. 
31. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is 
associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 
2009;27:3677-83.  
32. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint 
Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-25.  
8 
 
33. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of 
oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 
2008;26:5721-27. 
34. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from 
colorectal cancer: a systematic review of published studies. Br J Cancer 2006;94:982-99. 
35. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal 
cancer: a population-based study. Cancer 2007;109:718-26. 
36. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection 
for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 
247:125-35. 
37. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of 
colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575-80. 
38. Lin BR, Chang TC, Lee YC, et al. Pulmonary resection for colorectal cancer metastases: 
duration between cancer onset and lung metastasis as an important prognostic factor. Ann Surg 
Oncol 2009;16:1026-32. 
39. Brown RE, Bower MR, Martin RC. Hepatic resection for colorectal liver metastases. Surg Clin 
North Am. 2010; 90:839-52. 
40. Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV 
colorectal cancer. J Clin Oncol 2004;22: 3475–84. 
41. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present 
with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 
1988 to 2000. Ann Surg Oncol 2005;12: 637–45. 
42. Hu CY, Bailey CE, You YN, et al. Time trend analysis of primary tumor resection for stage 
IV colorectal cancer: less surgery, improved survival. JAMA Surg. 2015;150:245-51. 
43. Vergote I, van Gorp T, Amant F, et al. Timing of debulking surgery in advanced ovarian 
cancer. Int J Gynecol Cancer. 2008;18 Suppl 1:11-9. 
44. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based 
immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a 
randomized trial. Lancet. 2001;358:966-70. 
45. Merogi AJ, Ramesh R, Robinson WR, et al. Tumor-host interaction: analysis of cytokines, 
growth factors, and tumor –infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 
1997;28:321-31. 
46. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV 
colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 
2010;34:797-807. 
47. Loupakis F, Cremolini C, Masi G, et al. Initial Therapy with FOLFOXIRI and Bevacizumab 
for Metastatic Colorectal Cancer. N Engl J Med 2014;371:1609-1618. 
48. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use 
of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin 
Oncol. 2014; 32:513-8. 
49. Schrag D. Evolving role of neoadjuvant therapy in rectal cancer. Curr Treat Options 
Oncol. 2013;14:350-64. 
50. Karoui M, Koubaa W, Delbaldo C, et al. Chemotherapy has also an effect on primary tumor 
in colon carcinoma. Ann Surg Oncol. 2008;15:3440-3446. 
9 
 
51. Muratore A, Zorzi D, Bouzari H et al. Asymptomatic colorectal cancer with unresectable liver 
metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg 
Oncol 2007;14: 766–70.  
52. Sarela AI, Guthrie JA, Seymour MT et al. Non-operative management of the primary tumor in 
patients with incurable stage IV colorectal cancer. Br J Surg 2001;88:1352–56. 
53. Clements D, Dhruva Rao P, Ramanathan D, et al. Management of the asymptomatic primary 
in the palliative treatment of metastatic colorectal cancer. Colorectal Dis. 2009;11:845-8. 
54. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal 
cancer. Ann Surg Oncol. 2007;14:1860-69. 
55. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with 
synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery 
as initial treatment. J Clin Oncol. 2009;27:3379-84. 
56. McCahill LE,  Yothers GA, Sharif S, et al. Primary mFOLFOX6 Plus Bevacizumab Without 
Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable 
Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of 
NSABP Trial C-10. J Clin Oncol 2012;30:1-6. 
57. Ruo L, Gougoutas C, Paty PB, et al. Elective bowel resection for incurable stage IV colorectal 
cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003; 196:722–32. 
58. Kaufman MS, Radhakrishnan N, Roy R et al. Influence of palliative surgical resection on 
overall survival in patients with advanced colorectal cancer: a retrospective single institutional 
study. Colorectal Dis 2008;10:498–502. 
59. Bajwa A, Blunt N, Vyas S et al. Primary tumor resection and survival in the palliative 
management of metastatic colorectal cancer. Eur J Surg Oncol 2009;35:164–167. 
60. Aslam MA, Kelkar A, Sharpe D. Ten years experience of managing the primary tumors in 
patients with stage IV CRC. Int J Surg. 2010;8:305-13. 
61. Chan TW, Brown C, Ho CC, et al. Primary Tumor Resection in Patients Presenting With 
Metastatic Colorectal Cancer.  Am J Clin Oncol. 2010;33:52-55.  
62. Galizia G, Lieto E, Orditura M et al. First-line chemotherapy vs bowel tumor resection plus 
chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch 
Surg 2008;143:352–58. 
63. Karoui M, Roudot-Thoraval F, Mesli F, et al. Cancer and Unresectable Distant Metastases 
Improves Overall Survival: Results of a Multicentric Study. Dis Colon Rectum. 2011; 54:930-
38. 
64. Konyalian VR, Rosing DK, Haukoos JS, et al. The role of primary tumor resection in patients 
with stage IV colorectal cancer. Colorectal Dis. 2007;9:430-37. 
65. Seo GJ, Park JW, Yoo SB, et al. Intestinal Complications after Palliative Treatment for 
Asymptomatic Patients with Unresectable Stage IV Colorectal Cancer. J Surg Oncol. 2010; 
102:94-99. 
66. Venderbosch S, Wilt JH, Teerenstra S, et al. Prognostic Value of Resection of Primary Tumor 
in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized 
Studies and a Review of the Literature. Ann Surg Oncol. 2011;18:3252-60. 
67. Benoist S, Pautrat K, Mitry E et al. Treatment strategy for patients with colorectal cancer and 
synchronous irresectable liver metastases. Br J Surg 2005; 92:1155–60. 
10 
 
68. Evans MD, Escofet X, Karandikar SS, et al. Outcomes of resection and non-resection strategies 
in management of patients with advanced colorectal cancer. World J Surg Oncol. 2009;7:28-
35. 
69. Michel P, Roque I, Di Fiore F, et al.Colorectal cancer with non-resectable synchronous 
metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28:434-7. 
70. Scoggins CR, Meszoely IM, Blanke CD et al. Nonoperative management of primary colorectal 
cancer in patients with stage IV disease. Ann Surg Oncol 1999;6:651–57. 
71. Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy 
for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 
52:568–73.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
Figure 1.1: A management framework for CRC. Patients with early stages CRC (stage I-III) 
are treated with surgery with or without chemotherapy and radiation. Patients with stage 
IV CRC are primarily treated with chemotherapy. A selected group of patients can be cured 
with metastasectomy.  
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Figure 1.2: Potential factors that may correlate with outcome of patients with newly 
diagnosed metastatic colorectal cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
Figure 1.3: Current standard first-line combination treatments for patients with stage IV 
CRC and good performance status. 
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CHAPTER 2 - METHODS 
 
Our research was conducted in two phases. During the first phase, we performed a systematic 
review of the current literature. In the second phase, we conducted population-based cohort studies 
to evaluate the research objectives. The present chapter focuses on research methodology. The 
chapter begins with the introduction of systematic review and meta-analysis, it reviews the 
methods used in the systematic review and meta-analysis of the literature, discusses potential 
advantages and limitations of a cohort study, and ends with reviewing various steps of the second 
phase of our research.   
 
2.1 Systematic Review and Meta-Analysis  
 
Systematic reviews are different from narrative reviews and address a focused question in a 
systematic and reproducible manner (Table 2.1). “A systematic review is the assembly, critical 
appraisal, and synthesis of all relevant studies that address a specific question incorporating 
strategies to minimize bias” (1, 2).  
 
According to the Cochrane Collaboration, systematic reviews have the following features (3):  
• a clearly stated set of objectives with pre-defined eligibility criteria for studies  
• an explicit, reproducible methodology  
• a systematic search that attempts to identify all studies that would meet the eligibility 
criteria  
• an assessment of the validity of the findings of the studies included (e.g., thorough 
assessment of the risk of bias)  
• a systematic presentation, and synthesis, of the characteristics and findings of the studies 
included  
 
 “Meta-analyses are the statistical combination of results from two or more separate studies that 
use statistical methods to summarize the results of independent studies” (4). A meta-analysis 
combines information from selected studies in a review and provide more precise estimates of 
effect size of the outcomes of interest than those derived from the individual studies.  
A meta-analysis has following advantages (3).  
 
1. It increases the power to detect a real effect. For example, individual studies can be small to 
detect small effects but, when several studies are combined there is a higher possibility of 
detecting a statistically significant effect if it exists.  
 
2. The estimation of an intervention effect can be improved when it is based on more information; 
hence, a meta-analysis improves precision and provides a more precise estimate of an effect.  
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3. Meta-analyses are valuable to answer questions that are not addressed by individual studies. 
Most studies include specific groups of patients with explicitly defined interventions. Meta-
analyses facilitate investigations of the consistency of evidence across studies and the 
exploration of differences across studies.  
 
4. Meta-analyses are helpful to address controversies arising from conflicting results presented by 
different studies or to generate new hypotheses. Statistical analysis allows the degree of conflict 
to be formally assessed, and reasons for different results to be explored and quantified.  
 
Despite potential advantages the use of statistical methods in a meta-analysis does not necessarily 
guarantee that the results of a review are valid.  
 
2.1.1 Measuring Agreement in Systematic Review  
 
In systematic reviews, many steps are done in duplicate. Calculations for agreement statistics help 
to determine how well the two reviewers agreed at various time-points. Agreement statistics are 
also used to identify problem areas, i.e., where the two reviewers interpret questions/criteria 
differently.  
 
Kappa statistics are chance-corrected and represent the “standard” for reporting agreement in 
systematic reviews. Weighted kappa allows for partial agreement and gives 'partial credit' to partial 
agreement. One of the disadvantages of Kappa statistics is over-adjusts if distribution is highly 
skewed, i.e., very high number of positives (3). 
• 0.40-0.59: fair agreement 
• 0.60-0.74: good agreement 
• ≥0.75: excellent agreement 
 
2.1.2 Identifying and Measuring Heterogeneity 
 
Heterogeneity in meta-analysis refers to the variation in study outcomes among studies (Table 
2.2) [5-7]. A poor overlap in confidence intervals of the results of individual studies suggests 
presence of statistical heterogeneity. The amount of heterogeneity partly determines the difficulty 
in drawing overall conclusions (5,6). The chi-squared (χ2) test is a statistical test for heterogeneity 
included in the forest plots (6). It assesses whether observed differences in results are due to chance 
alone. A low P-value provides evidence of heterogeneity and suggests that variations in effect 
estimates are beyond chance. Although a statistically significant result may indicate a problem 
with heterogeneity, a non-significant result does not necessarily exclude heterogeneity. For 
example, if studies have small sample size or are few in number the test have low power to detect 
heterogeneity. Conversely when there are many studies in a meta-analysis, the test has high power 
to detect a small amount of heterogeneity which clinically may not be relevant. Huggins and others 
have suggested that statistical heterogeneity is inevitable since clinical and methodological 
diversity always occur in a meta-analysis (5). 
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Several methods have been developed for quantifying inconsistency across studies and a useful 
statistic for quantifying inconsistency is I2 (3,5,6). It describes the proportion of the variability in 
effect estimates from heterogeneity rather than sampling error.  
 
I² = 100% x (Q-df)/Q. 
 
Where Q is the chi-squared statistic and df is its degrees of freedom.   
Thresholds for the interpretation of I2 are usually as follows (3):  
•  0% to 40%: might not be important;  
• 30% to 60%: may represent moderate heterogeneity*;  
• 50% to 90%: may represent substantial heterogeneity*;  
• 75% to 100%: considerable heterogeneity*.  
 
*The importance of the observed value of I2 depends on (i) magnitude and direction of effects and 
(ii) strength of evidence for heterogeneity (e.g., P-value from the chi-squared test, or a confidence 
interval for I2).  
 
2.1.3 Models for Combining Data for Meta-Analysis 
 
In a meta-analysis results from two or more studies can be combined by using either a fixed-effect 
model or a random effect model (3,8-11). The fixed effect analysis assumes that all the included 
studies share a common effect size, μ and all factors which could influence the effect size are the 
same in all the study populations, and therefore the effect size is the same in all the study 
populations. It further assumes that the observed effect size varies from one study to the next only 
because of the random error inherent in each study.  
 
The random effects model assumes that the study samples were drawn from populations that differ 
from each other in ways that could impact on the treatment effect. For example, the intensity of 
the intervention or the age of the subjects may vary from one study to the next. The model assumes 
that the effect size will vary from one study to the next because of random error within studies, as 
in the fixed effect model and due to true variation in effect size from one study to the next. 
 
2.1.4 Objectives and Outcomes of Interest  
 
The systematic review was performed according to the PRISMA statement guidelines (12). The 
review and meta-analysis “Should Palliative Resection of Primary Tumor Be Performed in 
Patients with Advanced Colorectal Cancer? A Systematic Review & Meta-analysis” is published 
in the Current Oncology in October 2013 (please see chapter 3) [13].  In the following section we 
review key elements of the research methods.  
 
2.1.4.1 Primary Objective 
 
• To compare survival of patients with advanced CRC who underwent primary tumor 
resection with patients who did not have resection. 
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2.1.4.2 Secondary Objectives 
 
• To determine 30-day post-operative mortality and non-fatal complications rates in the 
intervention group, primary tumor complications rate in the control group, non-resection 
procedures and quality of life in the both groups.  
• To determine survival benefit of surgical intervention in the subgroups of patients with 
advanced CRC who were treated with second- and third-generation anticancer therapy. 
• To determine survival benefit of surgical intervention in the subgroups of relative 
asymptomatic or minimally symptomatic patients. 
 
2.1.5 Methods 
 
2.1.5.1 Definitions 
 
• Primary tumor complication: A primary tumor complication was defined as “proportion of 
patients who developed bleeding, obstruction, and perforation during the study period”.  
• Fatal primary tumor complication: It was defined as “death within 30 days of bleeding, 
obstruction and perforation secondary to an intact primary tumor.”  
• Postoperative surgical mortality: It was defined as “death within 30 days of surgery”. Non-
fatal surgical complication was defined as “postoperative infection, anastomotic leak, and 
all other complications recorded 30 days following primary tumor resection.” 
• Non-resection procedures: It included bypass surgery with colostomy formation, 
endoscopic laser therapy or placement of endoluminal stents.  
• Study utilizing second- and third-generation chemotherapy: All studies that specified the 
use of second- and third-generation therapy or either entire study or part of a study (≥50%) 
was conducted after the year 1999 were considered ‘studies utilizing second- and third-
generation anti-cancer therapy.’ 
 
2.1.5.2 Inclusion and Exclusion Criteria 
 
Studies involving patients with histologically documented adenocarcinoma of colon and rectum 
and evidence of metastases were included. Studies with other histological diagnosis including 
small cell carcinoma, gastrointestinal stromal tumor (GIST), lymphoma, melanoma, anal canal 
cancer, and sarcoma were excluded. Only studies that have comparative data on survival (resection 
vs. a non-resection group) were included. Studies involving groups with upfront metastasectomy, 
curative resection, or with non-surgical procedures were excluded. The inclusion criteria were 
specified using the PICO (population, intervention, comparison, outcome) format (please also see 
Appendix A). 
 
• Study Population 
o Patients with advanced adenocarcinoma of the colon and rectum 
• Intervention  
o Surgical resection of the primary tumor 
• Control group  
o no surgery  
• Outcome of interest 
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o Primary outcome of interest: overall survival. 
o Secondary outcomes of interest: postoperative mortality and morbidity, complications 
rate of the primary tumor, non-surgical interventions in the control group, and quality 
of life. 
• Research design. 
 Randomized controlled trial, controlled trials, cohort studies (prospective & retrospective), 
and case control studies. 
 
2.1.5.3 Information Sources 
  
An extensive literature search was performed using the Medline (Ovid interface; version 1946 to 
February 2012), EMBASE (Ovid interface; version 1947 to February 2012) and CENTRAL (The 
Cochrane Central Register of Controlled Trials, The Cochrane Library, Wiley, Issue 3 2012) by 
using a pre-specified protocol. In addition, grey literature (the American Society of Clinical 
Oncology (ASCO) and the European Society of Medical Oncology (ESMO) clinical practice 
guidelines, education books, the National Comprehensive Cancer Network (NCCN) guidelines) 
was reviewed for relevant studies. Flow of information through the different phases of literature 
search was recorded. Studies were selected by using pre-specified criteria with restriction to 
publication dates from January 1980 till May 2012, English language, and human studies 
(Appendix A).  
 
2.1.5.4 Search Strategies and Selection of Studies 
 
Literature search was performed in three stages. In the first stage, MEDLINE & EMBASE were 
searched for the relevant studies. All relevant studies were identified using the first 3 components 
of PICO format. Studies comparing survival of patients with advanced CRC who underwent 
primary tumor resection with patients who did not have surgery were included.  
Following concepts were used: 
 
• Advanced colorectal  cancer 
• Surgery 
 
We conducted a pilot search after consulting a health science librarian; various key words and 
controlled vocabulary (for different concepts) were used utilizing ‘explode’ and ‘focus’ (for 
controlled vocabulary) in various combination. Because of the use of ‘explode’ revealed mostly 
irrelevant articles, for the final search ‘explode’ and ‘focus’ were not utilized. Likewise, use of the 
key word “advanced colorectal cancer” with its synonyms only retrieved small number of articles. 
In order to increase the search sensitivity, the term “Advanced colorectal cancer” was entered 
separately as “advanced” AND “colorectal cancer”. 
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The following keywords, synonyms, and controlled vocabulary (MESH & EMTREE) were used: 
‘‘colorectal cancer’’ or ‘‘colon cancer’’ or ‘‘rectal cancer’’ or ‘‘colorectal neoplasm’’ or “colon 
neoplasm” or “rectal neoplasm” (Please see the Appendix B for search terms) 
“advanced” or “stage IV” or “stage 4” or “stage four” or “metastatic”…..   
“surgery” or “colorectal surgery” or ‘‘palliative surgery” or “palliative surgery” or “surgical 
removal.” 
 
The three sets of terms were joined together with the ‘AND’ operator. Studies were selected using 
pre-specified criteria with restriction to publication dates since 1980, English language, and human 
studies. The title and abstract of the searched articles were reviewed to identify relevant studies. 
In addition, further studies were identified using ‘similar study’. All relevant citations were 
exported to the Refwork. 
 
In the second stage CENTRAL was searched using the term “colorectal cancer" or "colon cancer" 
or rectal cancer" or “colorectal neoplasms” and “surgery”.  In order to increase the search 
sensitivity the term “advanced” or “Stage IV” were avoided.  
 
In the third and final stage of the search, the grey literature including education material from 
scientific proceedings and current practice guidelines in the management of colon and rectal cancer 
by ASCO, ESMO and NCCN were reviewed. Citation index was used to identify relevant articles 
in that subject.  
 
Based on the initial search results, two investigators independently evaluated the abstracts and 
selected the relevant articles matching the selection criteria. The Cohen’s kappa statistics was used 
to assess agreement between the two investigators on the selection of articles (14). All the 
subsequent related studies-hand search was performed by the primary investigator.  
 
The keywords, synonyms, and controlled vocabulary (MESH & EMTREE) that were used for the 
literature search are described in detail in the Appendix A & Appendix B. Due to lack of 
controlled trial addressing this question our search strategy included studies of all designs.  
 
The computerized literature search was augmented by manual review of citations of the relevant 
studies to identify additional articles for assessment.  The reference lists of retrieved articles, 
review articles and clinical practice guidelines were reviewed for identification of additional 
studies. Original publications were selected if the abstract contained safety and efficacy data of 
patients with and without primary tumor resection. In case of duplicate publications, the most 
recent and/or most complete studies were included.  
 
Two authors examined all citations and abstracts derived from the electronic search strategy and 
independently selected the articles to be included in the review. A standardized form was used for 
full text screening to assess eligibility of studies for inclusion in the review (Appendix C).  The 
Cohen’s kappa was used to assess agreement between investigators for the full-text screening of 
studies for inclusion. Any disagreement between the reviewers was resolved by discussion.  
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2.1.5.5 Data Collection  
 
The data extraction form was used to extract and record information on the results of included 
studies. It was piloted by a preliminary search and after discussion a final extraction form was 
developed. Two authors independently extracted the data. Results were compared between 
reviewers. Disagreements were resolved by discussion.  
 
The following data was extracted from included studies: study eligibility, design and 
characteristics, funding source, baseline patients characteristics (age, gender, co-morbid illnesses, 
Eastern Cooperative Oncology Group (ECOG) performance status [Table 2.3], etc.), primary 
tumor location, disease burden (extent of liver involvement, extra-hepatic disease, etc.), co-
interventions (radiation therapy, chemotherapy, second- and third-generation chemotherapy, 
metastasectomy rate, etc.), and primary and secondary outcomes (median overall survival, 30-day 
postoperative mortality, primary tumor complications, non-surgical procedures, and quality of life 
[Appendix D]). For relevant missing information attempts were made to contact the corresponding 
authors of all the eligible studies. A manual was written to clarify the electronic data abstraction 
sheet and to reduce the disagreement between the data extractors (Appendix E). 
 
2.1.5.6 Validity Assessment 
 
Study designs were evaluated according to the following: retrospective or prospective, and 
randomized or observational. Two authors independently evaluated all included studies using a list 
of selected quality items assessing components of validity and bias. Disagreements were resolved 
by discussion. The assessment of risk of bias for eligible studies was conducted by each reviewer 
using guidelines in the Cochrane Handbook for Systematic Reviews of Interventions. For 
randomized controlled trial the elements of risk of bias assessment included quality of random 
allocation and concealment, blinding’ during treatment and at outcome assessment, description of 
dropouts and withdrawals, analysis by intention to treat, and other bias such as early stopping, 
baseline imbalance, source of funding (3). For observational studies we applied “the Newcastle-
Ottawa Quality Assessment Scale (NOS)” [15]. The Newcastle-Ottawa score consists of nine items 
grouped in three sections that are relevant for high quality of an observational study. For cohort 
study these items are as follow (Appendices F1 & F2). Selection: (1) true representativeness of 
the exposed cohort in the community, (2) non exposed cohort drawn from the same community, 
(3) ascertainment of exposure, and (4) demonstration that outcome of interest was not present at 
start of study. Comparability of cohorts: (5) control for symptoms and (6) control for systemic 
therapy. Outcome: (7) assessment of outcome, (8) follow –up was long enough for outcomes to 
occur and (9) adequacy of follow up of cohorts. Please see Appendices F1-3 for further detail 
and items for case control study.   
 
For each outcome of interest validity scores were evaluated as follows: ≤ 5: low quality; 6-7 
medium quality; 8-9 high quality (15). The Cohen’s kappa statistics was used to assess agreement 
between the two investigators on the outcomes of interest (14).  
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2.1.5.7 Analysis & Synthesis of Result 
 
The results of the studies included were combined to evaluate primary outcome in a formal meta-
analysis to produce an overall estimate of surgical intervention. For a quantitative pooling the 
DerSimonian and Laird random effects model of meta-analysis was used using RevMan analysis 
software (RevMan 5.1.2) of the Cochrane Collaboration RevMan software (16). Treatment effects 
were expressed as hazard ratios (HR) with corresponding 95% confidence intervals (CI). For 
studies that have not provided numeric information about time to event, HR and variance were 
estimated using Kaplan-Meier survival curves (17). A P-value of 0.05 was used as the cut-off value 
to determine statistical significance. Funnel plots were constructed to evaluate potential 
publication bias. Heterogeneity across studies was assessed using statistical test and the proportion 
of variation was expressed as I2. All other outcomes were presented in a descriptive way and results 
were presented as mean or median of all variables in the analyzed studies. Single group analyses 
were done for surgical mortality and complications rate (intervention group) and primary tumor 
complication rates (control) as these outcomes were not applicable to the comparator group. 
Sensitivity analyses were performed if appropriate. Pre-specified subgroup analyses were 
performed to assess survival of patients with relatively asymptomatic or minimally symptomatic 
primary tumor and studies involving patients treated with second- and third-generation anticancer 
therapy. Minimal symptoms included abdominal discomfort, weight loss, and occult blood loss. 
Risk of bias for all outcomes across studies was done in duplicate by the two reviewers and was 
reported using the GRADE scale (18).   
 
The results and some of the limitations of the systematic review and meta-analysis are discussed 
in the next chapter.  
 
2.2 Cohort Study 
 
Observational studies are an important category of study designs (19). There is evidence that well-
designed observational studies have provided comparable results to randomized controlled trials 
(RCT) in many instances (19-21). For example, Benson and Hartz evaluated 136 studies in 19 
treatment areas. The estimates of the effects of treatment in observational studies and in RCTs 
were similar in most areas, and for only 2 of the 19 treatments, the magnitude of the effect in the 
combined observational studies were outside the 95 percent confidence interval for the combined 
RCTs. Observational studies can also complement RCTs in hypothesis generation, establishing 
questions for future RCTs, and defining clinical conditions (19). 
 
Cohort studies and case-control studies are two primary types of observational studies that aid in 
evaluating associations between exposures (interventions) and diseases (outcomes). Cohort studies 
are observational studies that compare the subsequent occurrence of illness, injury, or death among 
groups of people whose exposure status differs “naturally”, i.e. not as a result of random 
assignment (22). A cohort is defined as a “group of people with defined characteristics who are 
followed up to determine incidence of, or mortality from, some specific disease, all causes of death, 
or some other outcomes” (23). Cohort studies can be prospective or retrospective.  
 
22 
 
Prospective studies are carried out from the present time into the future. In retrospective cohort 
studies, a cohort of subjects is selected at the present time based on exposure status; event status, 
which was measured in the past, is reconstructed for analysis (22,23). A characteristic of cohort 
study is that both the exposed and unexposed groups are selected from the same source population. 
While a closed cohort enrolls a defined number of participants at study onset and follows them 
from that time forward, in open cohorts the study population is dynamic and people enter and leave 
the population at different points in time (22). 
 
Poor reporting of observation studies can affect the assessment of the strengths and weaknesses of 
a study and the generalizability of its results. The Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) group has established  guidelines on reporting observational 
research to improve the transparency of the methods, thereby facilitating the critical appraisal of a 
study's findings (24,25). Cohort studies are less prone to selection bias compared to case-control 
studies.  
 
2.2.1 Study Design 
 
Retrospective cohort study. 
 
2.2.2 Study Population  
 
Patients with synchronous metastatic CRC diagnosed between the period of 1992 and 2010 in the 
province of Saskatchewan, Canada. Survival benefit of primary tumor resection was evaluated 
initially in a patient cohort diagnosed during the period of 1992 to 2005. The findings were 
validated in a second cohort of patients diagnosed from 2006 to 2010. 
 
2.2.3 Eligibility Criteria 
 
2.2.3.1 Inclusion Criteria 
 
• Histologically documented adenocarcinoma of colon and rectum and evidence of 
metastases.  
• Age at least 18 years. 
• No other active secondary malignancy. 
 
2.2.3.2 Exclusion Criteria 
 
• Patients with other histological diagnosis including small cell carcinoma, gastrointestinal 
stromal tumor (GIST), lymphoma, melanoma, anal canal cancer, melanoma and sarcoma 
were excluded. 
• Patients with fixed un-operable primary tumor. 
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2.2.4 Definitions 
 
Major comorbid illnesses were defined as the presence of coronary artery disease, congestive heart 
failure, diabetes mellitus, chronic renal insufficiency, uncontrolled hypertension, peripheral 
vascular disease, stroke, chronic obstructive lung disease, interstitial lung disease, connective 
tissue disease, dementia, symptomatic multiple sclerosis, cirrhosis of the liver, mental illnesses 
(depression, bipolar disorder, schizophrenia, anxiety disorders, and others) and AIDS among 
others. The Charlson Comorbidity Index was used in the validation study to defined major 
comorbid illness (26, 27). It is a method to categorize comorbidities of patients based on the 
International Classification of Disease (ICD) diagnosis codes. The original index and the weights 
for the index have been modified (28, 29). The higher the score the more likely the predicted 
outcome will result in mortality. The asymptomatic or minimal symptomatic disease was defined 
as absence of obstruction, perforation or bleeding. Postoperative mortality was defined as death 
that occurred within 30 days of surgery. Second generation therapy was defined as use of 
bevacizumab or anti-epidermal growth factor receptor antibodies cetuximab or panitumumab 
and/or oxaliplatin or irinotecan based therapy (FOLFOX or FOLFIRI). 
 
The site of the primary tumor was classified as right colon (located between the cecum through to 
the transverse colon), transverse colon, left colon (from the splenic flexure to the sigmoid colon), 
sigmoid colon, or rectal (within 15 cm of the anal verge) or recto-sigmoid (involvement of both 
rectum and sigmoid colon). Sites of distant metastasis are categorized as follows: liver or extra-
hepatic which include lung, bone, brain, peritoneum (including malignant ascites diagnosed by 
cytology), and others such as distant lymph nodes (including supraclavicular, mediastinal, 
inguinal, conglomerated retroperitoneal, and para-aortic lymph nodes), spleen, pancreas, kidneys, 
and skin. 
 
2.2.5 Data Source  
 
One of the advantages of population-based cancer registries is that outcome can be determined for 
the entire population. Saskatchewan is home to one of the world’s oldest cancer registries. The 
Saskatchewan cancer registry is a population-based registry and information system, which is 
designed for the collection, management, and analysis of data for residents diagnosed with cancer 
in the province. The database is prospectively collected and updated. There are currently 
approximately 226,800 patients on the database. Using the Saskatchewan Cancer Registry patients 
with Stage IV CRC diagnosed between the period of 1992 and 2005 were identified. The following 
ICD codes were used to retrieve the medical records (ICD). 
 
C18.0 cecum and ileocecal valve, C18.1 appendix, C18.2 ascending colon, C18.3 hepatic flexure, 
C18.4 transverse colon, C18.5 splenic flexure, C18.6 descending colon, C18.7 sigmoid colon and 
sigmoid flexure, C18.8 overlapping lesion of colon, C18.9 colon include large intestine not 
otherwise specified, C 19 malignant neoplasm of rectosigmoid junction include colon with rectum 
and rectosigmoid colon, C 20 malignant neoplasm of rectum include rectal ampulla (30).  
 
For the purpose of accuracy in the staging and histopathology, individual records of patients 
diagnosed with all stages of CRC (stage I, II, III, and IV) were retrieved. All records were reviewed 
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manually for eligibility criteria. Stage IV or metastatic CRC is comprised about 20% of all cases 
of newly diagnosed CRC. Hence, this study required review of more than 10,000 individual 
patients’ records.  
 
The study period is chosen due to the fact that in early the 1990s palliative chemotherapy became 
available for patients with advanced CRC and in the year 2000, second-generation therapy 
(irinotecan and oxaliplatin) and subsequently third-generation therapy (biological treatment) 
became available for patients with advanced CRC in the province of Saskatchewan. Individual 
medical records of all patients diagnosed with CRC during the study period were reviewed for 
accuracy in staging and histology. All patients were followed until their death or until June 2014 
when the data entry was closed.  
 
2.2.6 Data Collection   
 
The following data were extracted from the individual patient record by a trained research 
associate. Baseline patients characteristics (age, gender, co-morbid illnesses, Eastern Cooperative 
Oncology Group (ECOG) performance status, smoking status), primary tumor location (right 
colon, left colon, rectum), disease burden (liver involvement, extra-hepatic disease including lung 
and peritoneum), co-interventions (radiation therapy, chemotherapy, second- or third-generation 
chemotherapy, metastasectomy rate), pathology (grade, mucinous histology), laboratory test 
(hemoglobin, white blood cell counts, platelets counts, sodium, creatinine, bilirubin, albumin, 
carcinoembryonic antigen (CEA) levels), and primary and secondary outcomes (median overall 
survival, 30-day post-operative mortality, 30 days post-operative morbidity, non-resection surgical 
procedures) (Appendices G & H). Performance status information was collected using ECOG 
scale. If the performance status was recorded using the Karnofsky performance status score, it was 
transformed into ECOG scale as described in the Appendix I.  
 
2.2.7 Statistical Consideration and Data Analysis 
 
2.2.7.1 Sample Size 
 
Since a high rate of primary tumor resection has been reported in the literature, assuming two 
thirds of patients in Saskatchewan underwent resection of primary tumor, a ratio of 1:2 was used 
for non-resection group versus resection group. Using a power of 90%, type 1 error of 0.05 with 2 
sided P-value, and survival difference of 20% in the two groups (resection vs. non-resection) with 
a follow-up period of 60 months, a total sample size of 959 patients was estimated (326 in the non-
resection group and 633 patients in the resection group) [Appendix J].   
 
2.2.7.2 Demographic and Baseline Characteristics 
 
Descriptive statistics are provided to summarize the studied population demographics and baseline 
characteristics parameters. Categorical data were summarized as frequency and its corresponding 
proportion. For continuous data frequency, median, minimum, maximum, mean (as appropriate), 
and standard deviation are provided for each parameter.  The chi-square test and Student’s t-test 
were performed for analysis of categorical and continuous variables. 
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2.2.7.3 Survival Analysis  
 
Survival analyses were performed to assess primary and secondary endpoints. Survival analysis 
typically focuses on time to event data (31). In survival analysis, subjects are usually followed 
over a specified time period and the focus is on the time at which the event of interest occurs (31-
34). Observations are called censored when the information about their survival time is incomplete. 
Three reasons of censoring are: when a person does not experience the event before the study ends, 
when a person is lost to follow-up, and when a person withdraws from the study (35). A non-
informative and random censoring is required to avoid bias in a survival analysis. The survival 
data has the following features: 1) the outcome variable, the time to a well-defined event and the 
status of the event; 2) censored observations, if the event of interest has not occurred at the time 
of data analysis; 3) the predictors or explanatory variables that could potentially influence the 
outcome variable (31).  
 
The survival and hazard functions are key elements in survival analysis for describing the 
distribution of event times. The survival function S (t) is fundamental to a survival analysis. It 
gives the probability that a person survives longer than some specified time t and that the random 
variable T exceeds the specified time t (31-35). The hazard function h (t) gives the instantaneous 
potential per unit time for the event to occur, given the individual has survived up to time t whereas 
the hazard ratio is an estimate of the ratio of the hazard rate in the treated versus the control group 
(36).  The hazard rate is the probability that if the event in question has not already occurred, it 
will occur in the next time interval, divided by the length of that interval. The time interval is made 
very short, so that in effect the hazard rate represents an instantaneous rate. 
 
The hazard function – denoted by h (t) – can be estimated using the following equation:  
h (t) = number of individuals experiencing an event in interval beginning at t/ (number of 
individuals surviving at time t) x (interval width). 
 
There are three primary goals of survival analysis, to estimate and interpret survival and / or hazard 
functions from the survival data; to compare survival and / or hazard functions, and to assess the 
relationship of explanatory variables to survival time (31). 
 
Unlike ordinary regression models, survival methods correctly incorporate information from both 
censored and uncensored observations in estimating important model parameters. There are three 
main approaches to analyze the relationship of a set of predictor variables with the survival time:  
nonparametric, parametric, and semi-parametric (31,33). Nonparametric methods provide simple 
and quick looks at the survival experience. The Kaplan-Meier method, a nonparametric estimator 
of the survival function, is widely used to estimate and graph survival probabilities as a function 
of time (37).  Parametric methods assume that the underlying distribution of the survival times 
follows certain known probability distributions. Popular parametric methods include the 
exponential, Weibull, and lognormal distributions (31). The Cox regression model is a semi-
parametric model which unlike parametric models, makes no assumptions about the shape of the 
so-called baseline hazard function.  The Cox proportional hazards regression model remains the 
dominant survival analysis method to test for differences in survival times of two or more groups 
of interest, while adjusting for covariates of interest.  
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2.2.7.3.1 The Kaplan–Meier Method  
 
Survival of the study cohorts were estimated by using the Kaplan-Meier (KM) method. The KM 
survival curve is defined as “the probability of surviving in a given length of time while 
considering time in many small intervals” (37). The KM estimate is also called as “product limit 
estimate”.  In KM the time is divided into periods of fixed length and each period or segment is 
the interval between two non-simultaneous terminal events. In addition, in each segment, 
calculation is made of the probability of survival as the product of the probability of survival at 
the start of the interval and the probability of survival at the end of the interval – since the subject 
was alive at the start (31,33,37). In KM three assumptions are made:  at any time subjects who are 
censored have the same survival prospects as those who continue to be followed, the survival 
probabilities are the same for subjects recruited early and late in the study, and the event happens 
at the time specified. 
 
2.2.7.3.2 The Log-Rank Test 
 
The survival distributions of different groups were compared by the log-rank test. The log-rank 
test is a form of chi-square test and is used to test the null hypothesis that there is no difference 
between the populations in the probability of an event at any time point (31,35,38). The analysis 
is based on the times of events. The log-rank test is based on the same assumptions as the Kaplan 
Meier survival curve that censoring is unrelated to prognosis and the survival probabilities are the 
same for subjects recruited early and late in the study, and the events happened at the times 
specified. The test is more likely to detect a difference between groups when the risk of an event 
is consistently greater for one group than another. The log-rank test is purely a test of significance 
and cannot provide an estimate of the size of the difference between the groups (38). Furthermore, 
the log-rank test cannot be used to explore and adjust for the effects of prognostic variables, such 
as age and disease duration, known to affect survival. 
 
2.2.7.3.3 The Cox Proportional Hazards (PH) Model 
 
There are several known variables that can affect the survival of patients with Stage IV CRC. 
These variables include age, comorbid illnesses, performance status, extent of cancer and systemic 
therapy (39-41). Furthermore, pretreatment hematologic abnormalities have been reported to have 
prognostic value in patients with solid tumors (42, 43). We performed multivariate analyses to 
determine the prognostic significance of the primary tumor resection in patients with Stage IV 
CRC. The Cox proportional hazard model was used and the hazard ratios and 95% confidence 
limit were estimated.  
 
The Cox proportional hazards model is a popular mathematical model that is both powerful and 
flexible for the analysis of survival data (31,33,44,45). Cox regression is considered a ‘semi-
parametric’ procedure because the baseline hazard function, h0 (t), does not have to be specified. 
In this model, the relative risk is described parametrically and the hazard functions non-
parametrically. The model simultaneously explores the effects of several variables on survival and 
allows the researchers to isolate the effects of treatment from the effects of other variables. It 
provides an estimate of the hazard ratio and its confidence interval and may improve the estimate 
of treatment effect by narrowing the confidence interval.  
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The Cox proportional hazard model makes assumptions that the hazard ratios of two people are 
independent of time, and are valid only for time-independent covariates and that the hazard 
functions for any two individuals at any point in time are proportional (31). In other words, if a 
person is at risk of death at some initial time point that is twice as high as that of another person, 
then at all later times the risk of death remains twice as high.  
 
Cox’s method is similar to multiple regression analysis, except that the dependent (Y) variable is 
the hazard function at a given time. If there are several explanatory (X) variables of interest such 
as age, gender, interventions, then the hazard or risk of dying at time t can be expressed as (31):  
 
ℎ(𝑡𝑡) = ℎ0(𝑡𝑡)exp(𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎 × 𝑎𝑎𝑎𝑎𝑎𝑎 + 𝛽𝛽𝑎𝑎𝑎𝑎𝑔𝑔𝑔𝑔𝑎𝑎𝑔𝑔 × 𝑎𝑎𝑎𝑎𝑔𝑔𝑔𝑔𝑎𝑎𝑔𝑔 +  ⋯+ 𝛽𝛽𝑎𝑎𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 × 𝑎𝑎𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔)                   
Taking natural logarithms of both sides: ln ℎ(𝑡𝑡) = ln ℎ0(𝑡𝑡)exp(𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎 × 𝑎𝑎𝑎𝑎𝑎𝑎 + 𝛽𝛽𝑎𝑎𝑎𝑎𝑔𝑔𝑔𝑔𝑎𝑎𝑔𝑔 × 𝑎𝑎𝑎𝑎𝑔𝑔𝑔𝑔𝑎𝑎𝑔𝑔 +  ⋯+ 𝛽𝛽𝑎𝑎𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 × 𝑎𝑎𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔) 
 
The quantity h0 (t) is the baseline or underlying hazard function and corresponds to the probability 
of death when all the explanatory variables are zero. The regression coefficients βage to βgroup give 
the proportional change that can be expected in the hazard, related to changes in the explanatory 
variables. 
 
The proportional hazards assumption can be tested using graphical, goodness of fit test and time-
dependent covariates (31). For example, with complementary log-log plot, if the hazards are 
proportional across the group, a plot of the logarithm of the negative logarithm of the estimated 
survivor function against the logarithm of survival time will yield parallel curves. Parameter (β) 
estimates in the Cox PH model are obtained by maximizing the partial likelihood (45). Cox and 
others have shown that this partial log-likelihood can be treated as an ordinary log-likelihood to 
derive valid (partial) maximum likelihoods of β (44,45). 
 
In our cohort studies we examined the following variables with respect to their prognostic 
significance: Interventions: Resection of primary tumor, metastasectomy, use of chemotherapy, 
second generation chemotherapy, second-line therapy, third-line therapy, and radiation therapy; 
clinical & demographic variables: age, gender, major comorbid illness, secondary cancer, ECOG 
performance status, cancer center, and active smoking; laboratory values: albumin, bilirubin, 
alkaline phosphatase, sodium level, serum creatinine, blood urea nitrogen (BUN), hemoglobin, 
white blood cell (WBC), platelet count, and carcinoembryonic antigen (CEA); disease 
characteristics: site, grade, mucinous tumor, symptomatic disease, extra-hepatic metastases, and 
stage.  
 
Following cutoffs were used to categorize continuous variables.  age (<65 vs. ≥65) or (<70 vs. 
≥70), albumin (≥36 vs. <36 g/l), bilirubin (≥26 vs. <26 um/l), alkaline phosphatase (≥120 vs. <120 
mm/l), sodium level (≤135 mEq/l vs. >135 mEq/l), serum creatinine (≥120 vs. <120 um/l), BUN 
(≥8 vs. <8 mm/l), hemoglobin (≥120 vs. <120 g/l), WBC (≥11 vs. <11 x 109/l), platelet count (≥450 
vs. <450 x109/l), and CEA (≥6 vs. <6 mcg/l). The categorical or ordinal variables were 
characterized as: site (colon vs. rectal), grade (3 vs. <3), and stage (Stage IVa vs. Stage IVb 
disease).  
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For the patients cohort that underwent surgical resection of the primary tumor , tumor-related 
characteristics including nodal status, T status, the ratio of metastatic to examined lymph node 
(LNR) [median number was used as a cutoff value] and number of lymph nodes removed (≥12 vs. 
r <12) were examined in a multivariate analysis. For the Cox proportional hazard model, the 
proportional hazards assumption was assessed for the variables using the log-log survival curves. 
All variables that were significant on univariate analysis with P<0.05, were examined in 
multivariate models. The likelihood ratio test and t test were used to determine if a variable 
correlates with survival in the model. Tests for interaction were performed for surgery and the 
other prognostic variables that were correlated with survival. In addition to the tests for interaction, 
secondary analyses were performed in subgroups of patients with asymptomatic or minimally 
symptomatic disease, patients who did not have metastasectomy, and patients who were treated 
with combination chemotherapy. A two-sided P-value of <0.05 was considered to be statistically 
significant. For missing data an imputation technique was used. The SPSS version 21-22 and the 
STATA MP version 13.1 (StataCorp College Station, TX) were used for statistical analysis (SPSS 
Inc. Chicago, IL). 
 
2.2.7.4 The Logistic Regression 
 
In our one of companion studies we used logistic regression method to assess the relationship 
between the use of chemotherapy and various variables in patients with newly diagnosed stage IV 
CRC. Regression methods are important to describe the relationship between a response variable 
and predictor variables (46). The logistic regression model has its basis in the odds of a two-level 
outcome of interest. The ratio of odds of disease in exposed individuals relative to the unexposed 
is called the odds ratio (47). Logistic regression analysis is a multiple regression technique that 
can be applied in research situations where the outcome variable is categorical. The logistic 
regression model takes the natural logarithm of the odds as a regression function of the predictors 
(48). With 1 predictor, X, this takes the form ln [odds(Y=1)] =β0+β1X, where ln stands for the 
natural logarithm, Y is the outcome and Y=1 when the event happens (versus Y=0 when it does 
not), β0 is the intercept term, and β1 represents the regression coefficient, the change in the 
logarithm of the odds of the event with a one-unit change in the predictor X (46).  
 
The goal of the regression analysis is to find the best fitting and most parsimonious, yet 
biologically reasonable model to describe the relationship between an outcome and a set of 
independent variables. The method of parameter estimation is maximum likelihood. The likelihood 
function expresses the probability of the observed data as a function of the unknown parameters. 
The maximum likelihood method is used to produce estimators that are consistent, asymptotically 
(for large n) efficient and asymptotically normal (46). The logistic regression modeling approach 
is based on the concept of logistic function.  
 
However, if the model and the data are not in good agreement, then these odds ratios are not very 
meaningful (48, 49).  
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2.2.7.5 Area-level Variables 
 
Few Canadian vital statistics include socio-economic data that would facilitate identification of 
disparities in the outcomes of cancer patients. Furthermore, most health system-generated data and 
disease registries lack socio-economic content. Hence, it is challenging to assess relationship 
between various social determinants of health and survival of newly diagnosed Canadian patients 
with stage IV CRC. Area-based socio-economic measures utilize information to characterize the 
socio-economic profile of geographic areas rather than of individuals. They serve as proxy for 
individual-level characteristics. Greater homogeneity within areas signifies greater reliability of 
this proxy status of the area data for micro-level data (50). Area-level socioeconomic status can be 
obtained by matching individuals to a spatial location using place of residence information such 
as postal codes.  
 
There is evidence that area-level indicators of socioeconomic status predict health outcomes 
independent of the individual-level variables (51-54). There are associations between area-level 
socioeconomic status (SES) and colorectal cancer.  For example, lower area-level SES has been 
associated with higher risk of colorectal cancer (55-57). It is important to recognize the extent to 
which observed associations between area-level SES and cancer outcomes are due to 
compositional factors such people living in lower-SES areas are themselves of lower SES with an 
increased risk of mortality or potentially influenced by contextual factors such as physical 
environment, and neighborhood resources, which may contribute to inferior outcomes independent 
of individual SES. This information can be very useful for appropriate interventions to reduce 
socioeconomic disparities (58, 59). 
 
2.2.7.5.1 Frailty Model 
 
A frailty model is a random-effects model, where the random effect (the frailty) has a 
multiplicative effect on the hazard function of an individual or a group or cluster of individuals 
(60). Frailty is a random component designed to account for variability due to unobserved 
individual-level factors that is otherwise unaccounted for by the other predictors in the model (31).  
 
2.2.7.5.2 Shared Frailty Models 
 
In the shared frailty model, individuals j in a group i are supposed to share the same frailty Zi. The 
conditional hazard for individual j in group i is:  
 
𝜆𝜆�𝑡𝑡𝑖𝑖𝑖𝑖�𝑍𝑍𝑖𝑖𝑖𝑖� = 𝑍𝑍𝑖𝑖𝜆𝜆(𝑡𝑡𝑖𝑖𝑖𝑖) where 𝜆𝜆�𝑡𝑡𝑖𝑖𝑖𝑖� = 𝜆𝜆0�𝑡𝑡𝑖𝑖𝑖𝑖�exp (𝛽𝛽𝑋𝑋𝑖𝑖𝑖𝑖) in the Cox-regression model. 
 
The interpretation of this model is that the between-group variability (the random variation of Z) 
leads to different risks for the groups, which then show up as dependence within the group. Small 
value of θ reflects a greater degree of heterogeneity among groups and a stronger association within 
groups and large value of θ corresponds to the case of independence. 
 
In an exploratory analysis we evaluated prognostic significance of area level variables in the 
patients’ cohort (2006-2010) who were treated with modern chemotherapy. The postal code 
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information was obtained for all individuals. The Census subdivision information was retrieved 
using the Postal Code Conversion File (PCCF) [61]. PCCF is a digital file which provides a 
correspondence between the Canada Post Corporation (CPC) six-character postal code and 
Statistics Canada’s standard geographic areas (Census subdivisions) for which census data and 
other statistics are produced (62). About 94% of the postal codes were linked to geographic areas 
using the new automated process.  
 
In the profile of the 2006 census subdivisions (Canadian Census Analyzer) information about total 
population, population of certain races and minorities, income, the level of education among others 
for all provinces, divisions and subdivisions are available. 
 
Cox models with shared frailty were fitted. The individual clinicopathological variables that 
demonstrated correlation with survival in a multivariate Cox Proportional Hazard model were used 
in the model. Following area level variables were examined with respect to their correlation with 
overall survival. Household income, family income, age dependency ratio, unemployment rate, 
aboriginal population, high school certificate, single parent, and minority. In addition, we used 
socio-economic Factor Index 2 (SAFEI 2). The SAFEI 2 includes four variables from the census: 
average household income, proportion of high school graduates, unemployment rate, and 
proportion of single-parent families (63, 64). The contribution of a variable to the factor is known 
as a factor loading and can range from -1 to +1. The larger the absolute size of the loading, the 
more important that variable is for the factor. All variables were categorized by using their mean 
values as a cutoff point. In addition, the variables were also examined using their quartiles (Table 
1). The result is provided in the Appendix K.  
 
In the following sections we reviewed the results of our research projects using the draft of the 
manuscripts published in the peer reviewed journals. The lead author made major contributions to 
concept and design, data analysis, interpretation, drafting and revising the manuscripts and 
correspondence.  In the Appendices L and M, certificate of ethics approval and permission to 
reproduce the articles, are provided, respectively.  
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Table 2.1: Comparison of systematic and narrative reviews.  
 
 
Characteristics Narrative Review Systematic Review 
Question General or non-existent  Focused question using PICO 
(population, intervention or 
exposure, comparison and outcomes 
of interest) 
Literature Search   not specified or if reported 
not a comprehensive search 
Explicit and comprehensive search 
of several evidence sources  
Selection of studies  Not specified or if reported 
potentially biased sample of 
selected studies  
Explicit eligibility criteria for 
inclusion and exclusion of studies    
Assessment of validity  Seldom reported and if 
reported are not systematic  
Rigorous methodological assessment 
of risk of bias of reported studies  
Summary of results  Qualitative non-systematic 
summary  
Qualitative or quantitative synthesis 
of findings of studies are systematic  
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Table 2.2: Source of heterogeneity in meta-analyses. 
 
Character Real Artefactual 
Population Disease severity, co-
morbidity, age and gender 
Improper randomization, 
differential follow up 
Intervention Time, duration, dose Non-compliance, cross over 
Co-intervention Therapy, drugs Undetected co-interventions 
Outcome Timing of outcome, event 
type 
Differential error, non-
differential error 
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Table 2.3: Eastern Cooperative Oncology Group (ECOG) or World Health Organization 
(WHO) performance scale. 
 
Performance 
status Definition 
0 Fully active; no performance restrictions 
1 Strenuous physical activity restricted; fully ambulatory and able to 
carry out light work 
2 Capable of all self-care but unable to carry out any work activities. Up 
and about >50 percent of waking hours. 
3 Capable of only limited self-care; confined to bed or chair >50 percent 
of waking hours 
4 Completely disabled; cannot carry out any self-care; totally confined 
to bed or chair 
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CHAPTER 3 – SYSTEMATIC REVIEW AND META-ANALYSIS OF THE 
PUBLISHED LITERATURE 
 
The following four chapters are comprised of four manuscripts and summaries of the results. The 
manuscripts address the results of the primary research objectives. The first manuscript 
systematically reviews the published literature and synthesizes the data in relation to primary 
tumor resection in stage IV CRC. It discusses the limitations of the results. The second paper 
describes the results of our population based cohort study, in a cohort of patients with synchronous 
metastatic CRC, diagnosed from January 1992 to December 2005.  The third paper reviews the 
survival benefit of primary tumor resection in a sub-cohort of patients with asymptomatic or 
minimally symptomatic primary tumor. The final paper validates the research findings in a cohort 
of patients with synchronous metastatic CRC, diagnosed from January 2006 to December 2010. 
 
The present chapter addresses the study objective “to systematically review the published literature 
and synthesize the data in relation to primary tumor resection in stage IV CRC” and reviews the 
published literature till February 2012. The study findings were presented in September 2012 at 
the European Society of Medical Oncology (ESMO) Annual Meeting in Vienna, Austria and in 
June 2013 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, 
USA in the poster sessions. The results were published in the Current Oncology “Ahmed S, Shahid 
RK, Leis A, Haider K, Kanthan S, Reeder B, Pahwa P. Should non-curative resection of primary 
tumor be performed in patients with stage IV colorectal cancer? A systematic review & meta-
analysis. Current Oncology 2013 Oct; 20(5):e420-41”.   
 
3.1 Abstract 
 
Purpose: Surgical resection of the primary tumor in patients with advanced CRC remains 
controversial. This review compares survival in patients with advanced CRC who underwent 
surgical resection of the primary tumor with that in patients not undergoing resection, and 
determines postoperative mortality & nonfatal complications rates, primary tumor complication 
rate (PTCR), the non-resection surgical procedures rate (NSPR) and quality of life (QOL).  
 
Patients and Methods: Reports in the CENTRAL, Medline, and EMBASE databases were 
searched for relevant studies, which were selected using pre-specified eligibility criteria. The 
search was also restricted to publication dates from 1980 onward, the English language, and studies 
involving human subjects. Screening, evaluation of relevant articles, and data abstraction were 
performed in duplicate, and agreement between the abstractors was assessed. Articles that met the 
inclusion criteria were assessed for quality using the Ottawa-Newcastle Scale. Data were collected 
and synthesized per protocol.  
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Results: From among the 3379 reports located, fifteen retrospective observational studies were 
selected. Of the 12456 patients in the selected studies, 8620 (69%) underwent surgery.   Median 
survival was 15.2 months (range: 10-30.7) in the resection group and 11.4 months (range: 3-22) in 
the non-resection group. Hazard ratio for survival was 0.69 (95% CI: 0.61-0.79) favoring surgical 
resection. Mean rates of postoperative mortality and nonfatal complications rates were 4.9% (95% 
CI: 0-9.7) and 25.9% (95% CI: 20.1-31.6) respectively. The mean primary tumor complications 
rate was 29.7% (95% CI: 18.5-41.0), and the non-resection surgical procedures rate in the non-
resection group was 27.6% (95% CI: 15.4-39.9). No study provided QOL data. 
 
Conclusions: Although this review supports primary tumor resection in advanced CRC, the results 
have significant biases. Randomized trials are warranted to confirm the findings. 
 
3.2 Introduction 
 
Colorectal cancer is one of the leading causes of cancer death in North America (1). The median 
overall survival of patients with stage IV CRC managed with best supportive care alone is about 
5-6 months (2). Systemic therapy provides meaningful improvements in median survival and 
progression-free survival. Overall, with the judicious use of novel cytotoxic and biologic agents, 
the median overall survival of patients with stage IV CRC has been extended to approximately 
two years (3-5).  
 
The optimal surgical management of stage IV CRC that is not amenable to curative resection is 
unknown. Although administration of systemic therapy in patients with stage IV CRC may convert 
unresectable into resectable disease, the principal goal of treatment in most patients is to prolong 
survival, and only about 10-15% patients are alive at five years. Consequently, in patients with 
stage IV CRC, the potential morbidity of treatment and the treatment’s impact on quality of life 
(QOL) of patients must be considered.  
 
Resection of the primary tumor in patients with stage IV cancer is often performed to deal with 
presenting primary tumor symptoms and to prevent future primary tumor complications. Potential 
advantages of resection of the primary tumor are prevention of obstruction and major bleeding, 
better pain control, and a potential reduction in serious adverse effects such as bleeding and 
perforation related to novel targeted therapy. Resection may facilitate treatment tolerance (with 
better response) and potentially improve survival.  Conversely, newer-generation chemotherapy 
in combination with targeted therapy has been associated with response rate of 40-60% (3-5). 
Systemic therapy not only reduces the size of metastatic lesions, but also shrinks the primary 
tumor, thereby potentially reducing local complications, such as bowel obstruction, related to 
primary tumors. Complications after resection of a primary tumor in patients with advanced CRC 
can delay or prevent initiation of systemic therapy and thereby preclude the associated benefit. 
Whether primary tumor resection improves disease control by reducing tumor bulk remains 
unknown. 
 
The available data about the potential benefit of primary tumor resection in patients with stage IV 
CRC and otherwise unresectable metastatic lesions are limited. Some authors have advocated for 
surgery (6-8), but other have failed to demonstrate a survival benefit for resection (9-12). Whether 
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a similar benefit can be achieved in the era of second- and third-generation anticancer agents, 
which are associated with higher response rates and better overall survival in patients with stage 
IV CRC, is not known.   In spite of uncertain survival benefit, a high rate of surgical resection of 
the primary tumor has been reported in patients with unresectable metastatic disease (13,14). 
 
We undertook the present comprehensive and critical analysis of the available literature to assess 
if surgical resection of the primary tumor in patients with advanced colorectal cancer improves 
outcome.  
 
3.3 Objectives & Outcomes of Interest 
 
3.3.1 Primary Objective 
 
The primary objective was to compare survival in patients with stage IV CRC who did and did not 
undergo primary tumor resection. 
 
3.3.2 Secondary Objectives 
 
Secondary objectives included determining 
• the rates of 30-day postoperative mortality and nonfatal complications in the intervention 
group. 
• the rate of primary tumor complications rate in the control group. 
• the rate of non-resection procedures and the QOL in both groups.  
• the survival benefit of surgical intervention in the subgroups of patients treated with 
second- and third-generation anticancer therapy. 
• the survival benefit of surgical intervention in the subgroups of minimally symptomatic 
patients. 
 
3.4 Definitions 
 
All the outcomes of interest were pre-specified and defined. “Primary tumor complications” was 
defined as development of bleeding, obstruction, and perforation during the study period. “Fatal 
primary tumor complications” was defined as death within 30 days of bleeding, obstruction and 
perforation secondary to an intact primary tumor. “Surgical mortality” was defined as death within 
30 days of surgery, and “non-fatal surgical complications” was defined as postoperative infection, 
anastomotic leak, or any other complications recorded 30 days after resection of primary tumor. 
“Non-resection procedures” included bypass surgery with colostomy formation, endoscopic laser 
therapy, or placement of endoluminal stents. “Modern chemotherapy” was defined as use of 
second-generation (irinotecan or oxaliplatin or both) chemotherapy alone or in combination with 
third-generation agents (bevacizumab or the anti-epidermal growth factor receptor monoclonal 
antibodies cetuximab or panitumumab). Second-generation chemotherapy became available for 
clinical use in most centers in the early 2000s.  Individual patients data were not available, and so 
for the purposes  of this analysis, all studies that specified the use of second- and third-generation 
therapy or those that were conducted in whole or in part (≥50%) after the year 1999 were 
considered studies using second- and third-generation anti-cancer therapy.   
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3.5 Methods 
 
Our method conformed to the PRISMA statement guidelines (15). Two investigators (SA & RKS) 
independently evaluated the abstracts, selected relevant articles matching the selection criteria, and 
independently extracted the data. The Cohen kappa coefficient was used to assess agreement 
between the two investigators (16). Disagreements between the reviewers were resolved by 
discussion. 
 
3.5.1 Inclusion and Exclusion Criteria 
 
Studies involving patients with histologically documented adenocarcinoma of colon and rectum 
and evidence of metastases were included. Only studies with comparative data on the survival of 
patients with advanced CRC with or without resection of the primary tumor were included. Studies 
that included data from patients who underwent upfront metastasectomy or from a comparison 
group of patients with nonsurgical procedures or curative resection were excluded. 
 
3.5.2 Information Sources, Search Strategies and Selection of Studies 
 
An extensive search of reports in the Medline (version 1946 to February 2012), EMBASE (version 
1947 to February 2012) and CENTRAL (The Cochrane Central Register of Controlled Trials, The 
Cochrane Library, Wiley, Issue 3 2012) databases was conducted. Studies were selected using the 
pre-specified criteria, with restriction to publication dates from 1980 onward, the English 
language, and studies involving human subjects.  
 
The keywords, synonyms, and controlled vocabulary (MESH & EMTREE) used for the literature 
search are described in Appendices A and B. The computerized literature search was augmented 
by a manual review of the citations from relevant studies to identify additional article for 
assessment.  The reference lists of all retrieved articles and relevant reviews and clinical practice 
guidelines were retrieved for identification of additional studies. In case of duplicate publications, 
the most recent or most complete study was included. A standardized form was used during full-
text screening to assess eligibility of studies for inclusion in the present review (Appendix C).    
 
3.5.3 Data Collection   
 
The data extracted from the included studies were these: study eligibility, design and 
characteristics, baseline patients characteristics (age, gender, co-morbid illnesses, Eastern 
Cooperative Oncology Group performance status, etc.), primary tumor location, disease burden 
(extent of liver involvement, extra-hepatic disease, etc.), co-interventions (radiation therapy, 
chemotherapy, second- and third-generation chemotherapy, metastasectomy rate, etc.), and 
primary and secondary outcomes (median overall survival, two-year survival, 30-day post-
operative mortality, primary tumor complications and nonsurgical procedures, and QOL). 
Attempts were made to contact the corresponding authors of all the eligible studies for relevant 
missing information (Appendices D & E).  
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3.5.4 Validity Assessment 
 
Study designs were evaluated according to whether they were retrospective or prospective, and 
randomized or observational. Two authors independently evaluated all the included studies using 
a list of selected quality items assessing components of validity and bias. Disagreements were 
resolved by discussion. Risk of bias in the eligible studies was assessed by each reviewer using 
guidelines in the Cochrane Handbook for Systematic Reviews of Interventions (17). For 
observational studies “the Newcastle-Ottawa Quality Assessment Scale” was applied [18]. The 
Newcastle-Ottawa Scale consists of nine items grouped into three sections that are relevant to the 
quality of an observational study (Appendix F).    
 
For each outcome of interest, validity scores were evaluated as follows: ≤ 5: low quality; 6-7 
medium quality; 8-9 high quality (18). The Cohen kappa coefficient was used to assess agreement 
between the two investigators with respect to the outcomes of interest (16).  
 
3.5.5 Analysis & Synthesis of Result 
 
Results of the included studies for primary outcome were combined in a formal meta-analysis to 
produce an overall estimate of surgical intervention. For quantitative pooling, the DerSimonian 
and Laird random-effects model was used, and all calculations were performed using the Review 
Manager analysis software (RevMan, version 5.1.2: The Cochrane Collaboration, 
http://ims.cochrane.org/revman). Treatment effects are expressed as hazard ratios (HR) with 
corresponding 95% confidence intervals (CI). For studies that did not provide numeric information 
about time to event, the HR and variance were estimated using Kaplan-Meier survival curves (19). 
A P-value of 0.05 was used as the cut-off value for statistical significance. Funnel plots were 
constructed to evaluate potential publication bias. Heterogeneity across studies was assessed using 
a statistical test, with the proportion of variation being expressed as I2. All other outcomes are 
presented descriptively, and results are presented as mean or median of variables in the analyzed 
studies. Single-group analyses were done for surgical mortality and complication rates 
(intervention group) and primary tumor complication rate (control), because those outcomes were 
not applicable to both groups. A sensitivity analysis was performed if appropriate.  
 
Pre-specified subgroup analyses were performed to assess the survival of patients with minimally 
symptomatic primary tumor and of patients involved in studies that offered treatment with second- 
and third-generation anticancer therapy. Risk of bias for all outcomes was assessed across the 
analyzed studies in duplicate by two reviewers and reported using the GRADE scale (20).   
 
3.6 Results 
 
3.6.1 Study Selection  
 
Figure 3.1 shows the flow chart of the search procedure, which identified 3379 citations. 
Publications not meeting the inclusion criteria and duplicate publications were excluded after a 
review of titles and abstracts.  Thirty-seven potentially eligible articles underwent full-text 
assessment to determine their eligibility for inclusion in the final analysis. Fifteen studies (reported 
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in fourteen articles) were identified as meeting the eligibility criteria (6-12,21-26). Kappa 
agreement scores between the two abstractors with respect to “screening for the citations” and “full 
text screening” were 0.68 and 0.86 respectively, suggesting substantial-to-excellent agreement.  
 
Of twenty-three full-text articles that were excluded, twelve had no comparator nonsurgical group 
(27-38); four used a non-resection group (that is, ostomy procedures) as comparators (39-42); and 
another four used patients who underwent curative surgery as the comparator group (43-46). Two 
studies, each with four comparator groups, provided minimal information about those groups, and 
one had a patients population that overlapped with the population of another study included in the 
present review (14,47). One study whose non-resection group contained fewer than five patients 
was excluded after discussion between the reviewers (48). The asymmetry of the funnel plot 
around the point estimate suggests an element of publication bias (Figure 3.2) 
 
3.6.2 Study Characteristics & Risk of Bias 
 
Table 3.1 describes the characteristics and risk of bias of the included studies. As anticipated, no 
prospective trial describing randomization between surgical and nonsurgical treatment was found. 
The study by Venderbosch et al. was a retrospective analysis of two randomized studies reported 
by Koopman et al. and Tol et al. (CAIRO and CAIRO I) [7,49,50]. Eight studies originated in 
Europe; five, in North American; and one, in Asia. Six studies exclusively involved minimally 
symptomatic patients, and ten studies met the pre-specified criteria for use of modern anticancer 
therapy. All but one study imposed no age restriction (13).  
 
All included publications reported retrospective observational studies. Using validity scoring for 
observational study, no study met the criteria for good quality study for any outcome of interest. 
For the primary outcome overall survival, nine of fifteen studies were of low quality, and the 
remaining six were of fair quality (Appendix N).  
 
With respect to secondary outcomes, the quality of evidence was lower overall than it had been 
for the primary outcome. Reporting bias was noted for all the secondary outcomes: six studies did 
not report postoperative mortality rate (7-10,22); eight studies did not provide data for post-
operative complications or morbidity (7,8,10,13,22,23,25); four lacked information about the rate 
of primary tumor complications (7,21,22); six provided no information on non-resection 
procedures (6,7,9,24,25); and no study provided information about QOL.   
 
3.6.3 Patients Characteristics 
 
The included studies involved a total of 12,456 patients, among whom 8620 (69%) underwent 
surgery as initial treatment, and 3796 (31%) were initially received systemic therapy. Several 
studies did not provide information about the baseline characteristics of the patients. All except 
one study provided information about systemic therapy (9); eight studies provided information 
about performance status (7,8,10,11,22,25,26); and only four studies provided information about 
comorbid illnesses (6,8,13,25). Table 3.2 describes the baseline characteristics of the patients in 
the analyzed studies.  Median age was 61 years (range: 19-96), and 41% (95% CI: 36.8-45.1) were 
women.  Of the patients overall, 16.6% (95% CI: 7.9-25.2) had an ECOG performance status 
greater than 1, and 54% (95% CI: 40-69) patients had more than 25% liver involvement.  The 
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tumor was located in the rectum in 26% (95% CI: 19.7-32.2) of the patients: 21.9% (95% CI: 14.3-
29.5) in the resection group, and 31% (95% CI: 22.8-39.2) in the control group. With respect to 
systemic therapy, 82% (95% CI: 73-92) patients received chemotherapy, and 64% (95%CI: 35-
84) received second- and third-generation therapy. Only in CAIRO and CAIRO II trials, patients 
in both groups uniformly received second-generation and third-generation therapy, respectively 
(49,50). The mean rate of metastasectomy was 11.4% (95% CI: 3.5-19.3) in the intervention group 
and 9.3% (95% CI: 0-18.2) in the control group.  
 
3.6.4 Overall Survival  
 
Table 3.1 describes survival and secondary outcomes for the individual studies, and Table 3.3 
describes summary findings and risk of bias for the studies overall. Median survival was 15.2 
months (range: 10-30.7) in the resection group and 11.4 months (range: 3-22) in the non-resection 
group. A quantitative meta-analysis using the data of all fifteen studies revealed that, compared 
with no surgery, primary tumor resection was associated with a significant improvement in 
survival (HR: 0.69; 95% CI: 0.61-0.79; P<0.00001; Figure 3.3). Subgroups analyses were 
performed for more homogenous patient population with respect to symptoms and type of systemic 
therapy (see the Subgroup Analyses section).  
 
3.6.5 Sensitivity Analysis 
 
Only seven studies reported HRs and 95% CI; for the remaining 8 studies, we used the method 
suggested by Tierney et al. to estimate HRs and variances (19). In a sensitivity analysis pooling 
the data of seven studies (7,8,10,11,24,26), the HR for survival was 0.52 (95% CI: 0.40-0.68) 
favoring the resection group (Figure 3.4).  Among fifteen studies reviewed, the study by Temple 
et al. was conducted in patients more than 65 years of age. A sensitivity analysis that excluded the 
Temple et al. study revealed a HR for survival of 0.68 (95% CI: 0.57-0.80; Figure 3.5).    
 
3.6.6 Secondary End Points  
 
The surgical mortality rate was reported in nine studies. The mean 30-day postoperative mortality 
rate was 4.9% (95% CI: 0-9.7%) in the intervention group. Only seven studies reported nonfatal 
surgical complications, including anastomic leaks, wound infection, and other complications. The 
mean surgical morbidity rate was 25.9% (95% CI: 20.1-31.6). Most studies did not separate major 
and minor complications. The mean rate of anastomotic leak, a serious postoperative complication, 
was 3.2% (95% CI: 0-8.3). 
 
The mean rates of primary tumor complications and intestinal obstruction secondary to the primary 
tumor were 29.7% (95%CI: 18.5-41.0) and 23.4% (95% CI: 14.1-32.7) respectively. Most studies 
failed to specify major and minor bleeding. No study specifically reported the rate of fatal primary 
tumor complications. The non-resection surgical procedures rate in the control group was 27.6% 
(95% CI: 15.4-39.9). Only three studies reported rates of non-resection surgical procedures in the 
intervention group, for whom the rate was 4.2 (95% CI: 0-10.1). Because all studies were 
retrospective, none assessed QOL.  
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3.6.7 Sub-Groups Analyses 
 
Table 3.4 presents information about various outcomes in the patient subgroups of interest.   
 
3.6.7.1 Studies Using Second- and Third-Generation Anti-Cancer Therapy  
 
In the subgroup of patients receiving modern chemotherapy, median overall survival in the group 
undergoing surgery was 18.7 months (range: 11-30.7); it was 12.85 months (range: 5.8-22) in the 
control group. The HR for survival in this subgroup was 0.68 (95% CI: 0.56-0.83) compared with 
a HR of 0.73 (95% CI: 0.59-0.90) in patients treated with an older regimen, which favors surgical 
intervention (Figure 3.6). A test for interaction between the groups was non-significant. The mean 
30-day postoperative mortality rate in the group treated with modern chemotherapy was 3.9% 
(95% CI: 0-11). The mean rates of primary tumor complications and non-resection procedure in 
the control group were 27.4% (95% CI: 16.4-38.5) and 27% (95% CI: 12.5-41.6).  
 
3.6.7.2 Studies with Minimally Symptomatic Patients 
 
The median overall survival in the resection group was 18.5 months (range: 14.5-23); it was 13.15 
months (range: 5.8-22) in the control group. The HR for survival in minimally symptomatic 
patients was 0.67 (95% CI: 0.48-0.94; Figure 3.7) compared with a HR of 0.75 (95% CI: 0.67-
0.84) in symptomatic patients (test for subgroups interaction, p=0.53), which favors the 
intervention group.  
 
In minimally symptomatic patients, the mean 30-day post-operative mortality rate was 1.6% (95% 
CI: 0-74.8), with four of six studies reported 0% surgical mortality. The mean rates of primary 
tumor complication and non-resection procedures in the control group were 25.6% (95% CI: 5.9-
45.2) and 22.2% (95% CI: 0-49.1)  
 
3.7 Discussion 
 
Our review demonstrates a consistent trend favoring noncurative surgical management of primary 
tumors in patients with stage IV CRC. Overall, the group treated with surgery experienced a 31% 
relative improvement in survival, with an absolute survival difference of approximately 4 months. 
A survival benefit of similar magnitude was demonstrated in the other reviews (51,52); however, 
a recent review did not support the surgical intervention (53). We found comparable survival 
benefit in studies using newer-generation chemotherapies and in minimally symptomatic patients. 
Notably, the pooled estimate for survival revealed considerable heterogeneity across the studies.  
Conceivably, those studies involved clinically heterogeneous groups with respect to patient 
population (age, performance status, co-morbid illnesses, disease burden, primary tumor related 
symptoms, for example) and co-intervention (type of systemic therapy, differing rate of 
metastasectomy). Likewise, considerable variability was noted across the different studies designs, 
and the risk of bias was suggestive of methodological diversity. Despite those limitations, we opted 
to report the pool result, because the direction of effect was consistent across the studies and 
subgroups albeit of varying different magnitude.   
Of special interest, a quantitative analysis excluding low-quality studies revealed a HR for survival 
of 0.64 (95% CI: 0.45-0.92) favoring surgical intervention (Figure 3.8). Because of selective 
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reporting and a lack of explicit information in some studies, examination of heterogeneity with 
respect to important clinical variables (with the exception of underlying symptoms and type of 
treatment) was not feasible. Notably, test for heterogeneity was no longer significant after 
exclusion from the pool of three studies that had either larger effect size or a very narrow 
confidence interval, suggesting statistical heterogeneity (Figure 3.9)[11,13,24].  Likewise, in the 
subgroup analysis, the test for heterogeneity was nonsignificant after exclusion of study by Glazia 
et al.  Because of the concern of publication bias, overestimation of the intervention effect relative 
to the true outcome is quite plausible.  
 
A high rate of postoperative complications can offset the survival benefit associated with surgery. 
Our review was limited by selective reporting of surgical mortality and morbidity across the 
included studies. Compared with patients having localized disease, those with advanced CRC 
tended to experience increased mortality after resection of the primary tumor. Although four of 
nine studies reported no postoperative mortality, the rate in some studies was not trivial, reaching 
up to 16%. As anticipated, a higher mortality rate has been associated with emergency surgery 
(21,23).  Fewer than half of the included studies reported nonfatal operative complications, and 
many failed to distinguish between major and minor complications, limiting the clinical relevance 
of the information.  
 
The mean rate of primary tumor complications was 27%, but reached as high as 63%. 
Complication rates of more than 50% were noted mostly in older studies.  Realistically, there is 
no evidence to suggest that response rates for the primary tumor are inferior to those for metastases. 
Three retrospective studies specifically investigated the risk of primary tumor complications in 
patients with non-resection management and reported complications rates between 3 and 17% (54-
56).   
 
When anti-vascular endothelial growth factor therapy is combined with cytotoxic agents in patients 
with an intact primary tumor, a concern about perforation risk arises (57). Two recent uncontrolled 
prospective studies did not support prophylactic resection of the primary tumor in minimally 
symptomatic patients treated with targeted therapy (58,59). In one cohort of 233 patients with 
intact primary tumor, only 7% of patients required emergency palliative surgery (58). Use of 
bevacizumab, primary tumor location, and metastatic disease burden were not associated with an 
increased intervention rate. The other phase II trial, which used an oxaliplatin and bevacizumab 
combination regimen, reported a 14% major complications rate related to the intact primary tumor 
(59). Median overall survival of the treated cohort was 19.9 months. The author concluded that 
survival is not compromised by leaving the primary colon tumor intact. The mean non-resection 
procedure rate was 28% in patients with an intact primary tumor, which accorded with the primary 
tumor complications rate of 30% reported by McCahill et al. (59). Only three studies reported non-
resection procedures in the intervention group, and as expected the numbers were much lower than 
those in the control group.  
 
Quality of life is an important outcome that helps patients and their physicians choose appropriate 
treatment. No study in our review reported QOL. Because major intestinal complications such as 
obstruction, perforation, and hemorrhage related to the primary tumor, and postoperative 
complications are likely to be associated with a significant adverse effect on QOL, QOL can be 
indirectly assessed by reviewing the rates of surgical and primary tumor complications. A surgical 
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intervention with a low complication rate could potentially result in a favorable QOL as a result of  
fewer non-resection interventions, lack of primary tumor related complications, and better 
tolerance for systemic therapy.  
 
Potential limitations of the present review are the substantial number of low-quality studies, 
publications bias, and selective reporting.  Importantly, all outcomes in the review were evaluated 
retrospectively, and patients were not randomized to surgery or non-surgical management. Several 
studies did not provide baseline prognostic characteristics for their groups, and others showed 
significant imbalance in baseline characteristics. Furthermore, few studies provided detail 
information about the use and type of systemic therapy in each group, making it difficult to assess 
the relative contribution of resection to outcomes. Those concerns affect the validity of the survival 
benefit observed in our review, which may simply reflect the selection of younger and healthier 
patients with good performance status and low disease burden for surgery.   
 
3.8 Conclusions 
 
The retrospective data favor resection of the primary tumors in patients with advanced CRC. 
However, the very low quality of the current evidence requires that good-quality cohort studies 
and adequately powered, well designed randomized trials be conducted to assess all the important 
outcomes in this patient population. We have begun a large population-based cohort study in the 
province of Saskatchewan, and European investigators are currently working on several 
randomized trials, including CAIRO 4, to resolve this matter.  
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Table 3.1: Study characteristics: Design, quality, population, interventions and outcomes of interest. 
 
Study & year 
of publication 
Study Design Duration 
of study & 
Country  
N Quality* 
 
Patients Co-interventions Outcomes 
        
Aslam et al, 
201021 
Retrospective 
multi-centers 
observational 
study 
1998-2007;    
UK 
T: 647            
I: 366            
C: 281 
low               
5/9 
minimally 
symptomatic 
chemotherapy      
I: 63%, C: 36%† 
median OS 14.5 (I) 
vs. 5.8 (c) months 
(p<0.05); POMRI 
7%; POCRI 32%; 
NRPC 46% 
Benoist  et al, 
200512 
Retrospective 
single 
institutional 
case-control 
study 
1997-2002; 
France 
 
T: 59              
I: 32              
C: 27 
fair               
6/9 
asymptomatic 
or minimally 
symptomatic 
chemo & novel 
therapy                  
I: 94%, C: 100%; 
metastasectomy  I: 
16%, C: 22% 
median OS 22 (I) 
vs. 23 (c) months 
(p=NS); POMRI 
0%; POCRI 22%; 
PTCRC 15%; 
NRPC 15% 
Chan et al, 
201022 
Retrospective 
population 
based study 
2000-2002;  
Canada 
T: 411            
I: 286              
C: 125 
low              
5/9 
symptomatic 
& 
asymptomatic  
chemotherapy      
I: 61%, C: 58%; 
novel therapy       
I: 57%, C: 36%; 
metastasectomy   
I: 10%, C: 0% 
median OS 14 (1) 
vs. 6 (c) months 
(p=<0.05); NRPC 
22%; NRPI 4% 
Evans et al, 
200923 
Retrospective 
single 
institutional 
observational 
study 
1999-2006;     
UK 
T: 97              
I: 45              
C: 52 
low         
4/9 
symptomatic 
& 
asymptomatic  
chemotherapy      
I: NP, C: 42%†; 
radiation therapy 
I: NP, C: 8% 
median OS 11 (I) 
vs. 7 (c) months 
(p=NS), POMRI 
16%; PTCRC 23%; 
NRPC 50%  
Galizia G et 
al, 200811 
Retrospective 
single 
institutional 
observational 
study 
1995-2005;   
Italy 
T: 65              
I: 42              
C: 23 
fair          
6/9 
asymptomatic 
or minimally 
symptomatic   
chemotherapy      
I: 100%, C: 
100%†; 
metastasectomy       
I: 12%, C: 4% 
Median OS 15.2 (I) 
vs. 12.3 (c) months 
(p=0.003); POMRI 
0%; POCRI 21% 
PTCRC 31%; 
NRPC 22% 
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Karoui M et 
al, 20118  
Retrospective 
multi-centers 
observational 
study 
1998-2007; 
France 
T: 208            
I: 123            
C: 85 
low       
5/9 
symptomatic 
& 
asymptomatic  
chemotherapy      
I: 100%, C: 99%; 
novel therapy                  
I: 89%, C: 93%; 
metastasectomy  I: 
23%, C: 29% 
Median OS 30.7 (I) 
vs. 21.9 (c) months 
(p=0.004); PTCRC 
27%; NRPC 27% 
Konyalian VR 
et al, 200724 
Retrospective 
single 
institutional 
cohort study 
1991-2002;  
USA 
T: 109            
I: 62              
C: 47 
low       
5/9 
symptomatic 
& 
asymptomatic  
chemotherapy†   I: 
71%,C: 60%; 
radiation therapy                  
I: 27%, C: 34% 
Median OS 12.5 (I) 
vs. 4.6 (c) months 
(p<0.05); POMRI 
5%; POCRI 20% 
PTCRC 57%  
Michel P et al, 
200425 
Retrospective 
single 
institutional 
observational 
study 
1996-1999; 
France 
T: 54              
I: 31              
C: 23 
low       
4/9 
asymptomatic 
or minimally 
symptomatic 
chemotherapy      
I: 97%,C: 100%; 
novel therapy                  
I: 80%, C: 83%; 
metastasectomy  I: 
NP, C: 9% 
Median OS 21 (I) 
vs. 14 (c) months 
(p=NS); POMRI 
0%;  PTCRC 35%  
Ruo L et al, 
20036 
Single 
institutional 
retrospective 
observational 
study 
1996-1999;   
USA 
T: 230            
I: 127               
C: 130 
low       
4/9 
asymptomatic 
or minimally 
symptomatic  
chemotherapy †  I: 
NP,C: 83%    
 
Median OS 16 (I) 
vs. 9 (C) months 
(p=<0.05); POMRI 
2%; POCRI  21%; 
PTCRC 29%  
Scoggins CR 
et al,19999 
Single 
institutional 
retrospective 
observational 
study 
1985-1997;  
USA 
T:89           
I:66               
C:23 
low       
4/9 
Symptomatic 
& 
asymptomatic  
No information 
was provided 
about other 
interventions 
Median OS 14.5 (I) 
vs. 16.6 (c) months 
(p=NS); POCRI 
30%; PTCRC 9%   
Seo JG et al 
201026 
Single 
institutional 
retrospective 
observational 
study 
2001-2008; 
South 
Korea 
T:277      
I:144         
C:83 
fair       
6/9 
asymptomatic 
or minimally 
symptomatic  
chemotherapy      
I: 100%, C: 100%; 
novel therapy                  
I: 85%, C: 82%; 
radiation therapy                  
I: 10%, C: 12% 
Median OS 22 (I) 
vs. 14 (c) months 
(p=NS); POMRI 
0%; POCRI 35%;  
PTCRC 19%; 
NRPC 7%; NRPI 
2%  
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Tebutt NC et 
al, 200310 
Single 
institutional 
retrospective 
observational 
study 
1990-2000;    
UK 
T:362  
I:208 
C:82 
low       
5/9 
symptomatic 
& 
asymptomatic  
Chemotherapy     
I: 100%, C:100%; 
novel therapy 0%; 
radiation therapy 
I: 10%, C: 18%; 
mestatasectomy  I: 
2%, C: 1% 
Median OS 14 (I) 
vs. 8.2 (c) months 
(p=NS); PTCRC 
19%;  NRPC 6.7%; 
NRPI 9.7% 
Temple et al, 
200413 
Population 
based study 
using SEERS 
& Medicare 
data 
1991-99;  
USA 
T:901
1 
I:6464 
C:254
2 
fair      
6/9 
65 yrs or older  
symptomatic 
& 
asymptomatic  
chemotherapy      
I: 47%, C: 31%; 
radiation I: 12%, 
15%; 
metastasectomy  I: 
5.2%, C: 1.3% 
Median OS 10 (I) 
vs. 3 (c) months  
(p<0.05); POMRI 
9%; PTCR 63%, 
NRPC 32% 
Venderbosch 
et al, 2011 
(CAIRO)7,49 
Retrospective 
multi-centers 
cohort of a 
RCT* 
2003-2004 
(recruited 
period); 
Netherland 
T:399 
I:258 
C:141 
fair      
6/9 
Symptomatic 
& 
asymptomatic  
100% novel 
therapy in both 
groups                                     
Median OS 16.7 (I) 
vs. 11.4 (c) months     
Venderbosch 
et al, 2011 
(CAIRO 2)7,50 
Retrospective 
multi-centers 
cohort of a 
RCT* 
2005-2006 
(recruited 
period); 
Netherland 
T:488 
I:289 
C:159 
fair      
6/9 
Symptomatic 
& 
asymptomatic  
100% novel 
therapy in both 
groups 
Median OS 20.7 (I) 
vs. 13.4 (c)months 
 
C=control group; I=intervention group; N=number; NP=not provided; NS=not significant; OS= overall survival; POMRI=Post-operative mortality rate 
intervention group; POCRI=Post-operative non-fatal complication rate intervention group; PTCRC= Primary tumor complication rate in control group; 
NRPC=Non resection procedures in control group; NRPI=Non resection procedures in intervention group;   T=total; UK= The United Kingdom; USA= The 
United States of America  *studies methodological quality was assessed by using Ottawa-Newcastle scale for non-randomized study, please see the text for score 
detail;  †Information about novel therapy (2nd and 3rd generation anti-cancer therapy) was not provided. 6 studies did not report post-operative mortality; 8 studies 
did not provide post-operative morbidity; 4 studies did not provide information on primary tumor complication rates; 6 studies did not provide any information 
on non-resection procedures in the control group and 12 studies did not provide information in the intervention group; no study provided information about 
quality of life.  
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Table 3.2: Baseline characteristics of the patients in the control and intervention groups.  
 
Patient 
Characteristics 
Totals 
N=12456 
Mean % (95% CI) 
Control group 
N=3796 (30.4%) 
Mean % (95% CI) 
Intervention group 
N=8620 (69.6%) 
Mean % (95% CI) 
 Median Age (range) 61 yrs (19-96) 63 yrs (19-96) 60 yrs (22-92) 
 Female*  41 (36.8-45.1) 38.7 (31.3-46.2) 43.5 (38.5-49.0) 
Rectal Tumor ** 26 (19.7-32.2)  31 (22.8-39.2) 21.9 (14.3-29.5) 
ECOG PS† >1 16.6 (7.9-25.2) 18.1 (2.5-33.7) 15 (3.0-27) 
>25% liver 
involvement‡                                        
54 (40-69)  54.7 (25.6-83.7) 54.2 (34.4-73.9) 
Peritoneal disease¥ 21.6 (13.3-30) 22 (2.3-41.7) 21.4 (6.5-36.3) 
Received RadiationѢ 16.2 (9.5-23.0) 17.4 (5.0-29.8) 14.8 (1.7-27.8) 
Received 
Chemotherapy††        
82 (73-92)  79.2 (63.3-95.1) 86.1 (73.6-98.6) 
 Single agent 
fluoropyrimidine‡‡  
88.6 (80-97.1) 88.1 (73.6-100) 89.0 (76.2-100) 
 2nd or 3rd generation 
therapy‡‡ 
64 (35-84)  66 (33.4-98.6) 67.2 (36.3-98.2) 
Underwent 
metastasectomy€ 
10.3 (4.6-16.1) 9.3 (0-18.2) 11.4 (3.5-19.3) 
 
ECOG= Eastern Oncology Cooperative Group Performance Status , *two studies did not provide gender distribution data9,23; ** 
two studies did not provide information about location of primary tumor23,24; †seven studies did not provide information about 
PS6,9,12,13,21,23,24; ‡ six studies provided information about extent of liver involvement6,11,12,21,25,26; ¥ Five studies provided 
information about peritoneal disease8,10,21,25,26; Ѣ Five studies provided data reading palliative radiation10,13,23,24,26; ††one study 
did not provide information about chemotherapy9; ‡‡six studies did not provide information6,11,13,21,23,24; € seven studies provided 
information8,0,11-13,22,25. 
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Table 3.3:  Evidence profile and summary of primary and secondary outcomes.  
 
Outcomes Number 
(studies)  
Control 
Group 
(range) 
Intervention 
Group 
(range) 
Quality 
of 
Evidence 
GRADE
20 
Comments 
Median overall 
survival in months 
(range) 
12,456  
(15 studies) 
11.4 (3-22) 15.2 (10-30.7) very low HR for survival 0.69 (95% CI: 
0.61-0.79) favoring the 
intervention group. Significant 
imbalance in patients 
characteristics; most studies did 
not provide information on 
performance status and co-
morbid illnesses 
Quality of life (QOL) 0 See 
comments 
see comments NA All studies were retrospective & 
QOL was not measured in any 
study 
Mean Surgical 
mortality rate % (95% 
CI) 
10,499 
(9 studies) 
NA 4.9 (0-9.7) low 4 studies reported 0 post-
operative mortality, mortality 
rate of >5% was noted in the 
older studies 
Mean Surgical 
morbidity rate (95% 
CI) 
1,426 
(7 studies) 
NA 25.9 (20.1-31.6) very low For post-operative complications 
most studies did not distinguish 
between major and minor  
complications 
Primary tumor 
complications rate % 
(95% CI) 
10,511 
(11 studies) 
29.7 (18.5-
41.0) 
NA very low 6 of 12 studies had both 
symptomatic & asymptomatic 
patients 
Mean non-surgical 
procedure rate % 
(95%CI)* 
10,725 
(9 studies) 
27.6 (15.4-
39.9) 
4.2 (0-10.1) 
See comments 
very low Only 3 studies (n=862) provided 
non-resection procedure rate in 
the intervention group  
 
 
NA=not applicable; *Non-surgical procedures include bypass surgery and placement of stent  
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Table 3.4: Primary and secondary outcomes in subgroups of patients with respect to 
patients population and interventions. 
 
Subgroups  Mean 
Survival 
months 
(95% CI) 
Hazard Ratio 
for survival 
(95% CI) 
Post-
operative 
mortality % 
(95% CI) 
I 
 
Non-fatal 
post-
operative  
complicati-
ons %          
(95% CI) I 
Primary 
tumor 
complicati
-ons % 
(95% CI)  
C 
Non-
surgical 
procedure 
% 
(95% CI)  
C 
QOL
Ђ 
Asymptomatic or 
minimally 
symptomatic 
patients 
  
 
     
  Intervention 18.6         
(14.6-22.6) 
0.67  
(0.48-0.94)‡ 
1.6 
(0-4.8) 
25.6 (5.9-
45.2) 
NA 2*  
  Control 12.8  
(7.1-18.6) 
0.78  
(0.72-0.84)† 
NA NA 25  
(15.3-36.1) 
22.2  
(0-49.1) 
 
Symptomatic and 
asymptomatic 
patients 
       
  Intervention 16.0 
(11.1-20.9) 
0.75  
(0.67-0.84)‡‡ 
10 
(0-23.8) 
25 (12.6-
37.4) 
NA 5.3 (2-8.7)  
  Control 10.0 
(5.1-14.9) 
0.79               
(0.70-0.90)†† 
NA NA 27 
(7.5-46.5) 
32.8 
(13.3-52.2) 
 
Studies with 2nd & 
3rd generation 
therapy  
       
  Intervention 18.9         
(14.8-23.0) 
0.68 
(0.56-0.83)ђ 
3.9  
(0-11) 
27.4 (16.4-
38.5) 
NA 3 (0-5.5)  
  Control 12.8           
(8.6-17.0) 
0.75 
(0.67-84)Ѣ 
NA NA 25  
(17-33) 
27  
(12.5-41.6) 
 
Studies with 1st 
generation therapy 
       
  Intervention 13.4 
(10.6-16.2) 
0.73 
(0.59-0.90)ђђ 
5.3 
(0-14.1) 
23.7 (10-
37.4) 
28.2 
(2.5-53.9) 
6.7**  
  Control 8.1 
(1.7-14.8) 
0.81 
(0.72-0.92)ѢѢ 
NA NA NA 32**  
 
I: intervention group, C: control group, QOL: quality of life; NA=not applicable. Ђ non study report QOL; * only 1 of 6 studies 
reported non-resection surgical procedure in the intervention group; *only one of 5 studies reported non-resection procedure in 
the intervention group & control group; ‡ test for heterogeneity was significant for data using 6 studies, †test for heterogeneity 
was not significant after excluding the data from study by Galizia et al11; ‡‡ test for heterogeneity was significant for data using 9 
studies, †† test for heterogeneity was not significant after excluding the data from studies by  Konyalian et al24, Temple et al13, 
and CAIRO7; ђ test for heterogeneity was significant for data using 10 studies, Ѣ test for heterogeneity was not significant after 
excluding the data from study by Aslam et al21,Galizia et al11; ђђ test for heterogeneity was significant for data using 5 studies, 
ѢѢ test for heterogeneity is not significant after excluding the data from study by Konyalian et al24. 
58 
 
Figure 3.1: Flow of information through the different phases of literature search.  
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Figure 3.2: Funnel plot shows asymmetry of studies around the point estimate, suggestive 
of publication bias. 
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Figure 3.3: Hazard ratio with 95% confidence interval for overall survival, all reviewed 
studies, favors the intervention group.  
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Figure 3.4: Sensitivty analysis of overall survival for seven studies reported a hazard ratio 
favoring the intervention group. 
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Figure 3.5: Sensitivity analysis of overall survival, excluding the stuy by Temple et al. 
favors the intervention group.  
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Figure 3.6: Hazard ratio with 95% confidence interval for overall survival, subgroups 
based on type of chemotherapy. 
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Figure 3.7: Hazrad ratio with 95% confidence interval for overall survival, subgroups 
based on extent of the symptoms. 
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Figure 3.8: Hazrad ratio with 95% confidence interval for overall survival in the 
subgroups, based on a score of “fair” on Ottawa-Newcastle Score. 
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Figure 3.9: Hazrad ratio with 95% confidence interval for overall survival, twelve studies 
(excluding three with a large effect size or narrow confifedence interval), favors the 
intervention group with low heterogeneity.  
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CHAPTER 4 – COHORT STUDY (1992-2005): PRIMARY TUMOR 
RESECTION IN METASTATIC COLORECTAL CANCER 
 
Although the retrospective data favors primary tumor resection in patients with stage IV CRC, 
many studies failed to provide baseline characteristics of patients in both groups. Others studies 
showed significant differences between the two groups and failed to control for the differences.  
Hence, validity of survival benefit observed in these studies has been questioned and is believed 
to be biased by the selection of healthier and younger patients for surgery. The current very low 
quality evidence necessitates the future need of good quality cohort studies and well-designed 
randomized trials assessing important outcomes. In the absence of randomized controlled trial, we 
undertook this study to investigate the optimal management of primary tumor in patients diagnosed 
with stage IV CRC cancer.  
 
This chapter addresses the study objective “to compare survival of patients with stage IV CRC 
who underwent primary tumor resection with the patients who did not have surgery and to 
determine the prognostic importance of surgery of the primary tumor in patients with stage IV 
CRC.” The study findings were presented in January 2013 at the Gastrointestinal Cancer 
Symposium in San Francisco, USA. Notably, our study met the criteria for good quality study and 
scored 9 of 9 for overall survival, in the Newcastle-Ottawa Quality Assessment Scale, the validity 
scoring for observational study (Appendices F and O). The results were published in the Cancer 
“Ahmed S, Leis A, Fields A, Chandra-Kanthan S, Haider K, Alvi R, Reeder B, Pahwa P. Survival 
impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: Results 
from a large population-based cohort study. Cancer. 2014 Mar 1; 120(5):683-91.” 
 
4.1 Abstract 
 
Background: Currently, there is very low-quality evidence available regarding benefit of primary 
tumor resection, in patients with stage IV CRC. In the absence of randomization, the reported 
benefit may reflect selection of younger and healthier patients with good performance status.  A 
large population-based cohort study was undertaken to determine the survival benefit of primary 
tumor resection in advanced CRC by eliminating various biases reported in the literature.  
 
Methods: A retrospective cohort study involving patients with stage IV CRC, diagnosed between 
1992 and 2005, in the province of Saskatchewan, Canada. Survival was estimated by using the 
Kaplan-Meier method. Survival distribution was compared by the log-rank test. Cox proportional 
multivariate regression analysis was performed to determine survival benefit of primary tumor 
resection by controlling other prognostic variables.  
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Results: A total of 1378 eligible patients were identified. Their median age was 70 years (range: 
22-98) and male: female ratio was 1.3:1; 944 (68.5%) of them underwent primary tumor resection. 
Among 1378 patients, 42.3% received chemotherapy and 19.1% received second-generation 
therapy. Patients who underwent surgery and received chemotherapy had median overall survival 
of 18.3 months (95% CI: 16.6-20) compared with 8.4 months (95% CI: 7.1-9.7) if they were treated 
with chemotherapy alone (p<0.0001). Cox proportional analysis revealed that use of chemotherapy 
(HR 0.47, 95% CI: 0.41-0.54), primary tumor resection (HR 0.49, 95% CI: 0.41-0.58), second-
line chemotherapy (0.47, 95% CI: 0.45-0.64), and metastasectomy (HR 0.54, 95% CI: 0.45-0.64) 
were correlated with superior survival. 
 
Conclusions: Primary tumor resection improves survival in patients with stage IV CRC, 
independent of other prognostic variables including age, performance status, comorbid illness and 
chemotherapy.  
 
4.2 Introduction 
 
Whereas surgery is the primary treatment of localized CRC, resection of the primary tumor in 
patients with incurable metastatic disease is usually recommended for palliative purposes to 
manage obstruction, perforation, or bleeding. Only a subset of patients with limited liver and or 
lung metastases can be cured with multimodality therapy. Complete resection of the primary tumor 
with metastatic lesions, in these patients, has been associated with durable remission in about 40% 
cases (1). The role of surgical resection of the primary tumor in patients with newly diagnosed 
incurable stage IV colorectal cancer remains controversial. Despite uncertain survival benefit, a 
high rate of surgical resection has been reported in patients with unresectable metastatic disease 
(2). Currently, there is very low-quality evidence available regarding survival benefit of resection 
of primary tumor, in patients with stage IV CRC and otherwise unresectable metastatic lesions. 
Although some have advocated for surgery (3,4), other have failed to demonstrate survival benefit 
with resection of primary tumor in patients with stage IV CRC (5,6). A recent meta-analysis of 
literature involving 15 observational studies revealed 31% reduction in mortality (HR: 0.69, 95% 
CI: 0.61-0.79) with surgical resection of the primary tumor, with an absolute difference in median 
survival of approximately 4 months (7,8). Notably, comparable survival benefits were noted in 
studies using newer generation chemotherapy versus older regimen, and in minimally symptomatic 
or asymptomatic patients versus symptomatic patients. Nevertheless, in the absence of 
randomization, the reported benefit may reflect selection of younger and healthier patients with 
good performance status. Taking selection bias into consideration, recent observational studies do 
not advocate surgery and suggest that outcomes are not compromised, by leaving the primary colon 
tumor intact, in patients treated with modern chemotherapy (9,10). 
  
To date, no randomized trial has assessed the survival impact of primary tumor resection, in 
patients with stage IV CRC. In the absence of randomized controlled trial, this study was 
undertaken to investigate the optimal surgical management of patients diagnosed with stage IV 
CRC cancer, by controlling for various know confounding factors including age, comorbid illness, 
performance status and other important prognostic variables.  
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4.3 Study Objectives 
 
The primary objective of this study was to compare survival of patients diagnosed with stage IV 
CRC, who underwent primary tumor resection, with that of patients who did not have surgery. The 
secondary objectives were as follows: 1) to compare survival of patients with stage IV CRC who 
were treated with chemotherapy and underwent resection of the primary tumor, with the survival 
of patients who did not have surgery; 2) to compare survival of asymptomatic or minimally 
symptomatic patients with stage IV CRC, who underwent surgical resection of the primary tumor, 
with the patients who did not have surgery; and 3) to determine survival benefit of primary tumor 
resection by controlling for various clinicopathological variables that affect the outcome of 
patients with metastatic CRC.   
 
4.4 Methods 
 
4.4.1 Study Population  
 
The study protocol was approved by the Research Ethics Board of the University of Saskatchewan, 
Canada. The study population was composed of a cohort of patients 18 years or older, with 
histologically documented adenocarcinoma of colon and rectum, intact primary tumor, and 
evidence of metastases (stage IV colorectal cancer), who were diagnosed between the period of 
1992 and 2005, in the province of Saskatchewan. Patients with other histological diagnosis or with 
other active secondary malignancy or with fixed inoperable primary tumor at the time of diagnosis 
were excluded. The Saskatchewan Cancer Registry database is prospectively collected and 
updated. Eligible patients were identified from the Saskatchewan Cancer Registry. All medical 
records were individually reviewed, and data was abstracted by a trained research associate, using 
a pre-specified and validated abstraction sheet. 
 
4.4.2 Sample Size 
 
Because a high rate of primary tumor resection has been reported in the literature, assuming two-
thirds of patients in Saskatchewan underwent resection of primary tumor, a ratio of 1:2 was used 
for the non-resection group versus the resection group. Using a power of 90%, type 1 error of 0.05 
with two sided P-value, and survival difference of 20% in the two groups (resection vs. non-
resection) with a follow up period of 60 months, a total sample size of 959 patients was estimated 
(326 in the non-resection group and 633 patients in the resection group).   
 
4.4.3 Analysis of Primary and Secondary Endpoints 
 
Overall survival was defined as “time from the diagnosis of stage IV CRC to death from any 
cause.” Patients who did not die at the end of the follow-up period, or were lost to follow-up during 
the study, were censored at the last date they were known to be alive. Survival of the entire cohort 
and subgroups was estimated by using the Kaplan-Meier method. Survival distribution of different 
groups was compared by the log-rank test. The overall significance level was set at 0.05. A 
multivariate analysis was performed to determine the prognostic significance of primary tumor 
resection in patients with stage IV CRC. The Cox proportional hazard model was used and the 
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hazard ratio and its 95% CI were estimated. Following variables were examined with respect to 
their prognostic significance: Resection of primary tumor, age (<65 vs. ≥65), gender, major 
comorbid illness, ECOG performance status (<2 vs. ≥2), smoking, sodium level (≤135 mEq/l vs. 
>135 mEq/l), serum creatinine (≥120 vs. <120 mm/l), BUN (≥8 vs. <8 mm/l), albumin (≥36 vs. 
<36 g/l), bilirubin (≥26 vs. <26 mm/l), alkaline phosphatase (≥120 vs. <120 U/l), hemoglobin 
(≥120 vs. <120 g/l), WBC (≥11 vs. <11 x 109/l), platelet (≥450 vs. <450 x109/l), CEA (≥6 vs. <6 
mcg/l),  site (colon vs. rectal), grade (Grade 3 vs. <3), symptomatic disease, extrahepatic 
metastases, disease burden (patients with metastasis confined to one organ or site vs. metastases 
in more than one organ or site), metastasectomy, use of chemotherapy, second-line chemotherapy 
and second-generation chemotherapy. For the variables examined in the final mathematical model, 
the proportional hazards assumption was assessed using log-log survival curves. 
 
The asymptomatic or minimal symptomatic disease was defined as absence of obstruction, 
perforation or bleeding. Major comorbid illnesses were defined as presence of coronary artery 
disease, diabetes mellitus, chronic renal insufficiency, chronic obstructive lung disease and others 
(uncontrolled hypertension, peripheral vascular disease, stroke or transient ischemic attack, 
interstitial lung disease, congestive heart failure, cardiac arrhythmia, among others). Post-
operative mortality was defined as death that occurred within 30 days of surgery. Second- 
generation therapy was defined as use of bevacizumab or the anti-epidermal growth factor receptor 
antibodies cetuxiamb or panitumumab and or oxaliplatin or irinotecan based therapy (FOLFOX or 
FOLFIRI). 
 
All variables with P<0.05, on univariate analysis, were examined, in a multivariate model, to assess 
their correlation with survival. A best-fitted but a most parsimonious model was built by 
identifying the important predictors for survival. The likelihood ratio test and t test were used to 
determine if the addition of independent variables of interest add significantly to the prediction of 
survival in the model. Test for interaction was performed for resection of primary tumor and all 
the variables that were significantly correlated with survival. An imputation technique was used 
for missing data. A two-sided P-value of <0.05 were considered to be statistically significant. SPSS 
versions 20.0 & 21.0, were used for statistical analysis (SPSS Inc. Chicago, IL). 
 
4.5 Results 
 
4.5.1 Patients’ Characteristics  
 
A total 1378 eligible patients were identified (Figure 4.1). Their median age was 70 years (range: 
22-98) and male-to-female ratio was 1.3:1. Seven-hundred eighty one (56.7%) patients were male, 
1,005 patients (72.9%) had ECOG performance status of <2, 856 (62.1%) patients had a comorbid 
illness, and 204 (14.8%) patients had a history of secondary malignancy. Patients’ characteristics 
are described in Table 4.1.  A significance difference was noted between the two groups with 
respect to age, performance status, extrahepatic disease, mean serum albumin, alkaline 
phosphatase, bilirubin, BUN, CEA, and WBC count. As expected, patients in the surgical group 
tended to be younger with better performance status and organ function and less likely to have 
extrahepatic disease.      
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Of 1378 patients, 29.5% had rectal or rectosigmoid tumor (rectal, 20.1%, rectosigmoid, 9.4%). 
One hundred ninety-seven (14.3%) patients had mucinous tumor. A total of 544 patients (39.5%) 
were symptomatic, among whom 454 (83%) had obstructive symptoms, 87 (16%) developed 
bowel perforation, and 56 (10%) had major bleeding (drop in hemoglobin of ≥20 gm/l or required 
blood transfusion). Symptoms were not mutually exclusive. One thousand thirty-eight (75.3%) 
patients had liver metastases and 698 (50.7%) had extrahepatic metastases. Among 698 patients 
with extrahepatic disease, 217 (31%) had lung metastases, 205 (29.3%) had peritoneal 
involvement, 31 (4.4%) had bony metastases, and 9 (1.3%) patients had documented brain 
metastases.  
 
4.5.2 Interventions 
 
Of 1378 patients, 944 (68.5%) underwent resection of the primary tumor and 434 (31.5%) did not 
have surgery. Five hundred and eighty-three (42.3%) patients received 5-fluorouracil based 
chemotherapy (Table 4.1). Of 583 patients, 222 (38%) patients, on progression, were treated with 
second-line chemotherapy mostly oxaliplatin- and/or irinotecan-based therapy with or without 
biologics.  A significantly higher number of patients in the surgical group were treated with 
chemotherapy, or received second-line or newer generation chemotherapy. Likewise, a 
significantly higher number of patients in the surgical group underwent metastasectomy.  
 
4.5.3 Follow-up and Survival  
 
Median follow-up time was 7.1 months (interquartile range 2.5-17.5 months) for the whole cohort. 
There was no loss of follow-up in both groups. Median survival of whole cohort of patients who 
underwent primary tumor resection was 10.6 months (95% CI: 9.5-11.7) compared with 3.0 
months (95% CI: 2.5-3.5) of patients who did not have surgery (P<0.0001).  Overall 30-day 
mortality rate in the surgical group was 6.6%. Median survival of cohort of patients who received 
chemotherapy was 15.9 months (95% CI: 14.5-17.3). Patients who underwent primary tumor 
resection and received chemotherapy had median overall survival of 18.3 months (95% CI: 16.6-
20) compared with 8.4 months (95% CI: 7.1-9.7) if they were treated with chemotherapy alone 
(p<0.0001; Figure 4.2). In a subgroup of patients who were treated with second-generation 
chemotherapy, median survival of patients who underwent primary tumor resection was 24.6 
months (95% CI: 20.2-29.0) versus 11.0 months (95% CI: 7.8-14.3) if they did not have surgery 
(p<0.0001).  
 
The median survival of subcohort of 834 asymptomatic or minimally symptomatic patients who 
were treated with chemotherapy and underwent primary tumor resection was 18.3 months (95% 
CI: 16.6-20.0) compared with 8.4 months (95% CI: 7.1-9.7) if they did not have surgery 
(p<0.0001) [Figure 4.3]. After excluding the patients who underwent metastasectomy, median 
survival of patients who underwent primary tumor resection was 15.2 months (95% CI: 13.5-16.9) 
compared with 8.3 months (95% CI:71.-9.6) if they did not have surgery (p<0.0001).  
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4.5.4 Multivariate Analysis 
 
On univariate analysis various clinicopathological factors were identified that were correlated with 
survival (Table 4.2). Among them, ECOG performance status of >1 was most strongly correlated 
with a poor survival, whereas use of chemotherapy was most strongly correlated with better 
survival. Tests for interaction between surgical resection of primary tumor and age, performance 
status, CEA level, second-line therapy or more than one metastatic sites were significant. Primary 
tumor resection was associated with better survival in younger patients, patients with good 
performance status, normal CEA level, patients treated with second-line therapy and patients with 
one metastatic site. For instance, unadjusted HR for mortality in patients 65 years or younger was 
0.28 (95% CI: 0.22-0.36) compared with 0.48 (95% CI: 0.42-0.55) in older patients in relationship 
with primary tumor resection. Likewise, with respect to surgery, unadjusted HR for mortality in 
patients with metastasis confined to one organ or site was 0.36 (95% CI 0.31-0.42) compared with 
HR of 0.56 (95% CI 0.45-0.68) in patients with metastases involving more than one organ or site. 
Cox proportional multivariate regression analysis using interaction terms revealed that use of 
chemotherapy (HR 0.47, 95% CI: 0.41-0.54), primary tumor resection (HR 0.49, 95% CI:0.41-
0.58), second-line chemotherapy (0.47, 95% CI: 0.45-0.64), and metastasectomy (HR 0.54, 95% 
CI: 0.45-0.64) were correlated with a favorable survival in patients with advanced CRC, whereas 
older age, poor performance status, low albumin, elevated bilirubin, elevated alkaline phosphatase, 
anemia, leukocytosis, colonic primary, and Grade 3 tumor were correlated with inferior survival 
(Table 4.3, Figure 4.4). After controlling for the other significant or clinically important variables, 
only the interactions between primary tumor resection and second-line therapy, or more than 2 
metastatic sites, were significant. Because approximately 86% patients who were treated with 
second-line therapy received second-generation chemotherapy, in order to avoid multicollinearity, 
second-generation therapy was not included in the final model. In a secondary analysis, after 
excluding 198 patients who underwent metastasectomy, primary tumor resection significantly 
correlated with better survival (HR, 0.43; 95% CI: 0.41-0.52). After adjusting for other important 
prognostic variables in a Cox proportional multivariate model, the HR for survival with primary 
tumor resection was 0.54 (95% CI: 0.48-0.62).  
   
4.6 Discussion 
 
This is the first large population-based cohort study that demonstrated survival advantage of 
surgical resection of primary tumor, in patients with stage IV CRC, independent of other important 
prognostic factors including age, performance status, comorbid illness and chemotherapy. Several 
studies previously have shown survival benefit of resection of the primary tumor. However, many 
studies did not provide baseline characteristics of patients in each group, whereas others showed 
significant differences between the two groups and failed to control for the differences (7,8).  
Hence, validity of survival benefit observed in these studies has been questioned and is believed 
to be biased by the selection of healthier and younger patients for surgery. Despite significant 
differences in the baseline characteristics between the two groups in the study cohort, when these 
variables were included in a multivariate model, primary tumor resection remained an important 
prognostic variable and was associated with 51% relative reduction in mortality when adjusted for 
age, performance status, comorbid illnesses, chemotherapy, metastasectomy, second-generation 
chemotherapy, disease burden and various other important prognostic factors. Notably, survival 
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differences between the two groups (resection versus non-resection), within the study cohort and 
various sub-groups, were consistently more than 6 months (range: 7.6 to 13.6 months).  
 
There is a general agreement that patients with evidence of perforation, significant obstruction, or 
uncontrolled bleeding should undergo resection of the symptomatic tumor. However, primary 
tumor resection, in patients with asymptomatic or minimally symptomatic disease and otherwise 
unresectable metastases, is not recommended. In the study cohort, about 60% of patients, were 
asymptomatic or had minimal symptoms. These patients had comparable survival benefit with 
surgical intervention. Moreover, the surgical intervention was independently associated with a 
survival benefit, after controlling for other important prognostic variables (analysis is not shown).  
 
Modern chemotherapy regimens incorporating novel cytotoxic and biologic agents have been 
associated with high response rates of 40-50% (11). Although only about 19% of the study cohort 
was treated with modern chemotherapy, the magnitude of benefit of surgical intervention was 
substantially higher in a subgroup of patients who were treated with second-generation and or 
second-line chemotherapy. In the study cohort, less than 2% of patients received biologics 
therapeutics including bevacizumab or the anti-epidermal growth factors receptor (EGFR) 
monoclonal antibodies such as cetuximab or panitumumab, hence, a subgroup analysis was not 
feasible. Nevertheless, a retrospective analysis of a Dutch trial that primarily assessed the efficacy 
of combination of chemotherapy and biologics, demonstrated a superior survival with surgical 
resection of primary tumor (3). In a subgroup of patients who underwent primary tumor resection, 
a significantly better median overall survival of 20 months was observed compared with 13.4 
months for the patients in the non-resection group, (P<0.0001; HR 0.65, 95% CI 0.52–0.80). 
Likewise, a pooled analysis of four French trials including study involving targeted therapy 
demonstrated 37% reduction in mortality (HR: 0.63, 95% CI: 0.53-0.75) with primary tumor 
resection (12). Therefore, evidence supports comparable benefit of resection of the primary tumor 
in patients treated with modern regimens. Notably, the tests for interactions between primary tumor 
resection and second-line therapy or disease burden were significant after adjusting for other 
variables, suggesting that patients who received second-line therapy or who had metastasis 
confined to one organ or site tend to get most benefit from surgical removal of primary tumor.   
 
The underlying mechanism of potential survival benefit with removal of the primary tumor is not 
known. It is well known that surgical resection of primary tumor, in some cancers, such as 
advanced ovarian and renal cell cancer, has been associated with significant survival benefit 
(13,14). The primary tumor may secrete cytokines that promote tumor growth and reduce response 
to cytotoxic agents (15). Moreover, noncurative resection of the primary tumor in patients with 
advanced cancer may prevent local tumor complications, improve disease control by reducing the 
tumor bulk, and tolerance to systemic therapy.  
 
A variety of clinical parameters such as age, performance status, WBC count, hemoglobin, serum 
albumin, alkaline phosphatase, CEA, pathological grading or localization of the primary tumor 
have been identified as prognostic markers in patients with stage IV CRC (16-19). In the study 
cohort, in addition to resection of primary tumor, use of 5-FU based chemotherapy, second-line 
chemotherapy, metastasectomy, older age, performance status, colonic primary, high-grade tumor; 
and baseline elevated alkaline phosphatase, bilirubin, anemia and leukocytosis were independently 
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correlated with survival. As expected, significantly more patients were diagnosed with a rectal or 
rectosigmoid tumor, in the control group. Despites that, for reason not clear, patients with rectal 
or rectosigmoid tumors compared with more proximal tumor had better survival. Frerrand and 
colleagues reported a similar observation in their retrospective analysis of FFCD 9601 trial (20).  
These differences in patient survival were maintained after exclusion of patients with rectal 
primary.  
 
To our knowledge, this is the only large population-based cohort study that examined age, co-
morbid illness, performance status, serum albumin, and other important clinical variables in a 
multivariate model and demonstrated survival benefit of primary tumor resection independent of 
other variables. One of the limitations of the current study is that it did not assess BRAF mutation, 
which is an important prognostic marker in stage IV CRC. In addition, disease burden was not 
measured in patients with single versus multiple site metastases. Hence, better survival secondary 
to selection of patients with low disease burden, who have better prognosis, cannot be eliminated.  
 
In summary, this well-designed population-based cohort study, with minimal selection and 
information biases, supports primary tumor resection in patients with stage IV CRC, independent 
of other important prognostic factors. In addition to systemic therapy and metastasectomy, primary 
tumor removal was associated with better survival. A Dutch randomized controlled trial (CARIO 
4) assessing survival benefit of primary tumor resection in patients with advanced CRC, with 
estimated improvement in median survival from 13 month to 19 months, once completed, will be 
valuable to confirm our findings (21).  
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Table 4.1: Baseline characteristics of patients in the two groups: patients who underwent 
primary tumor resection and the control group who did not have surgery.  
 
Variables 
Mean ±standard 
deviation 
(%) 
Total patients 
 
N=1378 
Surgical 
Group 
N=944 
Control 
 
N=434 
P value 
Age years 68.8±12.2 68.4±12.6 70±11.5 0.018 
Age >65 years 925 (67.1) 617 (65) 308 (71) 0.04 
Male 781 (56.7) 523 (55.4) 258 (59.4) 0.16 
Comorbid illness 514 (37.3) 362 (38.3) 152 (35) 0.26 
ECOG PS ≥2 373 (27.1) 207 (21.9) 166 (38.2) <0.001 
Active smoker 178 (12.9) 118 (12.5) 60 (13.8) 0.38 
Rectal tumors* 407 (29.6) 242 (25.6) 165 (38.1) <0.001 
Grade 3 cancer 271 (19.7) 202 (21.4) 69 (15.9) 0.01 
Extra-hepatic disease 698 (50.7) 455 (48.2) 243 (56) 0.004 
Metastases≥2 sites 408 (29.6) 247 (26.2) 161 (37.1) <0.001 
Symptomatic disease 544 (39.5) 423 (44.8) 121 (27.9) <0.001 
 Albumin g/l 34.1±5.4 34.7±5.6 32.8±4.8 <0.001 
Alkaline phosphatase  192±242 179.6±239.9 221.1±245.9 0.003 
Bilirubin mm/l 13.7±24.6 11.9±18.7 17.5±33.7 <0.001 
BUN 6.0±4.9 5.7±4.3 6.6±5.8 0.003 
Creatinine  89.2±32.1 88.4±32.2 90.9±31.9 0.19 
CEA  260±1554 197±894 398±2433 0.026 
Hemoglobin g/l 117.9±15.8 117.8±15.4 118.2±16.5 0.65 
Sodium  138±3 138±3 137±3.9 0.77 
White blood cell count  9.2±4.0 8.9±3.9 9.8±4.1 <0.001 
Received 5FU –based 
chemotherapy 
583 (42.3) 469 (49.7) 114 (19.6) <0.001 
Received 2nd line 
chemotherapy 
222 (16.1) 185 (19.6) 37 (8.5) <0.001 
Received 2nd generation 
chemotherapy 
263 (19.1) 203 (21.5) 60 (13.8) <0.001 
Received radiation 190 (13.8) 124 (13.1) 66 (15.2) 0.17 
Metastasectomy  198 (14.4) 183 (19.4) 15 (3.5) <0.001 
*Rectum or recto-sigmoid disease 
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Table 4.2: Univariate correlation between various clinicopathological variables and overall 
survival in patients with stage IV colorectal cancer.  
 
Variables Unadjusted 
Hazard Ratio 
95% Confidence 
Interval 
P value 
 
Age >65 years 1.45 1.29-1.62 <0.001 
Male 1.04 0.93-1.16 0.52 
Comorbid illness 1.21 1.09-1.36 0.001 
ECOG PS ≥2 2.51 2.22-2.84 <0.001 
Active smoker 1.16 1.04-1.29 0.008 
Extra-hepatic disease 1.10 0.99-1.23 0.078 
Symptomatic disease 1.10 0.98-1.22 0.10 
 Albumin <35 g/l 2.20 1.96-2.46 <0.001 
Alkaline phosphatase ≥ 120 IU 1.52 1.35-1.71 <0.001 
Bilirubin ≥26 mm/l 2.46 1.95-3.10 <0.001 
Sodium <136 meq/l 1.51 1.29-1.76 <0.001 
BUN  ≥8 mm/l 1.29 1.08-1.54 0.008 
Creatinine ≥120 mm/l 1.31 1.07-1.60 0.009 
CEA  ≥ 6 mcg/l 2.42 2.03-2.87 <0.001 
Hemoglobin <120 g/l 1.46 1.31-1.63 <0.001 
Platelets ≥450 x 109/l 1.03 0.88-1.19 0.72 
White blood cell count ≥11 x 109/l 1.79 1.56-2.06 <0.001 
Colon Cancer 1.18 1.05-1.33 0.005 
Grade 3 cancer 1.26 1.10-1.45 0.001 
Mucinous cancer 0.97 0.83-1.13 0.70 
Metastases ≥2 sites 1.5 1.3-1.6 <0.001 
Received 5-FU-based chemotherapy 0.33 0.29-0.37 <0.001 
Received 2nd line chemotherapy 0.42 0.36-0.48 <0.001 
Received 2nd generation chemotherapy 0.45 0.89-0.52 <0.001 
Surgical resection of primary tumor 0.40 0.36-46 <0.001 
Metastasectomy  0.37 0.31-0.43 <0.001 
Diagnosed ≥ Jan 1st 2000 0.94 0.85-1.1 0.94 
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Table 4.3: Multivariate correlation between various clinicopathological variables and 
overall survival, using Cox regression analysis, in patients with stage IV colorectal cancer.  
 
Variables Hazard Ratio 95% Confidence 
Interval 
P value 
 
Age >65 years 1.37 1.10-1.70 0.005 
Male 1.02 0.92-1.15 0.68 
Comorbid illness 1.09 0.97-1.22 0.14 
ECOG PS ≥2 1.44 1.26-1.64 <0.001 
 Albumin <35 g/l 1.50 1.32-1.71 <0.001 
Alkaline phosphatase ≥ 120 IU 1.41 1.23-1.61 <0.001 
Bilirubin ≥26 mm/l 1.47 1.15-1.89 0.002 
Hemoglobin <120 g/l 1.17 1.04-1.32 0.01 
White blood cell count ≥11 x 109/l 1.33 1.15-1.55 <0.001 
Colon Cancer 1.20 1.06-1.35 0.004 
≥Two metastatic sites 1.02 0.83-1.23 0.88 
Grade 3 cancer 1.37 1.19-1.57 <0.001 
Received 5-FU-based 
chemotherapy 
0.47 0.41-0.54 <0.001 
Received 2nd line chemotherapy 0.47 0.33-0.67 0.001 
Surgical resection of primary 
tumor 
0.49 0.41-0.58 <0.001 
Metastasectomy  0.54 0.45-0.64 <0.001 
*Median value was used for cut off.  
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Figure 4.1: Flow diagram of eligible patients with stage IV colorectal cancer patients who 
underwent surgical resection of the primary tumor or did not have surgery. 
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Figure 4.2: Kaplan-Meier survival curves are shown of (4.2A) patients who received 
chemotherapy and underwent resection of the primary tumor versus no surgery or (4.2B) 
patients who received second-generation chemotherapy and underwent resection of the 
primary tumor versus no surgery.   
 
Figure 4.2A: 
 
Figure 4.2B: 
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Figure 4.3: Kaplan-Meier survival curves of (3A) asymptomatic patients who received 
chemotherapy and underwent resection of the primary tumor versus no surgery or (3B) 
asymptomatic patients who received second-generation chemotherapy and underwent 
resection of the primary tumor versus no surgery. 
 
Figure 4.3A: 
 
 
 
Figure 4.3B:  
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Figure 4.4: Adjusted hazard ratios for survival in relationship with various 
clinicopathological variables in patients with advanced colorectal cancer.     
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CHAPTER 5 – COHORT STUDY (1992-2005): PRIMARY TUMOR 
RESECTION IN ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC  
PATIENTS 
 
Our well designed and good quality large population based cohort study, with minimal selection 
and information biases, supports surgical resection of the primary tumor in patients with stage IV 
CRC, independent of other important prognostic factors. In addition to systemic therapy and 
metastasectomy, primary tumor removal was associated with better survival. Nevertheless, the 
study cohort was inclusive of patients with symptomatic primary tumor, a group of patients who 
may get benefit from resection of the primary tumor.  
 
The current chapter focuses on the study objective “to determine survival advantage of primary 
tumor resection in a subcohort of patients with stage IV CRC and minimally symptomatic or 
asymptomatic primary tumor”. In the present study we examined the prognostic role of surgery in 
a cohort of patients with stage IV CRC and asymptomatic or minimally symptomatic primary 
tumor. The study findings were presented in June 2014 at the American Society of Clinical 
Oncology Poster Discussion session in Chicago, USA. The results were published in the Clinical 
Colorectal Cancer “Ahmed S, Fields A, Pahwa P, Chandra-Kanthan S, Zaidi A, Le D, Haider K, 
Reeder B, Leis A. Surgical Resection of Primary Tumor in Asymptomatic or Minimally 
Symptomatic Patients With Stage IV Colorectal Cancer: A Canadian Province Experience. Clin 
Colorectal Cancer. December 2015 Volume 14, Issue 4, Pages e41–e472015 Jun 6. pii: S1533-
0028(15)00066-3. doi: 10.1016/j.clcc.2015.05.008.” 
 
5.1 Abstract 
 
Background:   Surgical resection of the primary tumor in patients with stage IV CRC remains 
controversial. Survival benefit reported in literature has been attributed to the selection of 
younger and healthier patients with good performance status.  We have recently reported that 
primary tumor resection improves survival of patients with stage IV CRC. In this study we 
examined survival benefit of surgery in patients with asymptomatic or minimally symptomatic 
primary tumor.  
 
Methods:  A cohort of patients with stage IV CRC and asymptomatic or minimally symptomatic 
primary tumor, who were diagnosed during the period of 1992 to 2005, in the province of 
Saskatchewan, Canada, was evaluated. The Kaplan-Meier method was used to determine survival. 
A multivariate Cox proportional hazard regression analysis was performed to determine prognostic 
importance of resection of primary tumor and other important clinicopathological variables.  
Results:  A total of 834 patients with median age of 70 years (22-93) and M:F of 58:42 were 
identified. Among them 521 (63%) patients underwent surgery and 43.3% received chemotherapy. 
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Patients who underwent surgery and received chemotherapy had median overall survival of 19.7 
months (95% CI: 16.9-22.6) compared with 8.4 months (95% CI: 6.9-10.0) if they did not have 
surgery (p<0.0001). On multivariate analysis, 5FU-based chemotherapy (HR 0.43; 95% CI: 0.36-
0.53), primary tumor resection (HR 0.47; 95% CI 0.39-0.57), metastasectomy (HR 0.48; 95% CI 
0.38-0.62), and second-line chemotherapy (HR 0.72; 95% CI 0.58-0.92) were correlated with 
superior survival. A test for interaction between ≥1 metastatic sites and surgery was significant, 
which suggests a larger benefit of surgery in patients with stage IVa disease.  
 
Conclusions:  Results of this large population-based cohort study suggests that primary tumor 
resection in asymptomatic or minimally symptomatic patients with stage IV CRC improved 
survival independent of other prognostic variables. The benefit was more pronounced in Stage IVa 
disease.  
 
5.2 Introduction 
 
Colorectal cancer is one of the most common cancers and is the leading cause of cancer-related 
death in the Western world.  In 2008 over 1.2 million new cases were diagnosed and 608,700 
deaths were attributed to CRC (1). Approximately 20% of patients with CRC present with 
metastases or Stage IV disease but less than one-quarter of them are suitable candidate for radical 
resection. The role of surgery in the management of stage IV CRC has evolved. Although the 
benefit of metastasectomy is well established in the setting of oligometastases, primary tumor 
resection in patients with unresectable metastases and asymptomatic or minimally symptomatic 
primary tumor remains controversial. There is still considerable uncertainty, as to whether patients 
with advanced CRC with little or no symptoms related to the primary tumor should undergo 
surgery before systemic therapy (2-4). Because of the lack of level I evidence, the current 
guidelines do not support surgical resection of the primary tumor in asymptomatic or minimally 
symptomatic patients, and recommend surgery if there is a consideration of complete resection of 
the metastatic disease. A recent meta-analysis revealed that primary tumor resection in patients 
with stage IV CRC was associated with a lower mortality risk (odd ratio, 0.28; 95 % CI: 0.17–
0.47), which translates into a difference in mean survival of 6.4 months favoring resection (4).  
Similar results were reported by our research group. A meta-analysis of 15 observational studies 
showed better survival of patients who underwent primary tumor resection (HR for mortality: 0.69, 
95% CI: 0.61-0.79) [2]. Nevertheless, most studies failed to adjust for selection of younger and 
healthier patients with good performance status.  We conducted a large population based cohort 
study and showed that primary tumor resection in patients with stage IV CRC improves survival, 
independent of age, performance status, comorbid illness and chemotherapy (5). The study cohort 
was inclusive of patients with symptomatic primary tumor. In the present study we examined the 
prognostic role of surgery in a cohort of patients with stage IV CRC and asymptomatic or 
minimally symptomatic primary tumor.  
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5.3 Methods 
 
5.3.1 Eligibility Criteria 
 
The study protocol was approved by the Institutional Review Board at the University of 
Saskatchewan. The study population was comprised of a cohort of adult patients, with 
histologically documented stage IV adenocarcinoma of colon and rectum, diagnosed over a period 
of fourteen years (January 1992 to December 2005), in the province of Saskatchewan, Canada. 
Patients with other histological diagnosis including neuroendocrine tumor or with other active 
secondary malignancy at the time of diagnosis were excluded. In addition, patients with previous 
diagnosis of early stage CRC who were treated with curative resection and subsequently developed 
metastatic disease were excluded. Eligible patients were identified using Saskatchewan Cancer 
Registry – Canada. Individual medical records were reviewed and information was extracted using 
a validated abstraction sheet by a trained research associate. The asymptomatic or minimal 
symptomatic disease was defined as absence of obstruction, perforation or major bleeding 
(decrease in hemoglobin of ≥20 gm/l or required blood transfusion). The major comorbid illnesses 
were defined as presence of coronary artery disease, congestive heart failure, diabetes mellitus, 
chronic renal insufficiency, uncontrolled hypertension, peripheral vascular disease, stroke, chronic 
obstructive lung disease, interstitial lung disease, connective tissue disease, dementia, 
symptomatic multiple sclerosis, cirrhosis of the liver, and AIDS among others. Performance status 
information was collected using the ECOG scale. The Karnofsky performance status score was 
transformed into the ECOG scale.  
 
5.3.2 Statistical Analysis 
 
The baseline characteristics of patients were compared using the chi square test. Continuous 
variables were examined using the Student t test. Descriptive data are reported in mean (standard 
deviation) and median (range). Overall survival (OS) was the primary end point and was defined 
as time from the diagnosis of stage IV CRC to death from any cause or the date at which patient 
was last confirmed to be alive. Survival was estimated using the Kaplan-Meier method. Survival 
distribution of different groups was compared using the log-rank test. The overall significance 
level was set at 0.05.   
 
A multivariate Cox proportional hazard regression analysis was performed to determine 
relationship between survival and resection of the primary tumor and HR and its 95% CI were 
estimated. The following variables were examined with respect to their prognostic significance: 
Resection of the primary tumor, old age (<65 vs. ≥65), male sex, major comorbid illness, ECOG 
performance status (<2 vs. ≥2), smoking, hyponatremia (≤135 mEq/l vs. >135 mEq/l), renal 
insufficiency (serum creatinine ≥120 vs. <120 um/l), elevated BUN (≥8 vs. <8 mm/l), 
hypoalbuminemia (albumin ≥36 vs. <36 g/l), hyperbilirubinemia (≥26 vs. <26 um/l), increased 
alkaline phosphatase (≥120 vs. <120 IU/l), anemia (≥120 vs. <120 g/l), leukocytosis (≥11 vs. <11 
x 109/l), thromobocytosis (≥450 vs. <450 x109/l), increased CEA (≥6 vs. <6 mcg/l),  disease site 
(colon vs. rectal), high-grade tumor (Grade 3 vs. <3), extra-hepatic metastases, number of 
metastatic site (Stage IVa vs. > Stage IVb), metastasectomy, use of any fluoropyrimidine 
chemotherapy, second-line chemotherapy and second-generation (oxaliplatin or irinotecan ± 
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bevacizumab) chemotherapy. A univariate analysis was performed to assess relationship between 
survival and individual clinicopathological variables.  All variables that were significantly 
correlated with survival were fitted into a multivariate model. The proportional hazards assumption 
was assessed using log-log survival curves for all variables examined in the model. SPSS (SPSS 
Inc. Chicago, IL) versions 21.0 and STATA MP (StataCorp College Station, TX) version 13.1 
were used for statistical analysis.   
 
5.4 Results 
 
A total 834 patients with stage IV CRC who were asymptomatic or minimally symptomatic from 
the intact primary were identified. Four hundred and fifty-four patients, who were diagnosed 
during the study period, were excluded because of the presence of major symptoms from the 
underlying primary tumor. The median age of eligible patients was 70 years (range: 22-93) and 
male: female ratio was 58:42. Twenty-six percent patients had ECOG performance status of  ≥2 
and 62% had one or more than one comorbid illness.  Of 834 patients, 521 (63%) underwent 
resection of the primary tumor and 313 (43.3%) patients did not have surgery. Patient 
characteristics are described in Table 5.1.  There were statistically significance differences 
between the two groups with respect to age, performance status, serum albumin, alkaline 
phosphatase, bilirubin, CEA, sodium, white blood cell count, rectal tumor, tumor grade, number 
of metastatic sites, use of chemotherapy and metastasectomy.  For example, in the surgical group, 
54.9% and 4.8% patients compared with 79.9 % and 9.3% in the control group had low serum 
albumin and increased bilirubin levels, respectively. Overall, 32.7 % patients had rectal tumor, 
29.9% in the surgical group compared with 37.4% in the control group (p=0.027).  
 
Median OS of patients who received chemotherapy was 16 months (95% CI: 13.8-18.2). Patients 
who underwent primary tumor resection and received 5-fluorouracil/leucovorin had median OS of 
19.7 months (95% CI: 16.9-22.6) versus 8.4 months (95% CI: 6.9-10.0) if they did not have surgery 
(p<0.0001) [Figure 5.1A]. Patients who received oxaliplatin- or irinotecan-based chemotherapy 
and underwent surgery had median OS of 29.4 months (95% CI: 24.2-34.5) compared with 16.0 
months (95% CI: 13.2-18.9) when surgical resection of the primary tumor was not performed 
(p<0.001) [Figure 5.1B]. Patients with rectal cancer who underwent surgery and received any 
chemotherapy had median OS of 22.5 months (95%CI: 16.8-28.1) compared with 8.4 months (95% 
CI: 4.5-12.4) with no surgery (p<0.001). Conversely, patients with colon cancer who underwent 
surgery and received any chemotherapy had median OS of 18.0 months (95%CI: 14.6-21.5) 
compared with 8.1 months (95% CI: 5.2-11.0) if they did not have primary tumor resection 
(p<0.001). The 30-day mortality rate of all patients who underwent surgical intervention was 4.8%.  
 
In univariate analysis several clinicopathological variables were correlated with survival (Table 
5.2). Among them, use of any chemotherapy, second-line chemotherapy, metastasectomy, primary 
tumor resection, age, comorbid illness, performance status, tumor location were correlated with 
survival. In multivariate analysis 5FU-based chemotherapy (HR 0.43; 95% CI: 0.36-0.53), primary 
tumor resection (HR 0.47; 95% CI: 0.39-0.57), metastasectomy (HR 0.48; 95%CI: 0.38-0.62), and 
second-line chemotherapy (HR 0.72; 95% CI: 0.58-0.92) were correlated with a superior survival 
and increased bilirubin (HR 1.48; 95% CI: 1.11-1.62), low albumin (HR 1.48; 95% CI: 1.25-1.75), 
ECOG performance status ≥2 (HR 1.36; 95% CI: 1.15-1.62), high-grade tumor (HR 1.34; 95% CI: 
1.06-1.58),  leukocytosis (HR 1.30; 95% CI: 1.06-1.58), anemia (HR 1.28; 95% CI: 1.09-1.49), 
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and age ≥ 65 years (HR 1.20; 95% CI: 1.02-1.42) were correlated with inferior survival (Table 
5.3). A test for interaction between ≥1 metastatic sites and surgical resection of the primary tumor 
was significant (p=0.03), which suggests a larger benefit of surgical intervention in patients with 
stage IVa disease. 
 
In a secondary analysis, after excluding 116 patients who underwent metastasectomy, primary 
tumor resection was significantly correlated with better survival (HR 0.43, 95% CI: 0.38-0.51). 
After adjusting for other important prognostic variables in the Cox proportional multivariate 
model, the hazard ratio for survival for surgical resection of the primary tumor was 0.52 (95% CI: 
0.43-0.65). 
 
5.5 Discussion 
 
Our results suggest that after adjustment of age, performance status, comorbid illnesses and 
chemotherapy, primary tumor resection in patients with stage IV CRC and asymptomatic or 
minimally symptomatic primary tumor improves survival. The unadjusted survival difference 
between the groups with surgery versus no surgery was 11.3 months. The difference was more 
pronounced among patients who were treated with oxaliplatin- or irinotecan-based chemotherapy, 
with an absolute survival difference of 13.4 months (29.4 vs. 16 months). Several studies that used 
registry data have demonstrated survival benefit of resection of the primary tumor in stage IV CRC 
(2,4,6,7).  However, most studies failed to adjust for performance status and other important 
clinicopathological variables. In agreement with the other reports, our data revealed that patients 
who underwent surgery were younger with less disease burden compared with the nonsurgical 
group, which suggests a selection bias for the surgical intervention (2,4). Despite the significance 
differences between the two groups with respect to age, performance status, albumin, alkaline 
phosphatase, bilirubin, CEA, sodium, white blood cell count, rectal tumor, tumor grade, number 
of metastatic sites, use of chemotherapy and mestastasectomy, surgery of the primary tumor 
resulted in a 53% relative reduction in mortality after adjustment of other variables. To our 
knowledge, the present study is the only study that controlled for all the important clinical variables 
to minimize selection bias and has shown survival benefit with resection of the primary tumor. 
 
Our results also revealed a positive interaction between the disease burden, age, CEA level and 
second-line chemotherapy and resection of the primary tumor. However, in multivariate analysis, 
after adjustment for the other prognostic variables only the interaction term between resection of 
the primary tumor and stage IVA disease was significant. Although patients with stage IVa and 
IVb disease benefited from surgical removal of the primary tumor, the magnitude of benefit was 
significantly higher in patients with stage IVa disease. Patients with stage IVa disease who 
received chemotherapy and underwent surgery had median overall survival of 22.4 months 
(95%CI: 18.5-26.2) versus 12.7 months (95%CI: 7.7-17.6) if they had stage IVb disease. Of note, 
after excluding 116 patients who underwent metastasectomy, the survival benefit of resection of 
the primary tumor was maintained independent of other prognostic factors.  
 
A benefit for resection of the primary tumor in stage IV renal cell cancer has been demonstrated 
in two randomized controlled trials [8,9 ]. Furthermore, observational studies support resection of 
the primary tumor in women with metastatic breast cancer (10). The underlying mechanism that 
results in a better outcome in patients with the removal of the primary tumor remains speculative. 
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It has been proposed that removal of the primary tumor in advanced colorectal cancer by 
preventing local tumor complications and reducing the tumor bulk may improve outcome, yet 
recent reports suggest that in asymptomatic patients with stage IV CRC, leaving the primary tumor 
intact does not cause unacceptable complications or compromise their survival (3). There is 
evidence for the genetic variation between the primary tumors and metastases (11). Removal of 
the primary tumor might result in a decreased burden of chemotactic cytokines and tumor-
promoting factors that are produced by CRCs and regulate tumor cells growth and metastasis 
(12,13). In addition, alteration in immune response following surgery, with predominant T helper 
1 (Th1) response than one with a substantial T helper 2 component, might contribute to a better 
outcome (14).  
 
In this subcohort of asymptomatic or minimally symptomatic patients, in addition to resection of 
the primary tumor, use of any chemotherapy, metastasectomy, and second-line chemotherapy were 
correlated with superior survival. Conversely, old age, ECOG performance status of 2 or above, 
abnormal bilirubin, low albumin, high grade tumor, leukocytosis, and anemia, were associated 
with inferior survival. 
 
5.6 Conclusions 
 
Our results support survival benefit of resection of rectal or colonic tumor in patients with stage 
IV CRC and asymptomatic or minimally symptomatic primary tumor independent of age and 
performance status. The benefit was more pronounced in patients with limited burden of the 
disease. Two randomized controlled trials in Europe are currently enrolling patients to confirm 
benefit of surgery (15,16). In the SYNCHRNOUS trial resection of the primary tumor will be 
compared with no resection in patients with colon cancer and synchronous metastases who are not 
amenable to curative therapy (15). The CAIRO 4 trial is being conducted to evaluate this question 
in patients with both stage IV colon and rectal cancer (16). If the magnitude of survival benefits is 
confirmed in these randomized studies, primary tumor resection could potentially be a more cost-
effective intervention compared with novel systemic therapy in the management of metastatic 
CRC. 
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Table 5.1: Characteristics of study cohort and subgroups of patients who underwent 
surgery versus did not have surgical intervention. 
 
Variables  Total  
N=834 (100) 
Surgery    
N=521 (62.5) 
Control 
N=313 (37.5) 
P value 
Demographic (%)     
  Median Age (range) 70 (22-93) 69 (22-93) 71 (35-92) 0.001 
  Age Greater Than 65 yrs 560 (67.1) 330 (63.3) 230 (73.5) 0.003 
  Comorbid Illness 519 (62.2) 312 (59.9) 207 (66.1) 0.07 
  ECOG performance status ≥2 215 (25.8) 102 (19.6) 113 (36.1) <0.001 
  Male 483 (57.9) 297 (57) 186 (59.4) 0.51 
  Smoker (Active or Ex-smoker) 380 (45.6) 234 (44.9) 146 (46.6) 0.66 
  Diagnosed after year>1999 353 (42.2) 191 (36.7) 162 (51.8) <0.001 
Laboratory Value ± (SD)     
  Mean Albumin 34.0 ±5.4 34.7±5.6 32.8±4.8 <0.001 
  Mean Alkaline Phosphtase U/L 201 ±262 183±261 230±262 0.01 
  Mean Bilirubin umol/l 14±29 12.9±24.2 17.8±35.6 0.02 
  Mean BUN mmol/l 6.0±4.6 5.9±5.1 6.3±3.7 0.14 
  Mean CEA ug/l 287.6±1785 181.8±640.5 463.8±2789.6 0.027 
  Mean Sodium meq/l 138±3.5 138±3.0 137±4.1 0.007 
  Mean Creatinine umol/l 90.8±33.7 89.6±33.4 92.7±34 0.19 
  Mean Hemoglobin g/l 118±16.3 117.7±16.3 118.6±16.2 0.40 
  Mean Platelet 100 x 109/l 351±123 347±121 356±125 0.34 
  Mean WBC 1 x 109/l 9.2±4.2 8.9±4.2 9.8±4.1 0.002 
Clinco-pathological Features (%)     
  Rectal Tumor 273 (32.7) 156 (29.9) 117 (37.4) 0.027 
  High-grade 150 (18) 105 (20.2) 45 (14.4) 0.04 
  Liver Metastases 643 (77.1) 400 (76.8) 243 (77.6) 0.79 
  Extra-hepatic Disease 388 (46.5) 231 (44.3) 157 (50.2) 0.11 
  More than 1 Metastatic site 231 (27.7) 128 (24.6) 103 (32.9) 0.011 
  Mucinous Tumor 110 (13.2) 90 (17.3) 20 (6.4) <0.001 
Treatment (%)     
  Received Chemotherapy 361 (43.3) 274 (52.6) 87 (27.8) <0.001 
  Received Second Line Treatment 135 (16.2) 107 (20.5) 28 (8.9) <0.001 
  Received Radiation Therapy 128 (15.3) 80 (15.4) 48 (15.3) 1.0 
  Second Generation Chemotherapy 158 (18.9) 111 (21.3) 47 (15) 0.028 
  Metastasectomy 116 (13.9) 107 (20.5) 9 (2.9) <0.001 
BUN=blood urea nitrogen; CEA=carcinoembryonic antigen; ECOG=Eastern Cooperative Oncology Group; SD=standard deviation; WBC= 
white blood cell count. 
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Table 5.2: Univariate analysis of factors correlated with survival in patients with stage IV 
colorectal cancer. 
 
Variables HR 95% CI P value 
Interventions    
Received any chemotherapy 0.32 0.27-0.37 <0.0001 
Surgical Resection of the Primary Tumor 0.38 0.33-0.41 <0.0001 
Metastasectomy 0.34 0.27-0.42 <0.0001 
Second Line Therapy 0.42 0.35-0.51 <0.0001 
Second Generation Therapy 0.45 0.38-0.54 <0.0001 
Demographic    
Age ≥65 yrs 1.48 1.27-1.72 <0.0001 
Male 1.14 0.99-1.31 0.077 
ECOG Performance Status ≥2 2.54 2.16-3.0 <0.0001 
Comorbid Illness 1.24 1.08-1.44 0.003 
Smoker (active or ex-smoker) 1.09 0.94-1.25 0.23 
Time Period (year<2000) 1.04 0.90-1.19 0.63 
Laboratory Value    
Alkaline Phosphatase≥ 120 U/L 1.58 1.36-1.85 <0.0001 
BUN ≥8 mmol/l 1.23 0.97-1.55 0.078 
CEA >5 ug/l 2.51 2.01-3.14 <0.0001 
Creatinine ≥120 umol/l 1.31 1.02-1.69 0.036 
Sodium <136 meq/l 1.53 1.25-1.87 <0.0001 
Bilirubin ≥26 umol/l 2.67 2.02-3.54 <0.0001 
Albumin <35 g/l 2.28 1.96-2.65 <0.0001 
Hemoglobin <120 g/l 1.45 1.26-1.67 <0.0001 
WBC >11 x 109/l 1.89 1.57-2.26 <0.0001 
Platelets >450 x 109/l 1.01 0.83-1.22 0.91 
Tumor Characteristics    
Extra-Hepatic Disease 1.06 0.92-1.22 0.40 
Grade III Tumor  1.21 1.01-1.45 0.041 
Liver Metastases 1.36 1.15-1.61 <0.0001 
More than 1 Metastatic Sites (Stage IVB) 1.53 1.31-1.79 <0.0001 
Mucinous Cancer  0.83 0.68-1.03 0.085 
Colon Cancer 1.21 1.04-1.40 0.012 
Significant Interaction Terms     
  Age ≥65 * SRPT 1.54 1.12-2.10 0.007 
  CEA * SRPT 2.06 1.17-3.62 0.012 
  Moe than 1 metastatic site * SRPT 1.73 1.27-2.37 0.001 
  Second line therapy * SRPT 0.58 0.37-0.92 0.02 
BUN=blood urea nitrogen; CEA=carcinoembryonic antigen; ECOG=Eastern Cooperative Oncology Group; SRPT=surgical resection of primary 
tumor 
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Table 5.3: Cox Proportional multivariate analysis of factors correlated with survival in 
patients with stage IV colorectal cancer. 
 
Variables HR 95% CI P value 
Received Chemotherapy 0.44 0.36-53 <0.0001 
Surgical Resection of the Primary Tumor 0.47 0.39-57 <0.0001 
Metastasectomy 0.49 0.38-0.61 <0.0001 
Second Line Therapy 0.73 0.58-0.92 0.007 
Age ≥65 yrs 1.20 1.02-1.42 .031 
Male gender  1.12 0.97-1.30 0.13 
ECOG Performance Status ≥2 1.36 1.15-1.62 <0.0001 
Comorbid Illness 1.13 0.97-1.31 0.11 
Alkaline Phosphatase≥ 120 U/L 1.50 1.26-1.77 <0.0001 
Bilirubin ≥26 umol/l 1.48 1.08-2.01 0.014 
Albumin <35 g/l 1.48 1.25-1.75 <0.0001 
Hemoglobin <120 g/l 1.28 1.10-1.49 0.002 
WBC >11 x 109/l 1.30 1.06-1.58 0.01 
Grade III tumor 1.34 1.11-1.62 0.002 
More than 1 Metastatic Sites 0.96 0.76-1.22 0.74 
More than 1 Metastatic Sites * surgery of 
primary tumor  
1.43 1.04-1.97 0.03 
 
 
 
 
 
  
95 
 
Figure 5.1: Survival of patients who underwent surgery compared with if they did not have 
surgery adjusted for chemotherapy (5-FU-based monotherapy) (A) and (B) second-
generation chemotherapy (oxaliplatin or irinotecan).  
 
Figure 5.1A 
 
 
 
 
Figure 5.1B 
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CHAPTER 6– COHORT STUDY (2006-2010): PATIENTS DIAGNOSED 
 DURING THE PERIOD OF MODERN CHEMOTHERAPY 
 
Our research revealed that primary tumor resection improves survival of a cohort of patients with 
stage IV CRC, who were diagnosed between 1992-2005, independent of other important 
prognostic variables such as chemotherapy, metastasectomy, comorbid illness, and performance 
status. Overall primary tumor resection resulted in 46% relative reduction in mortality.  However, 
only 42% of patients were treated with systemic therapy and of treated patients, only about 45% 
received modern combination chemotherapy regimen. Moreover, less than 5% received a 
biological agent.  It is not known if the benefit of primary tumor resection maintains with the use 
of more effective systemic therapy.  The present study was conducted to validate our findings in a 
cohort of patients with stage IV CRC who were diagnosed during the period of modern systemic 
therapy. 
 
This chapter concentrates on the study objective “to determine survival advantage of primary 
tumor resection in patients with stage IV CRC during the period of modern chemotherapy”. The 
study findings were presented in January 2015 at the Gastrointestinal Cancer Symposium in San 
Francisco, USA. Notably, our study scored 9 of 9 using the ‘validity scoring for observational 
study’ for overall survival, and met the criteria for good quality study (Appendices F and O). The 
result was published in the Journal of Cancer “Ahmed S, Leis A, Kanthan S, Fields A, Reeder B, 
Iqbal N, Haider K, Le D, Pahwa P. Surgical management of the primary tumor in Stage IV 
colorectal cancer: a confirmatory retrospective cohort study. Journal of Cancer. 2016;7(7):837-
845.doi:10.7150/jca.14717 
 
6.1 Abstract 
 
Background: Previous observational studies have suggested that patients with stage IV colorectal 
cancer who undergo primary tumor resection have better survival. Yet the results are not confirmed 
in the setting of a randomized controlled trial. Lack of randomization and failure to control 
prognostic variables such as performance status are major critiques to the findings of the 
observational studies. We previously showed that primary tumor resection, independent of 
chemotherapy and performance status, improves survival of stage IV CRC patients. The current 
study aims to validate our findings in patients with stage IV CRC who were diagnosed during the 
period of modern chemotherapy.  
 
Methods: A cohort of 569 patients with stage IV CRC diagnosed during 2006-2010 in the province 
of Saskatchewan was evaluated. Cox regression model was used for the adjustment of 
prognostic variables.  
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Results: Median age was 69 years (59-95) and M: F was 1.4:1. Fifty-seven percent received 
chemotherapy, 91.4% received FOLFIRI or FOLFOX & 67% received a biologic agent. Median 
overall survival (OS) of patients who underwent primary tumor resection and received 
chemotherapy was 27 months compared with 14 months of the non-resection group (p<0.0001). 
Median OS of patients who received all active agents and had primary tumor resection was 39 
months (95% CI: 25.1-52.9). On multivariate analysis, primary tumor resection, HR: 0.44 (95% 
CI: 0.35-0.56), use of chemotherapy, HR: 0.33 (95% CI: 0.26-0.43), metastasectomy, HR: 0.43 
(95% CI: 0.31-0.58), second-line therapy, HR: 0.50 (95% CI: 0.35-0.70), and third-line therapy, 
HR: 0.58 (95% CI: 0.41-0.83) were correlated with superior survival.  
 
Conclusions: The present study confirms our findings and supports a favorable association 
between primary tumor resection and survival in patients with stage IV CRC who are treated with 
modern therapy.  
 
6.2 Introduction 
 
Several observational studies have demonstrated superior survival of patients with stage IV CRC 
who undergo primary tumor resection (1-6). For example, a systematic review and meta-analysis 
of 15 observational studies involving 12456 patients with stage IV CRC demonstrated a hazard 
ratio (HR) for mortality of 0.69 (95% CI: 0.61-0.79) favoring surgery (2). A subsequent meta-
analysis involving 44,226 patients in 21 studies indicated potential benefit of primary tumor 
resection in patients with unresectable metastases (odd ratio of 0.28; 95 % CI: 0.17-0.47), 
translating into a difference in mean survival of 6.4 months in favor of resection (3). Yet the results 
are not confirmed in the setting of a randomized controlled trial. Lack of randomization and failure 
to control prognostic variables that affect survival including systemic therapy and performance 
status are major critiques to the findings of the observational studies. Consequently, the survival 
benefit related to surgery has been attributed to selection bias and selection of younger and 
healthier patients with good performance status.  
 
Our group has demonstrated that primary tumor resection improves survival of a cohort of patients 
with stage IV CRC, who were diagnosed between 1992-2005, irrespective of age, comorbid illness, 
performance status, chemotherapy, metastasectomy and other important prognostic variables (1). 
In this group of patients primary tumor resection was associated with 46% relative reduction in 
mortality (HR 0.54, 95%CI: 0.41-0.58).  However, only 42% of patients were treated with systemic 
therapy. Among the treated patients about 45% received irinotecan or oxaliplatin based (FOLFIRI 
or FOLFOX) chemotherapy. Moreover, less than 5% patients received a biological agent.  It is not 
known if similar benefit can be achieved with the use of more effective chemotherapy and 
biological agents in the management of metastatic CRC.  We have undertaken the current study to 
confirm our findings in a cohort of patients with stage IV CRC who were diagnosed during the 
period of modern systemic therapy.  
 
6.3 Objectives 
 
The study objectives were to validate prognostic impact of primary tumor resection in patients 
with stage IV CRC who were treated with modern systemic therapy and to assess interaction of 
removal of primary tumor with other prognostic variables in order to identify subgroups of patients 
who received greater benefit from surgery. 
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6.4 Methods 
 
6.4.1 Eligibility Criteria  
 
The study protocol was approved by the University of Saskatchewan’s Ethics Board. Individual 
records of patients ≥18 years, diagnosed with synchronous stage IV CRC between 2006 and 2010 
in the province of Saskatchewan were reviewed. Patients with previous history of CRC, with 
another active second primary cancer, or who had pathology other than adenocarcinoma were 
excluded.  
 
6.4.2 Statistical Analysis  
 
The primary end point of this study was to determine relationship between primary tumor resection 
and overall survival (OS). Survival was estimated by using the Kaplan-Meier method. Survival 
distribution of subgroups was compared by the Log Rank test.  
 
Charlson comorbidity index was used in this confirmatory study to defined major comorbid illness 
(7). A multivariate analysis was performed to determine the prognostic significance of primary 
tumor resection in patients with stage IV CRC in relation to other clinicopathological variables. 
The Cox proportional hazard model was used and the hazard ratio and its 95% CI were estimated.  
 
The following variables were examined with respect to their prognostic significance:  
 
Interventions: Resection of the primary tumor, metastasectomy, use of chemotherapy with or 
without biologics , second line therapy, third line therapy, and radiation therapy; clinical & 
demographic variables: age (<65 vs. ≥65), gender, major comorbid illness (as per Charlson 
comorbidity index), secondary cancer, ECOG performance status (<2 vs. ≥2), cancer center, and 
smoking; laboratory values: albumin (≥36 vs. <36 g/l), bilirubin (≥26 vs. <26 um/l), alkaline 
phosphatase (≥120 vs. <120 U/l), sodium level (≤135 mEq/l vs. >135 mEq/l), serum creatinine 
(≥120 vs. <120 um/l), BU) (≥8 vs. <8 mm/l), hemoglobin (≥120 vs. <120 g/l), WBC (≥11 vs. <11 
x 109/l), platelet count (≥450 vs. <450 x109/l), and CEA (≥6 vs. <6 ug/l); disease characteristics: 
site (colon vs. rectal), grade (Grade 3 vs. <3), symptomatic disease, extra-hepatic metastases, and 
stage (stage IVa vs. stage IVb disease). For the Cox proportional hazard model, log-log survival 
curves was used to assess the proportional hazards assumption. 
 
All variables that were significant on univariate analysis with P<0.05, were examined in 
multivariate models. The likelihood ratio test and the t test were used to determine if a variable 
correlates with survival in the model. A test for interaction was performed for primary tumor 
resection and the other variables that were correlated with survival. In addition, secondary analyses 
were performed in subgroups of patients with asymptomatic disease, or patients who did not have 
metastasectomy. A two-sided P-value of <0.05 was considered to be statistically significant. For 
missing data imputation technique was used. All patients were followed till June 2014 when the 
data entry was closed. The SPSS version 22 was used for statistical analysis (SPSS Inc. Chicago, 
IL). 
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6.5 Results 
 
6.5.1 Baseline Characteristics  
 
Five hundred and sixty-nine eligible patients with synchronous stage IV CRC were identified 
(Figure 6.1). Their median age was 69 years (range: 59-95) and male: female was 1.4:1. Three 
hundred and thirteen (55%) patients underwent surgery and 256 (45%) did not have surgery.  Of 
569 patients, 340 (60%) were ≥65 years and 201 (35%) had ECOG performance status of ≥2 
(Table 6.1). Although no significant differences were noted between the two groups with respect 
to age, gender, comorbid illness, and smoking status, 122 (48%) patients in the non-resection group 
had ECOG performance status of >1 compared with 79 (25%) patients in the resection group 
(p<0.001). In addition, significant differences were noted between the two groups in relationship 
with serum creatinine, CEA and bilirubin.  
 
6.5.2 Systemic Therapy 
 
Overall 326 (57%) patients received chemotherapy, 199 (64%) in the resection group and 127 
(50%) in the non-resection group (p=0.001). Of 326 patients, 298 (91%) received either FOLFIRI 
(infusional 5 fluorouracil, leucovorin and irinotecan) or FOLFOX (infusional 5 fluorouracil, 
leucovorin and oxaliplatin), 157 (48%) received both FOLFIRI and FOLFOX, 213 (65%) received 
bevacizumab, and 34 (10%) patients with KRAS wild tumor (about 60% had KRAS wild disease) 
received cetuximab or panitumumab. Of 326 patients who were treated with chemotherapy, on 
progression, 174 (53%) received second-line chemotherapy and 52 (16%) received third-line 
therapy.  FOLFIRI in combination with bevacizumab was the preferred first line regimen in most 
patients who were treated with systemic therapy. On progression, FOLFOX was given as second-
line therapy and panitumumab or cetuximab alone or in combination with irinotecan was used as 
the standard third-line therapy in patients with KRAS wild tumor. There was no significant 
difference between the two groups in relation to second- and third-line therapies (Table 6.1). 
Furthermore, no significant difference was noted between the two groups with respect to types of 
systemic therapy, however, 45% patients in the resection group who were treated with systemic 
therapy received all available therapy (FOLFIRI, FOLFOX and a biologic agent) compared with 
35% of patients in the non-resection group (p=0.045). Of 199 patients in the resection group who 
received chemotherapy, 172 (86%) received chemotherapy after surgery. The median time to start 
chemotherapy was 79 days (IQR: 64-106).  
 
6.5.3 Disease Characteristics 
 
Overall about 41% patients in the non-resection group had rectal or rectosigmoid primary tumor 
compared with 28% in the resection group (p=0.001). In addition, approximately 54% patients in 
the non-resection group had stage IVb disease compared with 40% in the resection group 
(p=0.001). Patients in the resection group had significantly more often peritoneal disease compared 
with patients in the non-resection group who had more often lung or bone metastases.   
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6.5.4 Post-operative Morbidity and Mortality 
 
Median duration of hospital stay of was 9 days (inter-quartile range: 7-13). Of 313 patients who 
underwent surgery 74 (24%) patients developed post-operative complications. Among 74 patients 
who developed operative complications 65% had a symptomatic primary tumor. Post-operative 
complications rates were not mutually exclusive and were as followed: post-operative wound 
infection in 7% patients, non-wound infection in 5% patients, and anastomotic leak, wound 
dehiscence, bleeding, and pulmonary embolism in 2% each. Major complications including venous 
thromboembolism, sepsis, wound dehiscence, anastomotic leakage, post-operative bleeding, 
pelvic abscess and ischemic bowel were noted in 37 (12%) patients. Of note, 10 (7%) of 142 
patients with asymptomatic or minimally symptomatic tumor developed major complications 
compared with 27 (16%) of 171 patients with symptomatic primary tumor (p=0.01). 
 
Overall the 30-day mortality rate of the group that underwent surgery was 5%. Fifteen of 171 (9%) 
patients with symptomatic disease compared with 2 (1%) of 142 patients with asymptomatic or 
minimally symptomatic disease died within 30 days of surgery (p=0.003). 
 
6.5.5 Non-surgical Interventions 
 
Overall 30 (5%) patients required a stent for their symptoms. Eight (3%) of 313 patients who 
underwent surgery compared with 22 (9%) of 256 patients who did not have surgery required a 
stent (p=0.001). All eight patients in the surgery group had the stent placed prior to the surgery. In 
addition, 38 (15%) patients in the non-resection group developed obstructive symptoms and 
required a stoma formation (colostomy or ileostomy). Forty-five (14%) patients in the resection 
group compared with 45 (17.6) of 256 patients in the non-resection group received radiation 
therapy (p=0.30).  
 
6.5.6 Follow-up & Survival 
 
Median follow-up time for the entire cohort was 11 months (inter-quartile range: 2-26 months). 
No patient was lost to follow-up. Median overall survival of patients who underwent removal of 
the primary tumor, irrespective of the use of systemic therapy, was 18 months (95% CI: 15.4-20.6) 
compared with 4 months (95% CI: 2.6-5.4) if they did not have surgery (p<0.001). Median overall 
survival (OS) of patients who underwent primary tumor resection and received chemotherapy was 
27 months (95%CI: 23.3-30.8) versus 14 months (95%CI: 11.2-16.8) if they received 
chemotherapy but did not have surgery (p<0.001) [Figure 6.2]. Patients who received second-line 
therapy and underwent SRPT had median OS of 30 months (95%CI: 24.9-35.1) compared with 20 
months (95%CI: 17.7-22.3) if they did not have surgery (p<0.001) [Figures 6.3A & 6.3B]. About 
30% patients on progression received third-line therapy. The median OS of patients who received 
third-line therapy and underwent primary tumor resection was 39 months (95%CI: 22.1-44.9) 
compared with 26 months (95%CI: 10.3-41.7) if they did not have surgery (p=0.13). Median OS 
of patients who received FOLFIRI and FOLFOX and a biologic agent (bevacizumab or anti-EGFR 
monoclonal antibodies) and underwent primary tumor resection was 35 months (95% CI: 30-40) 
compared with 23 months (95%CI: 19.8-26.3) if they did not surgery (p<0.001) [Figure 6.4].  A 
subgroup of patients with asymptomatic or minimally symptomatic primary tumor who underwent 
surgery and received systemic therapy had a median OS of 34 months (95%CI: 26.6-43.4) 
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compared with median OS of 14 months (95%CI: 11.1-17.0) if they did not have surgery 
(p<0.001).  
 
6.5.7 Cox Proportional Multivariate Modeling for Survival  
 
One univariate analyses several variables were correlated with survival (Table 6.2). The tests for 
interaction were significant between resection of primary tumor and metastasectomy, second line 
therapy, stage IVb disease and elevated BUN. On multivariate analysis primary tumor resection 
independently correlated with superior survival with HR for mortality of 0.44 (95% CI: 0.35-0.56). 
In addition, chemotherapy, HR 0.33 (95%CI: 0.26-0.43), metastasectomy, HR 0.43 (95% CI: 0.31-
0.58), second-line therapy, HR 0.50 (95%CI:0.35-0.70), and third-line therapy, HR 0.58 (95% 
CI:0.41-0.83) were correlated with superior survival whereas elevated alkaline phosphatase, HR 
1.50 (95%CI:1.20-1.78), Grade 3 tumor, HR 1.33 (95% CI:1.10-1.62), leukocytosis, HR 1.32 (95% 
CI:1.05-1.66), stage IVb disease, HR 1.31 (95% CI:1.10-1.56), and ECOG PS >1, HR 1.30 (95% 
CI:1.04-1.57) were correlated with inferior survival (Table 6.3).  
 
After adjustment for other prognostic variables only the interaction between resection of primary 
tumor and subsequent line of therapy was significant, which suggests a differential benefit of 
removal of primary tumor in patients who received other line of therapies. Patients who underwent 
resection of primary tumor and received second-line therapy had a median OS of 30 months (95% 
CI: 24.9-35.1) compared with 20 months (95% CI: 17.7-22.3) if they did not have surgery (p 
<0.001). Conversely, patients who had resection of primary tumor but did not receive second-line 
therapy had a median OS of 19 months (95% CI: 11.8-26.2) compared with 7 months (95% CI: 
5.4-8.6) if they did not have surgery (P<0.001).   
 
6.5.8 Secondary Analyses 
 
In the secondary multivariate analyses that excluded the patients who underwent metastasectmy, 
SRPT was independently associated with significant reduction in mortality with HR, 0.48 (95% 
CI: 0.38-0.61). Likewise, in a subgroup of 345 patients with asymptomatic or relatively 
asymptomatic primary tumors, resection of primary tumor was significantly correlated with better 
survival with HR 0.32 (95% CI: 0.22-0.45). Similar benefits were noted in subcohorts of patients 
with colon cancer or ECOG performance status of 0 or 1. In the subgroup of 379 patients with 
colon cancer, surgery independently correlated with survival with HR for mortality of 0.39 (95% 
CI: 0.29-0.53). After excluding patients with poor performance status, primary tumor resection 
remained an independent prognostic variables with HR of 0.48 (95% CI: 0.35-0.66).   
 
6.6 Discussion 
 
The present study confirmed the survival benefit of primary tumor resection in patients who were 
treated with combination chemotherapy and biologics. In addition to surgery of the primary tumor, 
systemic therapy, subsequent line of therapies, metastasectomy, elevated alkaline phosphatase, 
Grade 3 tumor, leukocytosis, stage IVb disease, and performance status were correlated with 
survival. A significantly higher proportion of patients in the non-resection group had low 
performance status or larger number of metastatic sites involvement. Furthermore, there was 
imbalance between the two groups in relation to combination therapy and biologics. Nonetheless, 
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when these variables were included in a multivariate model, primary tumor resection remained an 
important independent prognostic factor. In fact, the survival benefit was stronger than the other 
well-established prognostic factors in stage IV CRC including performance status, alkaline 
phosphatase levels, and the number of metastatic sites (8,9).  
 
The median overall survival of patients with stage IV cancer, who are treated with combination of 
chemotherapy and biologics in the recent phase 3 clinical trials, has been reported in the range of 
24-30 months (10-12). However, our cohort was comprised of real world patients and was 
inclusive of patients with poor performance status and major comorbid illness. Although the 
median overall survival of the entire cohort was 11 months (8.8-13.2), the survival of patients who 
underwent primary tumor resection and received chemotherapy was 27 months (95% CI: 23.3-
30.8). Moreover, patients who underwent primary tumor resection and received second- and third-
line therapy had median OS of 30 months (95% CI: 24.9-35.1) and 39 months (95% CI: 22.1-
44.9), respectively. 
 
Recent literature also supports survival benefit of primary tumor resection in the era of modern 
chemotherapy.  A retrospective analysis of CAIRO study that compared combination versus 
sequential chemotherapy demonstrated a significantly better median OS of 16.7 months in patients 
who underwent primary tumor resection compared  with 11.4 months with no surgery (HR 0.61, 
95% CI:49–0.76) [6]. Likewise, a pool analysis of four French phase 3 trials involving 850 patients 
indicated survival benefit of surgery (4). More than two third of patients were treated with 
FOLFIRI or FOLFOX and about 12% received bevacizumab. The primary tumor resection was an 
independent predictor of superior survival (HR: 0.63, 95% CI: 0.53-0.75). In addition, our group’ 
meta-analysis of fifteen observational studies did not reveal a positive interaction between surgery 
and type of chemotherapy.  
 
In agreement with previous observation, patients with asymptomatic or minimally symptomatic 
disease following surgery had longer survival compared with patients with symptomatic primary 
tumor (13).  Of note, patients with symptomatic primary tumor had 30-day postoperative mortality 
rates of 8.8% compared 1.5 % if they had an elective surgery. Emergency surgery has consistently 
been demonstrated to be an important risk factor for inferior outcome in colorectal surgery (14). 
We believe that in addition to the biology of symptomatic disease, the 30-day mortality rates most 
likely accounted for the differences in survival between the two groups. In consistent with our 
previous observation, significantly higher number of patients with colon tumor underwent surgery 
compared with patients with rectal cancer. However, compared with the 1992-2005 cohort, 
patients with rectal cancer did not have better prognosis.  
 
Among the prognostic factors, systemic therapy was the most important prognostic variables. It is 
known that survival of patients with stage IV CRC is better if they are exposed to all available 
active therapeutic agents during the course of their disease (15). The subgroup of patients who 
received combination chemotherapy with bevacizumab and underwent surgery had median 
survival of 35 months (95% CI: 30-40) whereas patients with KRAS wild tumor who received 
FOLFIRI & FOLFOX in combination with bevacizumab and subsequently were treated with an 
anti-EGFR monoclonal antibody had a median OS of 39 months (95% CI: 25.1-52.9). 
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Due to presence of multicollinearity between various lines of chemotherapy and the type of 
regimens, these variables were not fitted together in the final model.  A secondary analysis using 
chemotherapy regimens and biological agents as opposed to the subsequent lines of therapies was 
performed (not reported). Both combination of chemotherapy (HR: 0.67, 95% CI: 0.52-0.87) and 
biological agents (HR:0.60, 95% CI:0.45-0.78) were independently correlated with superior 
survival. Of significant importance, when various chemotherapy regimens were fitted in the 
multivariate model, resection of primary tumor was independently correlated with survival.    
 
Our study revealed positive interaction between primary tumor resection and second-line therapy. 
The patients who had surgery and received second-line therapy had a median OS of 30 months 
compared with 19 months if they did not receive second-line therapy (p=0.005). With access to 
novel agents and their efficacy in the primary tumor as well as lack of major complications related 
to an intact primary tumor, primary tumor resection is less commonly performed (16-18).  Our 
results, however, support potential benefit of surgery in patients who are treated with modern 
chemotherapy and suggest a greater benefit in patients who are treated with subsequent line of 
therapy. Our study is unique that it included performance status, an important prognostic variables 
in metastatic CRC, in the multivariate model. Most population based studies that support benefit 
of surgery lack individual patients’ data and have failed to include performance status in the 
multivariate models.    
 
In summary, the current study suggests survival benefit of primary tumor resection in patients with 
advanced CRC. To date, no randomized trial has reported survival impact of primary tumor 
resection in stage IV CRC. Only a prospective randomized trial could confirm the survival benefit 
conferred by the primary tumor resection. Such trials are ongoing in Europe and will be important 
to solve this very important question in the management of stage IV CRC. 
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Table 6.1: Characteristics of patients in the entire cohort and subgroups of patients who 
were treated with surgery and systemic therapy versus systemic therapy alone. 
Variables Study cohort 
N=569 
Resection 
group 
N=313 (55) 
Non-resection 
group 
N=256 (45) 
P value 
Demographic     
Median age 69 (30-95) 68  (33-95) 70 (30-95) 0.23 
  Age 65 years or greater 340 (60) 180 (58) 160 (62) 0.23 
Previous History of Cancer 82 (14) 39 (13) 43 (17) 0.15 
ECOG performance status 2 or 
more 
201 (35) 79 (25) 122 (48) <0.001 
Charlson comorbidity index * 141 (25) 85 (27) 56 (22) 0.056 
Male 335 (59) 181 (58) 154 (60) 0.61 
Current or ex-smoker 344 (60) 196 (63) 148 (58) 0.26 
Laboratory values     
Albumin g/l 32 ±6 33 ±7 31 ±6 0.39 
Alkaline phosphatase U/l 202 ±277 179 ±309 230 ±229 0.12 
Bilirubin ug/l 15 ±24 11 ±11 18 ±34 <0.001 
Blood urea nitrogen mm/l 7 ±27 7 ±29 8 ±24 0.86 
CEA ug/l 581 ±3006 376 ±1988 830 ±3895 0.004 
Creatinine um/l 91 ±63 86 ±31 97 ±88 <0.001 
Hemoglobin g/l 111 ±119 123 ±16 118 ±17 0.82 
Platelet   109/l 350 ±124 334 ±114 368 ±135 0.061 
White blood cell count 109/l 11.3 ±47 8.9 ±8 10.2 ±4 0.61 
Sodium meq/l  137 ±3 138 ±3 137 ±3 0.27 
Treatment      
Chemotherapy 326 (57) 199 (64) 127 (50) 0.001 
   Second line therapy 174 (53) 110 (55) 64 (50) 0.23 
   Third line therapy 52 (16) 36 (18) 16 (13) 0.12 
   FOLFIRI OR FOLFOX 298 (91) 182 (92) 116 (91) 0.56 
   Biologics 218 (67) 137 (69) 81 (64) 0.24 
   FOLFIRI & FOLFOX plus a 
biologics 
133 (41) 89 (45) 44 (35) 0.045 
Radiation therapy 90 (16) 45 (14) 45 (18) 0.30 
Metastasectomy 89 (16) 81 (26) 8 (3) <0.001 
Metastatic sites     
Extra-hepatic disease 305 (54) 151 (48) 154 (60) 0.005 
  Bone 21 (7) 6 (4) 15 (10) 0.038 
   Brain 5 (2) 2 (1) 3 (2) 0.50 
   Lung 125 (41) 50 (33) 75 (49) 0.004 
  Peritoneum 124 (41) 73 (48) 51 (33) 0.005 
Tumor     
Stage IVb 264 (46) 126 (40) 138 (54) 0.001 
Grade 3 151 (27) 79 (25) 72 (28) 0.44 
Mucinous 55 (10) 39 (13) 16 (6) 0.015 
Rectum or rectosigmoid tumor 190 (33) 86 (28) 104 (41) 0.001 
Symptomatic primary tumor 224 (39) 171 (55) 53 (21) <0.001 
*Mean Chalrson comorbidity score 9.58±1.53 in resection group compared with 9.50±1.44 non-resection group. Biologics= 
cetuximab, panitumumab or bevacizumab; CEA= carcinoembryonic antigen; ECOG= Eastern Cooporative Oncology Group; 
FOLFIRI=Infusional 5-FU, leucovorin and irinotecan; FOLFOX=Infusional 5-FU, leucovorin and oxaliplatin;  
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Table 6.2: Relationship between various clinicopathological variables and survival in 
univariate analysis. 
Variables  HR (95% CI) P value HR (95% CI) for 
Interaction with 
SPRT 
P value 
Age ≥65 years 1.87 (1.56-2.25) <0.001 1.36 (0.95-1.94) 0.096 
Male gender 0.90 (0.75-1.10) 0.22 1.17 (0.83-1.67) 0.37 
ECOG PS 2.51 (2.09-3.02) <0.001 0.94 (0.65-1.36) 0.75 
Comorbid illness 1.50 (1.23-1.85) <0.001 1.11 (0.74-1.67) 0.63 
Current Smoking 0.86 (0.69-1.08) 0.20 0.80 (0.52-1.26) 0.35 
Ex-Smoking 0.91 (0.76-1.09) 0.31 1 (0.70-1.43) 0.98 
Treatment Centers 1.04 (0.87-1.23) 0.68 1.33 (0.94-1.89) 0.11 
Albumin <35 g/l 1.95 (1.60-2.39) <0.001 0.76 (0.49-1.19) 0.23 
Alkaline phosphatase >120 U/l 2.17 (1.79-2.62) <0.001 1.04 (0.70-1.55) 0.85 
Bilirubin ≥26 um/l  1.77 (1.28-2.46) 0.001 1.93 (0.97-3.87 0.06 
BUN ≥8 mm/l 1.48 (1.13-1.93) 0.007 1.82 (1.05-3.16) 0.034 
CEA  ≥5 ug/l 2.11 (1.63-2.76) <0.001 1.18 (0.64-2.20) 0.60 
Creatinine ≥120 um/l 1.46 (1.06-1.99) 0.026 1.36 (0.72-2.57) 0.34 
Hemoglobin <120 g/l 1.82 (1.49-2.22) <0.001 0.90 (0.60-1.34) 0.60 
Platelet count, ≥450 x109/l  0.92 (0.73-1.17) 0.51 1.14 (0.70-1.86) 0.60 
WBC ≥11 x 109/l  1.39 (1.12-1.71) 0.004 1.30 (0.84-2.01) 0.23 
Sodium <135 meq/l 1.19 (0.95-1.48) 0.14 1.02 (0.65-1.60) 0.92 
Extra-hepatic disease 1.21 (1.02-1.44) 0.031 1.36 (0.96-1.94) 0.08 
Grade 3 1.48 (1.22-1.79) <0.001 1.34 (0.91-1.97) 0.14 
Mucinous pathology 1.13 (0.85-1.51) 0.40 1.74 (0.92-3.28) 0.09 
Rectum 0.80 (0.66-0.96) 0.014 0.84 (0.58-1.24) 0.39 
Stage IVb disease 1.38 (1.16-1.64) <0.001 1.43 (1.01-2.03) 0.04 
Symptomatic primary tumor 1.08 (0.90-1.28) 0.42 1.05 (0.71-1.55) 0.82 
Primary tumor resection 0.44 (0.37-0.53) <0.001 NA NA 
Metastasectomy 0.30 (0.22-0.40) <0.001 0.74 (0.58-0.94) 0.015 
Chemotherapy 0.24 (0.20-0.29) <0.001 1.36 (0.95-1.94) 0.09 
Second line Treatment 0.44 (0.36-0.53) 0.025 2.10 (1.28-3.35) 0.003 
Third line Treatment 0.41 (0.30-0.56) <0.001 1.77 (0.89-3.49) 0.10 
FOLFOX or FOLFIRI 0.27 (0.23-0.33) <0.001 1.49 (1.04-2.12) 0.029 
Biologics 0.34 (0.28-0.41) <0.001 1.44 (1.0-2.08) 0.05 
Radiation 0.66 (0.52-0.84) <0.001 0.97 (0.60-1.57) 0.90 
Biologics= cetuximab, panitumumab or bevacizumab; CEA= carcinoembryonic antigen; ECOG 
PS= Eastern Cooporative Oncology Group performance status; FOLFIRI=Infusional 5-FU, 
leucovorin and irinotecan; FOLFOX=Infusional 5-FU, leucovorin and oxaliplatin; 
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Table 6.3: Relationship between various clinicopathological variables and survival in 
multivariate analysis. 
 
Variables  HR (95% CI) 
Primary tumor resection   
   Yes 0.44 (0.35-0.56) 
   No 1 
Chemotherapy   
  Yes 0.33 (0.26-0.43) 
  No 1 
Metastasectomy  
  Yes 0.43 (0.31-0.58) 
  No 1 
Second line therapy  
  Yes 0.50 (0.35-0.70) 
  No 1 
Third line therapy   
  Yes 0.58 (0.41-0.83) 
  No 1 
Alkaline phosphatase >120 U/l  
 Yes 1.50 (1.20-1.78) 
  No 1 
Grade 3 tumors  
  Yes 1.33 (1.10-1.62) 
  No 1 
Leukocytosis  
  Yes 1.32 (1.05-1.66) 
  No 1 
Stage IVb disease   
  Yes 1.31 (1.10-1.56) 
   No  
ECOG performance status >1  
  Yes 1.30   (1.04-1.57) 
  No 1 
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Figure 6.1: Flow diagram of eligible patients with stage IV colorectal cancer patients who 
underwent surgical resection of primary tumor or did not have surgery.  
Assessed for eligibility (n=765)  
Analysed (n=313) 
 
Lost to follow-up (n=0) 
Underwent resection of primary tumor            
(n=313) 
Lost to follow-up (n=0) 
Did not have surgery                              
(n=256) 
 
Analysed (n=256) 
 
 
Intervention 
Analysis 
Follow-Up 
Excluded (n= 196) 
♦   Not meeting inclusion criteria (n=182) 
       
Eligible patients (n=569)    
 
Enrollment 
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Figure 6.2: Overall survival of patients who underwent surgery compared with no surgical 
intervention during the period of modern chemotherapy.  
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Figure 6.3: Overall survival of patients who received second-line therapy and underwent 
surgery of the primary tumor (6.3A) versus if they did not receive second-line therapy 
(6.3B).  
 
Figure 6.3A 
 
 
Figure 6.3B 
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Figure 6.4: Overall survival of patients with stage IV colorectal cancer who were treated 
with combination of chemotherapy and biologics and underwent surgery compared with no 
surgery.  
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CHAPTER 7 – CAMPANION STUDY I: PREDICTIVE FACTORS FOR THE USE 
 OF CHEMOTHERPAY IN METASTATIC COLORECTAL CANCER  
 
The following two chapters will review the results of the two companion studies that are related 
to our primary research objectives. The present chapter will evaluate the prevalence of the use of 
chemotherapy in patients with stage IV CRC and its relationship with various variables. The next 
chapter will assess the prognostic importance of the primary tumor-related factors including 
regional lymph nodes status and the ratio of metastatic to examined lymph node in metastatic CRC. 
 
Over the past decade combination chemotherapy and biologics have significantly improved the 
prognosis of patients with stage IV CRC. The aims of chemotherapy in patients with advanced 
CRC are to prolong survival, to control cancer-related symptoms, and to maintain or improve 
quality of life. In our 1992-2005 cohort study, chemotherapy was found to be the most important 
prognostic variable. In a multivariate analysis, after adjustments for other prognostic variables, 
5FU-based chemotherapy was associated with 57% relative reduction in mortality (HR for 
mortality 0.43, 95% CI: 0.36-0.53). The findings were confirmed in the second cohort (2006-
2010). For example, use of modern chemotherapy was associated with 67% relative reduction in 
mortality compared with no chemotherapy (HR 33; 95% CI: 0.26-0.43). Notably, in the 1992-2005 
cohort, less than 50% patients received chemotherapy. In general, patients’ medical condition is 
the prime consideration in making a treatment recommendation. Although in a clinical trial setting 
strict eligibility criteria are used for utilization of chemotherapy, little is known about the use of 
chemotherapy in general population and whether its utilization is truly guided by patient medical 
conditions.  
 
The present chapter examines various patients- and tumor-related characteristics and co-
interventions that are associated with the use of chemotherapy in patients with stage IV colorectal 
cancer. Part of the data was presented in June 2011 at the American Society of Clinical Oncology 
annual meeting in Chicago, USA. The result was published in the Oncology “Ahmed S, Pahwa P, 
Fields A, Chandra-Kanthan S, Iqbal N, Zaidi A, Reeder B, Plaza FA, Zhu T, Leis A. Predictive 
Factors of the Use of Systemic Therapy in Stage IV Colorectal Cancer: Who Gets Chemotherapy? 
Oncology. 2015;88(5):289-97”.  
 
7.1 Abstract  
 
Background: Chemotherapy improves survival in patients with stage IV CRC. Although in a 
clinical trial setting, strict eligibility criteria are used for chemotherapy, little is known about the 
use of chemotherapy in the general population. The study aims to assess clinicopathological 
variables that correlate with the use of chemotherapy in patients with stage IV CRC.  
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Methods: A retrospective cohort study involving patients with stage IV CRC, diagnosed between 
1992 and 2005, in the province of Saskatchewan was carried out. A logistic regression analysis 
was performed to assess correlation of various clinicopathological factors with the use of 
chemotherapy.  
 
Results: A total of 1,237 eligible patients were identified. Their median age was 70 years (range: 
22-98) and M: F ratio was 1.3:1. 23.8% had an ECOG performance status (PS) of ≥2 and 61.8% 
patients had a comorbid illness. 46.8% patients received chemotherapy. The multivariate logistic 
regression analysis revealed that age <65 year (OR 3.82, 95% CI: 2.59-5.63), metastasectomy (OR 
3.60, 95% CI:1.82-7.10), normal albumin (OR 3.26, 95% CI:2.44-4.36), no comorbid illness (OR 
2.87, 95% CI:1.34-6.16), ECOG PS of <2 (OR 2.72, 95% CI:1.94-3.82), normal blood urea 
nitrogen (OR 2.24, 95% CI:1.40-3.59), palliative radiation (OR 2.03, 95% CI:1.38-2.99), primary 
tumor resection (OR 2.00, 95% CI:1.47-2.73), and the time period (OR 1.85, 95% CI:1.41-2.42) 
were significantly correlated with the use of chemotherapy. 
 
Conclusions: The use of chemotherapy appears to be increasing in stage IV CRC.  Patients treated 
with curative intention or who underwent primary tumor resection were more likely to receive 
chemotherapy. Despite a known benefit of chemotherapy in elderly patients, a differential use of 
chemotherapy was noted in this population.  
 
7.2 Introduction 
 
Colorectal cancer is the second leading cause of cancer-related death in North America. It is 
expected to cause more than 50,000 deaths during year 2014 (1). Despite the advent of colorectal 
cancer screening program approximately 20-30% patients with CRC are diagnosed with stage IV 
disease. The median overall survival of patients with stage IV CRC with best supportive care alone 
is about 5-6 months (2).  The introduction of novel therapies including two cytotoxic agents, 
irinotecan and oxaliplatin, and three monoclonal antibodies, bevacizumab, cetuximab and 
panitumumab, has significantly improved the prognosis of patients with stage IV CRC. Overall, 
with the judicious use of active agents in the management of CRC, the median overall survival of 
patients with stage IV CRC has approached to about 30 months (3-6).  
 
Palliative chemotherapy is now offered to an increasing proportion of patients with stage IV CRC. 
Several groups have published guidelines on the management of advanced CRC (7-9). All groups 
endorse the use of chemotherapy in stage IV CRC. The aims of chemotherapy in patients with 
advanced CRC are to prolong survival, control symptoms, and to maintain or improve quality of 
life. Hence, potential morbidity of treatment and the impact of treatment on patients’ quality of 
life must be considered. The patients’ general medical condition is the prime consideration when 
making a treatment recommendation.  In a clinical trial setting, strict eligibility criteria are used 
for chemotherapy. However, little is known about the use of chemotherapy in the general 
population and whether its use is truly guided by patients’ medical conditions. We conducted a 
cohort study to assess prognostic significance of the resection of primary tumor in patients with 
stage IV CRC and noted that less than 50% of patients received chemotherapy (10). The current 
study aims to assess prevalence of the use of chemotherapy in patients with stage IV CRC and to 
examine various patients- and tumor-related characteristics and cointerventions that are associated 
with the use of chemotherapy in patients with stage IV colorectal cancer.  
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7.3 Methods 
 
7.3.1 Study Population   
 
The study protocol was approved by the Research Ethics Board of the University of Saskatchewan. 
The study population was comprised of a cohort of consecutive adult patients with histologically 
documented stage IV adenocarcinoma of colon and rectum, diagnosed in the period of 1992 and 
2005, in the province of Saskatchewan, Canada. Patients with other histological diagnosis or with 
other active secondary malignancy were excluded. In addition, patients who died within 30 days 
of diagnosis of the cancer were excluded. The Saskatchewan Cancer Registry was used to identify 
eligible patients. In addition to registry data, individual patients’ medical records were 
retrospectively reviewed. All information was abstracted by a trained research associate using a 
validated abstraction sheet.  
 
7.3.2 Definitions 
 
The symptomatic primary tumor was defined as the presence of obstruction, perforation or major 
bleeding. Major comorbid illnesses were defined as the presence of coronary artery disease, 
diabetes mellitus, chronic renal insufficiency, chronic obstructive lung disease and others 
(uncontrolled hypertension, peripheral vascular disease, stroke or transient ischemic attack, 
interstitial lung disease, congestive heart failure, and cardiac arrhythmia). Performance status 
information was collected using the ECOG scale. If the Karnofsky performance status scale was 
used, it was converted to ECOG score (11). If performance status was not documented, information 
was captured by reviewing the consultation notes using a validated abstraction sheet.  
 
7.3.3 Statistical Analysis 
 
 The baseline characteristics of patients were compared using the chi square and Student t test. The 
cumulative survival rate was calculated using the Kaplan-Meier method, and differences between 
survival curves were tested with the log-rank test. A multivariate analysis was performed to 
determine the factors correlated with the use of chemotherapy in patients with stage IV CRC. A 
logistic regression analysis was done and the odd ratio (OR) and its 95% CI were estimated. The 
following variables were examined with respect to their correlation with the use of chemotherapy: 
Age (<65 vs. ≥65), sex, major comorbid illness, ECOG performance status (<2 vs. ≥2), smoking, 
sodium level (≤135 mEq/l vs. >135 mEq/l), serum creatinine (≥120 vs. <120 um/l), blood urea 
nitrogen (BUN) (≥8 vs. <8 mm/l), albumin (≥35 vs. <35 g/l), bilirubin (≥26 vs. <26 um/l), alkaline 
phosphatase (≥100 vs. <100 U/l), hemoglobin (≥120 vs. <120 g/l), WBC (≥11 vs. <11 x 109/l), 
metastatic sites (≥2 or <2), symptomatic primary tumor, extrahepatic metastases, radiation therapy, 
resection of primary tumor, metastasectomy, and time period (≥ year 2000 vs. <2000). The study 
cutoff was chosen due to the fact that in the early 1990s, 5-fluorouracil became available for 
patients with advanced CRC and in the year 2000, irinotecan and subsequently oxaliplatin and 
monoclonal antibodies became available in the province of Saskatchewan. Tests for interaction 
were performed for age, performance status, comorbid illness and the other variables. 
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A two-sided P-value of <0.05 were considered to be statistically significant. All variables that were 
significant on univariate analysis were subsequently examined in a multivariate model, to assess 
their correlation with the use of chemotherapy. The likelihood ratio test and t test were used to 
determine whether the addition of independent variables of interest add significantly to the 
association with the use of chemotherapy in the model. The imputation technique was used for 
missing data. SPSS version 20 & 21.0 were used for statistical analysis (SPSS Inc. Chicago, IL). 
 
7.5 Results 
 
7.5.1 Patients’ Characteristics  
 
Fifteen hundred twenty-nine patients with newly diagnosed stage IV colorectal cancer were 
assessed for their eligibility. Of those 151 patients were excluded; 114 did not meet the inclusion 
criteria and 37 had limited medical information. Of remaing1378 patients, 141 were died within 
30 days of diagnosis and were excluded from the analysis.    A total of 1,237 eligible patients were 
identified. Their median age was 70 years (range: 22-98) and male to female ratio was 1.3:1. Seven 
hundred eighty-one (56.8%) patients were male, 294 (23.8%) had ECOG performance status of 2 
or greater and 764 (61.8%) patients had a comorbid illness. Of the 1,237 patients, 580 (46.8%) 
received palliative chemotherapy. Among the patients who received chemotherapy, 263 (45.3%) 
received irinotecan- or oxaliplation-based combination chemotherapy during the course of their 
disease. Less than 5% patients were treated with biologics. Of the 263 patients who were treated 
with novel agents, 218 (83%) received this treatment after the year 1999. The patients’ 
characteristics are described in Table 7.1.  Significance differences were noted between the two 
groups with respect to their age, performance status, presence of a comorbid illness, mean serum 
albumin level, serum bilirubin level, serum creatinine, BUN, CEA, hemoglobin, and presence of 
leukocytosis. In addition, a significantly higher proportion of patients in the chemotherapy group 
underwent surgical resection of primary tumor or metastasectomy and received palliative radiation 
therapy.  Three hundred (36.9%) of 812 patients who were ≥65 years of age received palliative 
chemotherapy compared with 280 (65.9%) of 425 patients who were <65 year (<0.001).  Of the 
580 patients who received chemotherapy, on progression 83 (37.4%) of the 300 patients ≥65 years 
of age received second-line therapy compared with 139 (62.6%) of the 280 patients <65 year 
(<0.001).  During the year 2000 and onward, 292 (51.9%) of the 553 patients with advanced CRC 
received chemotherapy compared with 288 (42.7%) of the 674 patients who were diagnosed before 
the year 2000 (P<0.001) (Figure 7.1). The use of chemotherapy increased with the availability of 
second-line therapy, but decreased with increasing age at the diagnosis (Figure 2).   
 
7.5.2 Multivariate Analysis 
 
On univariate logistic analysis, various clinicopathological factors were identified that were 
correlated with use of chemotherapy (Table 7.2). Among them ECOG performance status of <2, 
age <65 years, normal albumin, metastasectomy, surgical resection of primary tumor, palliative 
radiation therapy, and time period were most strongly correlated with the use of chemotherapy.  
Tests for interaction were significant between age and elevated alkaline phosphatase, 
metastasectomy, elevated BUN, anemia, extrahepatic disease, male sex, and high grade-tumor, 
and comorbid illness and metastasectomy. All the significant variables were fitted into a 
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multivariate logistic regression model. The multivariate logistic regression analysis revealed that 
age <65 year (OR 3.82, 95% CI:2.59-5.63), metastasectomy (OR 3.60, 95% CI:1.82-7.10), normal 
albumin (OR 3.26, 95% CI:2.44-4.36), absence of a comorbid illness (OR 2.87, 95% CI:1.34-
6.16), ECOG PS of <2 (OR 2.72, 95% CI:1.94-3.82), normal blood urea nitrogen (OR 2.24, 95% 
CI:1.40-3.59), palliative radiation therapy (OR 2.03, 95% CI:1.38-2.99), primary tumor resection 
(OR 2.00, 95% CI:1.47-2.73), and the time period (OR 1.85, 95% CI:1.41-2.42) were most 
strongly correlated with the use of chemotherapy in patients with newly diagnosed stage IV CRC 
(Table 7.3).  
 
7.5.3 Survival  
 
Median time to initiation of chemotherapy from the date of diagnosis was 70 days (interquartile 
range: 46-107 days). The median follow-up period was 8.8 months (interquartile range: 3.7-19.1). 
Median survival of the whole cohort was 8.8 months (95% CI: 8.0-9.6) [Figure 7.3]. Patients who 
were treated with chemotherapy had median survival of 16 months (95% CI: 14.6-17.5) compared 
with 4.6 months (95% CI: 4.1-5.1) if they did not receive chemotherapy (p<0.001). Patients who 
were diagnosed after the year 1999 and received chemotherapy had a median survival of 17.5 
months (95% CI: 15.2-19.9) compared with 14.8 months (95% CI: 13.3-16.3) if they were 
diagnosed before the year 2000 (P=0.15). With respect to age, patients ≥65 years of age who 
received chemotherapy had median survival of 15.1 months (95%CI: 13.6-16.6) compared with 
17.5 months (95% CI: 15.1-20.0) of patients who were <65 years of age (p=0.01) [Figure 7.3]. 
With respect to performance status, patients with ECOG PS ≥2 who received chemotherapy had 
median overall survival of 7.6 months (95% CI: 4.0-11.2) compared with a survival of 17.3 months 
(95% CI: 15.8-18.9) if they have ECOG PS of <2 (P<0.001).  
 
7.6 Discussion 
 
The current study is the first large population-based cohort study, over a time span of fourteen 
years that assessed the use of chemotherapy in patients with stage IV CRC. Overall, 47% patients 
were treated with chemotherapy. However, with the availability of novel chemotherapeutic agents 
in the management of advanced CRC, the prevalence of use of chemotherapy increased from 
approximately 43 to 52%.  
 
The current study revealed that age, resection of metastatic lesions, normal serum albumin, good 
performance status, and lack of comorbid illness were most strongly correlated with the use of 
chemotherapy in patients with newly diagnosed advanced CRC. While the decision to commence 
chemotherapy is a complex one that must be made on individual basis, our results revealed that 
independent of comorbid illness, the use of chemotherapy progressively declined with increasing 
age. Patients of ≥65 years of age were about four times more likely to receive no treatment than 
younger patients. Moreover, the positive interaction between age and hemoglobin suggests that 
elderly patients with normal hemoglobin are more likely to receive chemotherapy than patients 
with anemia.  Of note, the majority of colorectal cancers are diagnosed in the elderly population. 
Moreover, the median age of the study cohort was 70 years. Although few chemotherapy studies 
in CRC have been specifically designed for elderly patients, there is evidence that elderly patients 
with good performance status tolerate palliative chemotherapy as well as younger patients and 
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have similar benefits from palliative chemotherapy (12,13). In the current study elderly patients 
who received chemotherapy had median survival of 15 months compared with approximately 5 
months with best supportive care.  There are several clinician- and patient-related factors that may 
influence the use of chemotherapy in the elderly population. For instance, the oncologist’s decision 
regarding chemotherapy for elderly patients is likely to be based on estimated risk versus benefit. 
The physiological changes of ageing, presence of comorbid illnesses, and polypharmacy are the 
key factors that particularly amplify complications of chemotherapy in elderly patients. 
Conversely, older patients may have different perspective than younger patients when deciding 
whether to accept chemotherapy, and short-term quality of life may be more important than a 
modest survival advantage. Furthermore, nonmedical barriers to care such as absence of supportive 
caregivers may contribute to differential use of chemotherapy in elderly patients.  
 
Our data also demonstrate a strong association between serum albumin and the use of 
chemotherapy in advanced CRC.  Serum albumin provides a simple method of estimating visceral 
protein function. Malnutrition and inflammation suppress albumin synthesis (14).  Low serum 
albumin is one of the surrogate markers of malnutrition in patients with advanced cancer.  Several 
observational studies have suggested that low serum albumin is associated with higher mortality 
from cancer (14). Malnutrition in patients with advanced cancer is not uncommon and results from 
underlying cancer, the host response to the cancer, and anticancer therapies. It has been associated 
with an increased risk of chemotherapy-related toxicity as well as decreased response to treatment, 
poor quality of life, and an inferior survival (14,15).  
 
With few exceptions, in most advanced solid tumors, poor performance status correlates closely 
with reduced survival and in many cases reduced response to chemotherapy (16). Hence, there is 
a belief that patients with advanced solid tumors with a poor performance status would gain little 
benefit from chemotherapy. Data on patients with advanced CRC and a poor performance status 
are scant. Clinical trials often excluded patients with ECOG performance status of ≥2 or with a 
limited life expectancy. In our study cohort, patients with poor performance status, who received 
chemotherapy had median overall survival of 7.5 months compared with 17 months if they had a 
good performance status. The modification in the chemotherapeutic regimen and dose reduction 
may reduce major complications in patients with borderline performance status.  In addition, 
treatment should be started as soon as possible before the performance status further deteriorates. 
It is not known if access to more effective anticancer therapy, better antiemetics, and growth 
factors support improve outcomes of such patients.  
 
Of note, for reasons which are not well understood, elevated BUN was inversely correlated with 
the use of chemotherapy. Elevated BUN, also known as azotemia, is a marker of dehydration and 
gastrointestinal bleeding. It has been identified as a poor prognostic variable in patients with 
advanced cancer and correlates with seven days’ mortality (17). Furthermore, a negative 
correlation was noted between comorbid illness and use of chemotherapy.  Ageing is associated 
with a high prevalence of comorbid diseases including hypertension, coronary artery disease, 
diabetes mellitus, and chronic obstructive lung disease among others. These comorbid illnesses 
may have a considerable impact on the patient’s tolerance to chemotherapy and hence influence 
the use of chemotherapy. 
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Our results suggest that the use of chemotherapy is increasing over time. For many years, 5-
fluorouracil was the only active agent available in the management of patients with advanced CRC. 
More recently access to several novel agents including two cytotoxic agents, irinotecan and 
oxaliplatin, and three humanized monoclonal antibodies, including bevacizumab and cetuximab 
and panitumumab that target vascular endothelial growth factor (VEGF) and the epidermal growth 
factor receptor, respectively, has resulted in significant improvement in survival of patients with 
stage IV CRC (3-6). With the availability of novel agents in the management of advanced CRC, 
we noted an approximately 25% increase in the use of chemotherapy. A Canadian study also 
demonstrated similar findings (18). Between 2003-04 (pre-bevacizumab era) and 2006 
(bevacizumab era), the proportion of patients treated with systemic therapy for stage IV CRC 
significantly increased from 61.1% to 67.6%. In addition, the likelihood of the use of 
chemotherapy was higher in patients who underwent surgical resection of primary tumor or 
metastasectomy. Between 30% and 38% of patients diagnosed with stage IV CRC undergo one or 
more major surgical procedures (19). Surgical intervention may be performed with a curative 
intention or for symptomatic palliation (20). Selected patients with metastases limited to the lung 
and or liver can be cured with metastasectomy and adjuvant use of chemotherapy. The better 
prognosis of patients with limited disease burden supports a greater use of chemotherapy in such 
patients (3,20).  
 
Our results revealed a sex ratio difference of 1.3:1. The incidence rates of CRC have been 
decreasing for most of the past two decades, which has largely been attributed to increases in the 
use of screening tests. Overall, incidence rates are lower in women than men, with a particularly 
striking discrepancy between premenopausal women and age-matched men (21,22). The estimated 
age standardized incidence of colorectal cancer in Canada, in 2014, is 59.4 per 100,000 cases in 
male versus 39.8 per 100,000 cases in female (23).  
 
There are several limitations of this study. It is a retrospective study that was performed before the 
era of monoclonal antibodies. With the growing number of novel therapies in the management of 
colorectal cancer and the increasing awareness of the benefit of systemic therapy in advanced 
CRC, our results may not reflect the current clinical practice.  Furthermore, in this study we did 
not assess the role of nonmedical factors such as ethnicity, socioeconomic status, family support 
and patients’ perspectives on benefits and toxicities of treatment that can affect their likelihood of 
receiving chemotherapy. Data regarding variation in the use of chemotherapy, in relationship with 
various sociocultural variables in stage IV CRC, are scarce and are mostly limited to the use of 
adjuvant therapy. For instance, Potosky et al. investigated the disparity in the use of adjuvant 
therapies according to age, sex, and race/ethnicity and found differential uses of chemotherapy in 
elderly or African American patients with stage II & III CRC (24). Mcleod also showed that 
patients’ characteristics, the areas in which they are resident, and the hospitals to which they are 
referred impact upon the type of treatment they receive (25). However, this analysis was not 
limited to stage IV CRC. We have undertaken a cohort study involving patients diagnosed during 
the period of 2006-2010 to validate our findings. In this study, information about various area level 
variables will be collected to assess their influence on the use of palliative chemotherapy. The 
research will also explore the relationship between the distance to the cancer center and the use of 
chemotherapy in patients with stage IV CRC. 
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In conclusion, this first large population-based study using various clinical variables including 
performance status demonstrates that the use of palliative chemotherapy is increasing. In addition 
to known variables such as good performance status and comborbid illness, patients who are 
treated with curative intent or who undergo resection of the primary tumor are more likely to 
receive chemotherapy. Despite the known benefit of chemotherapy in elderly patients with CRC, 
a differential use of cancer therapy is noted in this population. Future research to clarify patients’ 
preference for chemotherapy is warranted, in order to minimize age-related bias on treatment 
decisions. 
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Table 7.1: Baseline characteristics of patients who received chemotherapy and patients in 
the control group who did not receive chemotherapy.  
 
Variables 
(Mean) 
Total patients 
N=1237 
(%)±SD 
Chemotherapy 
N=580 
(%)±SD 
Control 
N=657 
(%)±SD 
P value 
Median age years  70 (range: 22-
98) 
65 (22-89) 75 (33-98) <0.001 
Age >65 years 812 (65.6) 300 (51.7) 512 (77.9) <0.001 
Male 703 (56.8) 340 (58.6) 363 (55.3) 0.13 
Comorbid illness 764 (61.8) 333 (57.4) 431 (65.6) 0.002 
ECOG PS ≥2 294 (23.8) 64 (11) 230 (35) <0.001 
Active smoker 159 (12.9) 82 (14.1) 77 (11.7) 0.23 
Rectal tumors* 386 (31.2) 184 (31.7) 202 (30.7) 0.37 
Grade 3 cancer 234 (18.9) 109 (18.8) 125 (19) 0.48 
Extra-hepatic disease 619 (50) 291 (50.2) 328 (49.9) 0.48 
Metastases≥2 sites 360 (29.1) 167 (28.8) 193 (29.4) 0.43 
Symptomatic disease 483 (39) 222 (38.3) 261 (39.7) 0.32 
 Albumin g/l 34.3±5.5 35.5±5.3 33.3±5.5 <0.001 
Alkaline phosphatase U/l 187±234 179±191 200±266 0.20 
Bilirubin um/l 13.2±24.8 11.7±24.6 14.7±24.9 0.04 
BUN mm/l 5.8±4.4 5.1±2.6 6.5±5.5 <0.001 
Creatinine um/l 88.1±30.8 83.7±28.4 92.0±32.4 <0.001 
CEA mcg/l 253±1532 368±2155 152±550 0.013 
Hemoglobin g/l 118±16 120±17 117±15 0.001 
Sodium <135 mEq/l 168 (13.6) 72 (12.4) 96 (14.6) 0.14 
White blood cell count 
≥12 x 109/l 
222 (17.9) 91 (15.7) 131 (19.9) 0.03 
Received radiation 185 (15) 125 (21.6) 60 (9.1) <0.001 
Resection of primary 
tumor 
881 (71.2) 469 (80.9) 412 (62.7) <0.001 
Metastasectomy  194 (15.7) 130 (22.4) 64 (9.7) <0.001 
*Rectum or recto-sigmoid disease, SD=standard deviation 
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Table 7.2: Univariate correlation between various clinicopathological variables and the use 
of chemotherapy in patients with stage IV colorectal cancer.  
Variables Odd Ratio 95% Confidence 
Interval 
P value 
 
Age ≤65 years 3.30 2.58-4.22 <0.001 
Male 1.15 0.92-1.44 0.23 
No comorbid illness 1.42 1.12-1.78 0.003 
ECOG PS <2 4.34 3.20-5.89 <0.001 
Extra-hepatic disease 1.01 0.81-1.26 0.93 
Symptomatic disease 1.06 0.85-1.34 0.60 
 Albumin <35 g/l 4.53 3.54-5.78 <0.001 
Alkaline phosphatase <100 IU 2.17 1.68-2.80 <0.001 
Bilirubin <26 mm/l 2.15 1.20-3.83 <0.001 
Sodium ≥136 meq/l 1.21 0.87-1.68 0.26 
BUN  <8 mm/l 2.35 1.55-3.57 <0.001 
Creatinine <120 mm/l 1.24 0.81-1.91 0.32 
Hemoglobin ≥120 g/l 1.91 1.52-2.40 <0.001 
White blood cell count <12 x 109/l 1.34 1.0-1.80 0.052 
Metastases <2 sites 1.01 0.76-1.24 0.82 
Surgical resection of primary tumor 2.51 1.94-3.26 <0.001 
Received radiation 2.73 1.96-3.81 <0.001 
Metastasectomy  2.68 1.94-3.70 <0.001 
Time Period* 1.44 1.15-1.81 0.001 
* Diagnosed ≥ Jan 1st 2000 during the era of second line therapy.  
  
125 
 
Table 7.3: Multivariate correlation between various clinicopathological variables and the 
use of chemotherapy in patients with stage IV colorectal cancer.  
 
Variables Odd Ratio 95% Confidence 
Interval 
P value 
 
Age ≤65 years 3.82 2.59-5.61 <0.001 
Male 1.19 0.90-1.56 0.22 
No comorbid illness 2.87 1.34-6.16 0.007 
ECOG PS <2 2.72 1.94-3.82 <0.001 
 Albumin ≥35 g/l 3.26 2.44-4.36 <0.001 
BUN  <8 mm/l 2.24 1.40-3.59 0.001 
Hemoglobin ≥120 g/l 1.48 0.93-2.34 0.10 
Surgical resection of primary tumor 2.00 1.47-2.73 <0.001 
Received radiation 2.03 1.38-3.00 <0.001 
Metastasectomy  3.60 1.82-7.10 <0.001 
Time Period* 1.85 1.41-2.42 <0.001 
Age X hemoglobin 0.45 0.27-0.82 0.007 
comorbid illness x metastesectomy 0.29 0.13-0.66 0.003 
* Diagnosed ≥ Jan 1st 2000 during the era of second line therapy.  
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Figure 7.1: Prevalence of chemotherapy in patients with advanced colorectal cancer in two 
different time periods in relationship with the availability of novel therapy.   
 
 
 
 
 
 
 
 
  
42.7% vs. 51.9% patients 
received chemotherapy (p<0.01) 
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Figure 7.2: Association between increasing age (2A) and year of diagnosis (2B), and the use 
of chemotherapy in patients with advanced colorectal cancer.   
7.2A 
 
 
 
 
 
 
 7.2B 
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Figure 7.3: Survival of the whole cohort (3A) and subcohort of patients ≥65 year old (3B) 
with advanced CRC who received chemotherapy versus best supportive care.  
 
7.3A 
 
 
7.3B
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CHAPTER 8 – CAMPANION STUDY II: THE IMPORTANCE OF REGIONAL 
LYMPH NODES STATUS IN METASTATIC COLORECTAL CANCER  
 
The pathological staging such as the degree of tumor infiltration through the bowel wall, 
histological grade, number of examined lymph nodes, and nodal metastases are known prognostic 
factors in the early-stage CRC. However, their significance in patients with stage IV CRC remains 
unknown. The present chapter addresses the importance of regional lymph nodes status in patients 
with metastatic CRC.  
 
Our research findings suggest that primary tumor resection in patients with stage IV CRC improves 
survival independent of chemotherapy, metastasectomy, comorbid illness, and performance status. 
Given the fact that there is a very little knowledge about the prognostic significance of primary 
tumor-related factors including regional nodes status in stage IV CRC, in this companion study we 
explored the relationship between nodal status or the ratio of metastatic to examined lymph node 
(LNR) and survival in patients with metastatic CRC. The study findings were presented at the 
European Society of Medical Oncology (ESMO) 2015 Annual Meeting in Vienna, Austria and at 
the Gastrointestinal Cancers Symposium 2016 Annual Meeting in San Francisco, USA in the 
poster sessions. The results were published in the Annals of Surgical Oncology “Ahmed S, Leis A, 
Chandra-Kanthan S, Fields A, Zaidi A, Abbas T, Le D, Reeder B, Pahwa P.Regional Lymph Nodes 
Status and Ratio of Metastatic to Examined Lymph Nodes Correlate with Survival in Stage IV 
Colorectal Cancer. Ann Surg Oncol. 2016 Mar 25. [Epub ahead of print]”.  
 
8.1 Abstract 
 
Background:  Although lymph nodes status and the ratio of metastatic to examined lymph node 
(LNR) are important prognostic factor in early-stage colorectal cancer (CRC), their significance 
in patients with metastatic disease remains unknown. The study aims to determine prognostic 
importance of nodal status and LNR in patients with stage IV CRC. 
 
Methods:  A cohort of 1109 eligible patients who were diagnosed with synchronous metastatic 
CRC in Saskatchewan during 1992-2010 and underwent primary tumor resection was evaluated. 
We conducted the Cox Proportional multivariate analyses to determine the prognostic significance 
of nodal status & LNR. 
 
Results:  Median age was 70 years (22-98) and M:F was 1.2:1. Rectal cancer was found in 26% 
patients; 96% had T3/T4 tumor, and 82% had node positive disease. The median LNR was 0.36 
(0-1.0). Fifty-four percent patients received chemotherapy. Median overall survival of patients 
who had LNR of < 0.36 and received chemotherapy was 29.7 months (95% CI: 26.6-32.9) 
compared with 15.6 months (95%
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CI: 13.6-17.6) with LNR of ≥ 0.36 (p < 0.001). On multivariate analyses, no chemotherapy, HR: 
2.36 (95% CI: 2.0-2.79); not having metastasectomy, HR: 1.94 (95% CI: 1.63-2.32); LNR ≥0.36, 
HR: 1.59 (95% CI: 1.38-1.84); nodal status, HR 1.34 (95% CI: 1.14-1.59); and T status, HR 1.23 
(95% CI: 1.07-1.40) were correlated with survival. Test for interaction was positive for LNR and 
high-grade cancer, HR1.51 (95% CI: 1.10-2.10). 
 
Conclusions:  Our results suggest that nodal status and LNR are important prognostic factors 
independent of chemotherapy and metastasectomy in stage IV CRC patients.  
 
8.2 Introduction 
 
Although pathological staging such as the degree of tumor infiltration through the bowel wall, 
histological grade, number of examined lymph nodes, and nodal metastases are important 
prognostic factors in the early-stage CRC, their significance in patients with stage IV CRC remains 
unknown. Lymph node involvement is one of the most important prognostic variables in early-
stage CRC (1). Adjuvant chemotherapy is recommended for node-positive CRC. In addition to 
nodal involvement, the numbers of lymph nodes harvested and examined are important prognostic 
factors. A systematic review examined relationship of the number of lymph nodes retrieved 
following colon resection and survival. Of 17 studies involving a total of 61,371 patients, 16 
showed a positive association between the number of lymph nodes examined and survival in stage 
II and III colon cancer patients (2). Nevertheless, a higher number of nodes examined do not 
necessarily predict having more nodes involved. There is evidence that the ratio of metastatic to 
examined lymph nodes (LNR) is an important prognostic factor in early-stage CRC (3).  
 
Approximately 20% patients are diagnosed with synchronous metastatic CRC with an in situ 
primary tumor. Combination chemotherapy with a biological agent is the standard treatment for 
most patients with newly diagnosed stage IV CRC (1). The optimal management of primary tumor 
in these patients remains controversial. We have reported that surgical resection of primary tumor 
improves survival independent of chemotherapy, metastasectomy, and performance status in 
patients with stage IV CRC (4,5). We hypothesized that regional nodal status in stage IV CRC has 
prognostic importance and correlates with survival. In this retrospective cohort study, we 
examined the relationship between nodal status or LNR and survival in patients with stage IV 
CRC.  
 
8.3 Methods 
 
8.3.1 Study Population  
 
The University of Saskatchewan’s Research Ethics Board approved the study protocol. The study 
population was comprised a cohort of adult patients with newly diagnosed stage IV 
adenocarcinoma of colon and rectum who underwent resection of primary tumor, from January 
1992 to December 2010, in the province of Saskatchewan, Canada. Patients with other histological 
diagnoses or with an intact primary tumor were excluded. The Saskatchewan Cancer Registry 
prospectively collects and updates its Registry. Using the Saskatchewan Cancer Registry, eligible 
patients were identified. A trained research associate reviewed the individual patient records and 
abstracted data. All patients were followed until their death or until June 2014 when the data entry 
was closed. 
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8.3.2 Statistical Analysis  
 
Overall survival was defined as “time from the diagnosis of stage IV CRC to death from any 
cause”. The Kaplan-Meier method was used to estimate survival. The log-rank tests were 
performed to compare survival distribution of different groups. Multivariate analyses were 
performed to determine the prognostic significance of nodal status and the LNR.  The continuous 
variables were dichotomized by specifying various cutoff points such as abnormal laboratory 
values.  For LNR, we used median value to divide the cohort into two groups. The Cox proportional 
hazard model was used, and the hazard ratio and its 95% CI were estimated. The following 
variables were examined with respect to their prognostic significance: age (<70 vs. ≥70), gender, 
major comorbid illness as per Charlson comorbid index, ECOG performance status (<2 vs. ≥2), 
active smoking, previous history of cancer, serum creatinine (≥120 vs. <120 mm/l), BUN (≥8 vs. 
<8 mm/l), albumin (≥36 vs. <36 g/l), bilirubin (≥26 vs. <26 um/l), alkaline phosphatase (≥120 vs. 
<120 mm/l), hemoglobin (≥120 vs. <120 g/l), WBC (≥11 vs. <11 x 109/l), platelet (≥450 vs. <450 
x109/l), CEA (≥5 vs. <5 mcg/l),  site (colon vs. rectal), grade (3 vs. <3), symptomatic disease, 
extra-hepatic metastases, stage (stage IVa vs. IVb), mucinous tumor, T status, LNR (<0.36 vs. 
≥0.36), number of lymph nodes removes (≥12 vs. r <12), nodal status, use of any chemotherapy, 
second-generation chemotherapy, metastasectomy,  and radiation therapy. We used log-log 
survival curves to assess the proportional hazards assumption for the variables examined in the 
final mathematical model.  
 
All variables with P<0.05, on univariate analysis, were examined, in a multivariate model to assess 
their correlation with survival. The likelihood ratio test and t test were used for each variable to 
determine if the addition of independent variable of interest adds significantly to the prediction of 
survival in the model. Test for interaction was performed for LNR and the variables that were 
significantly correlated with survival in the univariate analysis. A two-sided P-value of <0.05 were 
considered to be statistically significant. Because the time period for the study was long, a 
secondary analysis was performed in a sub-cohort of patients diagnosed from January 2006 to 
December 2010 during the period of combination chemotherapy and biologics. The SPSS version 
23.0 was used for statistical analysis (SPSS Inc. Chicago, IL).  
 
8.4 Results  
 
8.4.1 Patients Characteristics  
 
A total of 1257 patients with stage IV CRC who underwent resection of primary tumor during the 
study period were identified. Of these, 148 patients did not have information about lymph nodes 
status and were excluded (Figure 8.1). Median age of eligible patients was 70 years (range: 22-98 
years) and M:F was 1.2:1. Two hundred and eighty-three (25.5%) patients had rectal or 
rectosigmoid cancer; 1161 (95.7%) had T3/T4 tumor (mostly T4a), and 353 (31.8%) had stage IVb 
disease (Table 8.1). A total of 905 (81.6%) patients had node-positive disease. Of these, 407 
(45.0%) had N1 (up to 3 node were involved) and 498 (55.0%) had N2 (4 or more nodes 
involvement) disease. The median LNR was 0.36 (0-1.0). Based on median LNR score of 0.36 the 
patients’ cohort was divided into two groups. Group I with LNR of <0.36 and group II with LNR 
of ≥0.36. The median number of lymph nodes removed was 10 (range: 1-55); 10 (1-46) in group 
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with LNR ≥36 compared with 12 (1-55) in the group with LNR<36 (p=0.003). The median number 
of positive lymph node was 3 (0-46): 6 (1-46) in the group with LNR ≥0.36 compared with 1 (0-
10) in the group with LNR<0.36 (p<0.001). A total of 597 patients (53.8%) received 
chemotherapy; of those 44% received second-generation chemotherapy (FOLFIRI and or 
FOLFOX with a biologic). Also, 537 patients (47.8%) had extrahepatic disease, 286 (51.7%) in 
the group with LNR of ≥0.36 compared with 244 (43.9%) patients with LNR <0.36 (p=0.01). 
Lungs, peritoneum and distant lymph nodes were the most common extrahepatic sites. In addition, 
patients with LNR ≥0.36 has significantly increased proportion of high-grade tumor or mucinous 
cancer.  
 
8.4.2 Survival 
 
Median follow-up period was 13 months (inter-quartile range: 4.6-27.0 months). Median overall 
survival (OS) of whole cohort was 13 months (95% CI: 11.90-14.24). The group with LNR of 
<0.36 had median OS of 18 months (95% CI: 16.14-19.86) compared with 8.9 months (95% CI: 
7.60-10.25) with LNR of  ≥0.36 (p<0.001) [Figure 8.2]. A subcohort of 597 patients who received 
chemotherapy had median OS of 21 months (95% CI:18.79-23.21). Among 597 patients who 
received chemotherapy the group with LNR of <0.36 had median OS of 29.73 months (95% CI: 
26.60-32.87) compared with survival of 15 months (95% CI: 13.62-17.65) if they had LNR of 
≥0.36 (P<0.001) [Figure 8.3].  
 
With respect to lymph node status, the median OS of patients with node-negative disease who 
received chemotherapy was 31.4 months (95% CI: 25.66-37.20) compared with 19.4 months (95% 
CI: 17.96-20.84) if they had node-positive disease (p=0.002). Among patients with node-positive 
disease, patients with up to 6 node positive disease had median OS of 21months (95% CI:18.3-
23.7) compared with 16 months (95% CI:13.1-18.9) if they had more than 6 nodes involved by the 
cancer (<0.001) [Table 8.2] [Figure 8.4].  
 
In a subgroup of 237 patients who underwent metastasectomy, patients with node-negative disease 
had median OS of 53.5 months (95% CI: 38.1-68.9) compared with 39.8 (95% CI: 31.1-48.4) if 
they had regional lymph nodes involvement (p=0.003).   
 
8.4.3 Multivariate Modelling  
 
On univariate analysis several patients-related factors (age, performance status, and Chalrson 
comorbid index); tumor-related factors (T status, grade 3 tumor, colon cancer, mucinous disease, 
stage IVb cancer, LNR, node positive disease, number of node harvested, and symptomatic 
primary tumor); interventions (use of any chemotherapy, second-generation chemotherapy, 
metastasectomy, and radiation therapy) and abnormal laboratory values (low albumin, elevated 
alkaline phosphatise, elevated BUN, abnormal CEA, elevated bilirubin, anemia, and leukocytosis) 
were correlated with survival (Table 8.3). Test for interaction was significant for LNR and serum 
creatinine, tumor grade, second-generation chemotherapy, and radiation therapy.  In a multivariate 
model after adjustment for other variables, LNR ≥0.36 correlated with survival with hazard ratio 
for mortality of 1.59 (95% CI: 1.38-1.84). In addition, chemotherapy, metastasectomy, second-
generation chemotherapy, T status, stage IVb disease, elevated bilirubin, alkaline phosphatase, 
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CEA, leukocytosis, and tumor location were correlated with survival (Table 8.4).  In the final 
model, only the interaction between LNR and tumor grade was significant. The median OS of 
patients with low- or intermediate-grade tumor was 23.7 months (95% CI: 21.20-26.20) compared 
with 15 months (95% CI: 12.80-17.21) in patients who had high-grade tumor (p=0.002).  Patients 
with low-grade tumor and LNR < 0.36 had median OS of 30 months (95% CI: 27.10-32.92) 
compared with 11.8 months in patients with high-grade tumor with LNR ≥0.36 (P<0.001). 
 
Due to presence of multicollinearity between LNR and lymph nodes status, a separate model 
(model B) was fitted. In this model lymph node status (positive vs. negative) was used instead of 
LNR. Lymph node status was correlated with survival with HR for mortality of 1.34 (95% CI: 
1.14-1.59) for node-positive disease. In a subcohort of patients who underwent metastasectomy, 
both LNR using a cut-off of 0.36 and nodal status, independent of chemotherapy and other 
prognostic variables, were correlated with survival, HR of 2.38 (95%: 1.64-3.47) for LNR ≥ 36 
and 1.57 (95% CI: 1.05-2.34) for node-positive disease.   
 
8.4.4 Secondary Analysis  
 
In a subcohort of 308 eligible patients who were diagnosed with synchronous metastatic CRC and 
underwent primary tumor resection during the period of modern chemotherapy both LNR and 
nodal status correlated with survival. Median overall survival of patients with low LNR who 
received chemotherapy was 45 months (34.9-55.1) compared with 20 months (16.3-23.7), if they 
had high LNR (p < 0.001). On multivariate analyses, no chemotherapy, HR: 2.53 (1.77-3.61), not 
having metastasectomy, HR: 2.30 (1.63-3.24), no biologics, HR: 1.80 (1.27-2.56), nodal status, 
HR 1.87 (1.25-2.80), and LNR, HR: 1.64 (1.26-2.13) were correlated with survival. 
 
8.5 Discussion   
 
Our results suggest that lymph node status and LNR are important prognostic factors and correlate 
with survival independent of systemic therapy and other patient- and tumor-related factors in 
patients with stage IV CRC.  
 
Colorectal cancer spread by both lymphatic and hematogenous dissemination. Furthermore, 
contiguous and transperitoneal routes are important ways of dissemination of the disease. The most 
common metastatic sites are the regional lymph nodes, liver, lungs, and peritoneum (1,6). In early-
stage CRC, both the number of examined lymph node and presence of nodal metastases guide the 
use of adjuvant therapy. The LNR has been proposed as a better prognostic factor than the number 
of metastatic lymph nodes (7-9). If the total nodes examined remains unchanged but the number 
of positive nodes increases, the LNR will increase.  
 
Our results support that regional nodal status is not only important in early-stage CRC but also in 
stage IV CRC. Since LNR and lymph node status are linearly dependent covariate, they were fitted 
in separate models to assess their prognostic significance. The present study revealed an inverse 
relationship between number of positive regional lymph nodes or LNR and survival. For example, 
patients with node-negative disease had median OS of 31 months compared with 16 months if they 
had 7 or more regional node were involved. The effect size was larger in patients who were treated 
with second-generation chemotherapy (FOLFIRI and or FOLFOX with a biologic) or during the 
period of combination chemotherapy and biologics. Both LNR and lymph node status can be used 
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as comparable prognostic markers in patients with stage IV CRC undergoing resection of the 
primary tumor. Notably, nodal status and LNR were important prognostic variables in patients 
who underwent metastasectomy and independently correlated with survival.   
 
The histologic grade of a tumor provides prognostic information. Poorly differentiated tumors are 
known to pursue a more aggressive course than their well-differentiated counterparts do (12). We 
noted a positive interaction between tumor grade and LNR. High-grade tumors had a higher 
number of metastatic nodes and higher LNR. For example, 45.7% low-grade tumors had LNR 
≥0.36 compared with 64.6% high-grade tumors had LNR ≥0.36.  Patients with LNR ≥0.36 and 
low-grade tumor had a better median OS of 15.9 months compared with 11.8 months if they had 
high-grade tumor.  
 
Only few studies have evaluated the prognostic significance of regional lymph nodes in stage IV 
CRC. Our findings support a previous study by Thomay et al. which examined the prognostic 
effect of regional nodal metastases in stage IV CRC. In their study, an increasing number of 
positive regional nodes and LNR correlated with inferior survival (13). Derwinger and Gustavsson 
also evaluated importance of regional nodal status in patients with stage IV CRC and found that 
the lymph node ratio along with chemotherapy and tumor grade correlated with overall survival 
(14). In contrast to studies by Derwinger and Gustavsson and Thomay et al. which were performed 
in patients treated at selected centers, our study was a population-based study with limited selection 
bias. Furthermore, unlike Thomay et al., who included patients with previous diagnosis of early 
stage CRC and metachronous metastases, our study population was comprised only patients with 
synchronous metastatic CRC.  Similar to Thomay et al. the present study included patients who 
were treated with both older and modern chemotherapy regimens. Because the study spanned a 
long period, we examined the study period as a prognostic variable. When the year of diagnosis 
was evaluated as a continuous variable, it was correlated with survival (not shown). We performed 
a secondary analysis involving the patients diagnosed during the period of combination 
chemotherapy and biologics and noted prognostic significance of regional lymph nodes during the 
period of modern chemotherapy. 
 
The mechanisms underlying the relationship between the regional node status and survival in 
stage IV CRC remain uncertain. It is plausible that lymph node status signifies underlying tumor 
biology. Unlike early-stage CRC where LNR and nodal status reflect accurate tumor staging, 
efficacious surgical intervention, and superior quality of pathology service and correlate with 
better survival, other factors may account for difference in survival in stage IV CRC. For 
example, a greater host immune response among patients with a larger negative lymph node 
count, or other unknown underlying molecular/biological characteristics of tumor may account 
for difference in survival. 
 
Of note, the depth of local tumor invasion (T status) was found to be an independent prognostic 
variable. Majority of patients with stage IV CRC had T3 or T4 (mostly T4a tumor). When T 
status was examined as a continuous variable, it was independently correlated with survival. The 
depth of local tumor invasion is a well-known prognostic factor in node-positive early-stage 
colorectal cancer (15). However, relative to regional lymph node status the association between 
T status and lymph node was weak. 
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One of the limitations of the current study is that we do not have information about BRAF 
mutation, which is reported in about 5-11% stage IV CRC and is an important prognostic marker 
(16). It is not known if differential distributions of BRAF mutation in the study groups have 
accounted for difference in survival in relation to the regional nodal status. Recently, Gleisner et 
al. using a complex statistical model examined the interactive effect of total number of lymph 
nodes examined (TNLE) and the number of metastatic lymph nodes (NMLN) on survival in 
patients with early-stage CRC (17). The author concluded that the combined effect of NMLN 
and TNLE is complex and may not appropriately represented by the LNR and proposed N score 
as an alternative prognostic biomarker. Nevertheless, other investigators have not validated the N 
score.   
 
In summary, our results suggest that the regional lymph node status including the number of 
negative lymph nodes or the ratio of metastatic to examined lymph node are important 
prognostic factors and correlate with survival in patients with stage IV CRC. Furthermore, 
regional nodal status correlates with survival in patients treated with curative resection.  To our 
knowledge, this is the only population-based study that has addressed this question by reviewing 
individual patient’s data. Future studies are required to confirm our findings and to elucidate the 
mechanism by which nodal status and LNR affect survival of patients with stage IV CRC. 
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Table 8.1: Characteristics of patients in the entire cohort and subgroups of patients with 
the ratio of metastatic to examined lymph node (LNR) of 0.36. 
 
Variables Study 
cohort 
N=1109 
Group 1 
N=553   
LNR ≥0.36 
Group 2 
N=556 
LNR <0.36 
P value 
Demographic     
Median age 70 (22-98) 70 (22-92) 69 (31-98) 0.72 
  Age 70 years or greater 555 (50) 278 (50.3) 277 (49.7) 0.90 
Secondary  Cancer 164 (14.8) 74 (13.4) 90 (16.2) 0.20 
ECOG performance status 2 or more 249 (22.5) 137 (24.8) 112 (20.1) 0.07 
Charlson comorbidity index  279 (25.2) 137 (24.8) 142 (25.5) 0.78 
  Mean Charlson score 9.6±1.50 9.6±1.47 9.6±1.49 0.76 
Male 618 (55.7) 312 (56.4) 306 (55) 0.67 
Active smoker 197 (17.8) 86 (15.6) 111 (20) 0.06 
Mean laboratory values     
Albumin g/l 34.2±6 34.1±6 34.5±6 0.32 
Alkaline phosphatase U/l 174±248 198±292 150±191 0.001 
Bilirubin ug/l 11.9±17.7 12.8±21.1 11.0±13.6 0.093 
Blood urea nitrogen mm/l 5.6±4.1 5.7±4.2 5.5±3.9 0.40 
CEA ug/l 258±1328 297±1446 220±1200 0.33 
Creatinine um/l 88.1±32.6 88.1±32.1 88.0±33.0 0.94 
Hemoglobin g/l 119±15.8 118±15.3 120±16 0.03 
Platelet   109/l 343±119 353±117 334±120 0.009 
White blood cell count 109/l 8.8±4.8 8.9±3.2 8.7±5.9 0.46 
Treatment      
Chemotherapy 597 (53.8) 282 (51.0) 315 (56.7) 0.06 
   Second or third line therapy 272 (45.6) 128 (45.3) 144 (45.7) 0.29 
   FOLFIRI or FOLFOX± biologics 266 (44.5) 123 (43.6) 143 (45.4) 0.18 
Radiation therapy 144 (13) 69 (12.5) 75 (13.5) 0.65 
Metastasectomy 237 (21.4) 98 (17.7) 139 (25) 0.03 
Metastatic sites     
Liver 830 (74.8) 420 (75.9) 410 (73.7) 0.40 
Extra-hepatic disease 530 (47.8) 286 (51.7) 244 (43.9) 0.01 
Stage IVb 353 (31.8) 208 (37.6) 145 (26.1) <0.001 
Primary Tumor     
T3 or 4 tumor  1061 (95.7) 533 (96.4) 528 (95) 0.32 
Node Positive disease  905 (81.6) 553 (100) 352 (63.3) <0.001 
  0 204 (18.4) 0 204 (36.7) <0.001 
  1-6 positive nodes 640 (57.7) 294 (53.2) 346 (62.2) <0.001 
  More than 6 positive nodes 265 (23.9) 259 (46.8) 6 (1.1) <0.001 
  Median number of nodes removed 10 (1-55) 10 (1-46) 12 (1-55) 0.023 
  Median number of nodes involved  3 (0-46) 6 (1-46) 1 (0-10) <0.001 
Grade 3 246 (22.2) 159 (28.7) 87 (15.6) <0.001 
Mucinous 178 (16.1) 104 (18.8) 74 (13.3) 0.014 
Rectum or rectosigmoid tumor 283 (25.5) 135 (24.4) 148 (26.6) 0.22 
Symptomatic primary tumor 523 (47.2) 273 (49.4) 250 (45.2) 0.14 
Biologics= cetuximab, panitumumab or bevacizumab; CEA= carcinoembryonic antigen; ECOG= Eastern 
Cooporative Oncology Group; FOLFIRI=Infusional 5-FU, leucovorin and irinotecan; FOLFOX=Infusional 5-FU, 
leucovorin and oxaliplatin;  
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Table 8. 2: Survival of patients in relationship with regional lymph node status.  
Nodal Status  Median Overall Survival 95% Confidence Interval 
All patients  21.0 months 18.79-23.21 
Patients with more than 6 nodes 
involved 
16.0 months 13.07-18.93 
Patients with up to 6 nodes 
involved  
21.0 months 18.34-23.66 
Patients with node negative 
disease 
31.4 months  25.66-37.20 
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Table 8. 3: Relationship between various clinicopathological variables and survival in 
univariate analysis. 
 
Variables  HR (95% CI) P value HR (95% CI) for 
Interaction with 
node ratio 
P value 
Age ≥70 years 1.73 (1.53-1.96) <0.001 0.89 (0.70-1.14) 0.35 
Albumin <35 g/l 1.91 (1.69-2.17) <0.001 1.09 (0.85-1.41) 0.49 
Alkaline phosphatase >120 U/l 2.10 (1.81-2.33) <0.001 1.06 (0.83-1.37) 0.64 
Bilirubin ≥26 um/l  2.23 (1.65-3.0) <0.001 0.88 (0.47-1.64) 0.69 
BUN ≥8 mm/l 1.40 (1.14-1.73) 0.002 0.68 (0.45-1.05) 0.08 
CEA  ≥5 ug/l 2.24 (1.90-2.64) <0.001 0.90 (0.65-1.25) 0.52 
Charlson Comorbid Score 1.67(1.47-1.89) <0.001 1.13 (0.88-1.45) 0.34 
No chemotherapy (Any) 3.29 (2.89-3.740 <0.001 0.97 (0.76-1.25) 0.83 
Colon tumor 1.43 (1.24-1.66) <0.001 0.79 (0.59-1.06) 0.11 
Creatinine ≥120 um/l 1.48 (1.18-1.86) 0.001 0.56 (0.35-0.89) 0.013 
Current Smoking 0.92 (0.78-1.09) 0.33 0.92 (0.66-1.28) 0.63 
ECOG performance status ≥2 2.53 (2.16-2.93) <0.001 0.80 (0.60-1.07) 0.13 
Extra-hepatic disease 1.10 (0.97-1.24) 0.16 1.09 (0.85-1.40) 0.49 
Grade 3 1.45 (1.25-1.68) <0.001 0.72 (0.53-0.99) 0.04 
Hemoglobin <120 g/l 1.43 (1.26-1.62) <0.001 1.24 (0.96-1.59) 0.08 
Higher positive node ratio (LNR) 
≥0.36 
1.80 (1.59-2.04) <0.001   
Less than 12 nodes removed 1.35 (1.19-1.55) <0.001 0.99 (0.76-1.29) 0.95 
Male gender 0.73 (0.86-1.11) 0.98 0.95 (0.74-1.22) 0.67 
Not having metastasectomy 2.72 (2.30-3.21) <0.001 0.74 (0.54-1.03) 0.078 
Mucinous pathology 1.21 (1.03-1.43) 0.023 0.99 (0.71-1.39) 0.98 
Nodal positive*  1.32 (1.12-1.55) 0.001   
Platelet count, ≥450 x109/l  1.06 (0.89-1.26) 0.54 1.29 (0.91-1.83) 0.15 
Radiation 1.76 (1.46-2.13) <0.001 1.52 (1.04-2.21) 0.029 
Lack of second line Treatment 2.06 (1.78-2.38) <0.001 1.55 (1.16-2.10) 0.003 
Lack of second generation 
therapy**  
2.10 (1.81-2.44) <0.001 1.64 (1.22-2.20) 0.001 
Secondary cancers 1.01 (0.85-1.20) 0.91 1.03 (0.73-1.45) 0.87 
Stage IVb disease 1.45 (1.27-1.65) <0.001 0.87 (0.67-1.145) 0.33 
Symptomatic primary tumor 1.30 (1.15-1.47) <0.001 0.94 (0.74-1.20) 0.62 
T status 1.20 (1.06-1.36) 0.003 0.85 (0.67-1.09) 0.21 
WBC count ≥11 x 109/l  1.73 (1.46-2.04) <0.001 1.12 (0.79-1.58) 0.51 
*Linearly dependent covariate **FOLFIRI (infusional 5-FU, leucovorin and irinotecan) and or FOLFOX 
(infusional 5-FU, leucovorin and oxaliplatin) with or without Biologics (cetuximab, panitumumab or 
bevacizumab); CEA= carcinoembryonic antigen; ECOG PS= Eastern Cooporative Oncology Group 
performance status; WBC=white blood cell;  
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Table 8.4: Multivariate analysis with variables independently correlated with superior 
survival in patients with stage IV colorectal cancer.  
 
Variables  HR (95% CI) P value HR (95% CI) P value 
 Model A Model B 
Age ≥70 1.21 (0.90-1.61) 0.20 1.16 (0.87-1.54) 0.32 
Alkaline Phosphatase >120 U/l 1.33 (1.20-1.52) <0.001 1.33 (1.16-1.52) <0.001 
Bilirubin ≥26 um/l 1.55 (1.13-2.11) 0.006 1.65 (1.21-2.25) 0.001 
CEA  ≥5 ug/l 1.67 (1.40-2.0) <0.001 1.64 (1.38-1.96) <0.001 
Charlson Comorbid Score 1.30 (0.95-1.70) 0.10 1.20 (0.89-1.60) 0.22 
No chemotherapy 2.36 (2.0-2.79) <0.001 2.44 (2.07-2.89) <0.001 
Colon cancer  1.21 (1.05-1.41) 0.01 1.15 (0.99-1.38) 0.06 
ECOG performance status ≥2 1.43 (1.22-1.68) <0.001 1.39 (1.18-1.62) <0.001 
Grade III 1.10 (0.83-1.39) 0.56 1.43 (1.23-1.66) <0.001 
Higher positive node ratio ≥0.36 1.59 (1.38-1.84) <0.001   
Not having metastasectomy 1.94 (1.63-2.32) <0.001 1.96 (1.64-2.33) <0.001 
Node positive disease   1.34 (1.14-1.59) 0.001 
Lack of second generation 
chemotherapy 
1.46 (1.22-1.75) <0.001 1.41 (1.17-1.69) <0.001 
Stage IVB disease  1.22 (1.10-1.40) 0.004 1.29 (1.12-1.47) <0.001 
T status 1.23 (1.07-1.40) 0.003 1.22 (1.07-1.40) 0.004 
WBC ≥11 x 109/l 1.46 (1.22-1.74) <0.001 1.53 (1.28-1.83) <0.001 
Grade* Higher positive node 
ratio ≥0.36 
1.51 (1.10-2.10) 0.01   
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Figure 8.1: Flow of information about eligible patients’ cohort.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2294 patients were identified with newly 
diagnosed stage IV CRC during Jan 1992-Dec 
2010 
347 patients were excluded 
for other pathological 
diagnoses (neuroendocrine 
tumor, lymphoma, GIST, 
squamous cell cancer, etc) 
or no tissue diagnosis or if 
they were diagnosed on 
autopsy 
1947 patients have advanced 
colorectal adenocarcinoma with 
an intact in situ primary tumor  
1257 patients underwent resection of 
primary tumor 
 148 patients did not have 
any lymph node harvested 
or have no information 
about nodal status 
1109 eligible patients were identified 
553 patients with LNR≥ 
0.36 
556 patients with LNR 
<0.36 
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Figure 8.2: Survival of patients with stage IV colorectal cancer based on the ratio of 
metastatic to examined lymph node (LNR) using a median cutoff value of 0.36.  
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Figure 8.3: Survival of patients with stage IV colorectal cancer based on the ratio of 
metastatic to examined lymph node (LNR) using a median cutoff value of 0.36 who 
received chemotherapy.  
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Figure 8.4: Survival of patients with stage IV colorectal cancer based on regional lymph 
node status. 
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CHAPTER 9– DISCUSSION AND CONCLUSIONS 
 
Our results favor surgical resection of the primary tumor in patients with stage IV CRC (1-3). The 
analysis of this large population-based data that spanned over a period of eighteen years 
demonstrated that the primary tumor resection was associated with better survival and the benefit 
was independent of other important prognostic factors including age, performance status, 
comorbid illness, chemotherapy and metastasectomy. The survival benefit of surgery was observed 
in patients with asymptomatic or minimally symptomatic primary tumor and in patients who were 
treated with modern chemotherapy (2, 3).  
 
In a cohort of 1378 patients, who were diagnosed with synchronous stage IV CRC from 1992 to 
2005, primary tumor resection was associated with 51% relative reduction in mortality (1). In a 
subgroup of 834 patients with asymptomatic or minimally symptomatic primary tumors, surgical 
resection of the primary tumor was associated with similar survival benefit with about 53% relative 
reduction in mortality (2).   Of note, less than half of the cohort received chemotherapy and most 
patients were treated with single agent 5-FU based chemotherapy. Nevertheless, the findings were 
validated in a second cohort of 569 patients who were diagnosed during the period of 2006-2010 
and were treated with modern chemotherapy regimens (3). The study revealed that patients who 
were treated with combination chemotherapy with or without a biological agent and underwent 
surgical resection of the primary tumor had better survival compared with the non-resection group. 
For example, primary tumor resection was associated with 56% relative reduction in mortality 
during the period of modern chemotherapy.  In addition to surgery of the primary tumor, systemic 
therapy, subsequent line of therapies, metastasectomy, elevated alkaline phosphatase, Grade 3 
tumor, leukocytosis, stage IVb disease, and ECOG performance status were correlated with 
survival.  
 
9.1 Systematic Review and Meta-analysis 
 
We conducted a systemic review and meta-analysis of published literature to determine the 
survival benefit and complications rates of surgical resection of the primary tumors in patients 
with stage IV CRC.  Previous reviews addressing these questions were mostly restricted to studies 
performed during the era of single agent chemotherapy or older regimens and included studies 
with no comparator group (4-6). For example, the review by Eisenberger et al. suggested a 
potential survival advantage of surgery (4). However, 5 of 12 studies did not have a comparator 
control group and most studies involved patients treated with single agent 5-FU.  An additional 
review by Scheer et al. that specifically focused on complication rates of the primary tumor did 
not support surgery (5). Of note, 2 of 7 studies in this review did not have a surgical intervention 
group.  Lastly, Stillwell et al. performed a meta-analysis that favored surgery. Although their 
review exclusively involved minimally symptomatic patients, 1 of 8 selected
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studies did not have a comparator (6). Since the publication of previous systematic reviews 
additional studies have been reported.  Our review exclusively focused on studies with a non-
surgical comparator group with a special emphasis on survival and complications rates of subgroup 
of patients. The review was limited to fifteen retrospective observational studies with their inherent 
bias. The study period was selected as palliative chemotherapy only became available in the early 
1980s. Due to scarcity of resources to translate literatures in other languages we applied English 
language restriction. Since most relevant studies in CRC management tend to publish in the 
English literature, we believe that such restriction would have very little if any impact on validity 
and generalizability of the results.  
 
The review demonstrates a consistent trend favoring non-curative surgical management of the 
primary tumors in patients with advanced CRC. Overall, 31% relative improvement in survival 
was noted in the groups treated with surgery. Due to the fact that we did not have individual 
patients’ data about the type of treatment, we used pre-specified criteria for eligible studies to 
categorize them study using old- versus new-generation therapy. Using these criteria, comparable 
survival benefit was noted in the studies conducted during the period of new-generation 
chemotherapy. In agreement with Stillwell et al. meta-analysis, survival advantage was also noted 
in minimally symptomatic or relatively asymptomatic patients (6). Notably, the pooled estimate of 
survival revealed considerable inconsistency across the studies.  Conceivably, these studies were 
done in clinically heterogeneous groups with respect to patients population and co-intervention 
such as age, performance status, comorbid illnesses, disease burden, primary tumor related 
symptoms, type of systemic therapy and differential rate of metastasectomy. Likewise, 
considerable variability was noted across the studies design and risk of bias, which suggests 
methodological diversity. Despite those limitations we opted to report the pool result as the 
direction of effect was consistent across the studies and subgroups, albeit in different magnitude.  
 
Due to selected reporting and lack of explicit information across the individual studies, 
examination of heterogeneity with respect to important clinical variables with the exception of 
underlying symptoms and type of treatment was not feasible. Of note, test for heterogeneity was 
no longer significant after excluding three studies from the pool estimate which had either larger 
effect size or were very precise (narrow confidence intervals) suggestive of statistical 
heterogeneity (7-9). Due to the concern of publication bias, overestimation of the intervention 
effect relative to the true outcome is quite plausible.  
 
A high postoperative complication can offset the survival benefit related to surgery. Our review 
was limited by selective reporting of surgical mortality and morbidity across the included studies. 
Patients with advanced CRC compared with localized disease tend to have an increased mortality 
rate following primary tumor resection. Although four of nine studies reported no postoperative 
mortality, in some studies it was not trivial, ranging up to 16%. As anticipated, a higher mortality 
rate has been noted for emergency surgery (10, 11).  The mean primary tumor complication rate 
including obstruction, perforation, and hemorrhage was 27% but noted to be as high as 63%. A 
higher complication rate of greater than 50% was mostly noted in the older studies.   
 
Quality of life (QOL) is an important outcome that helps patients and their physicians to choose 
appropriate treatment. Since the incidence of major intestinal complications related to the primary 
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tumor such as obstruction, perforation, and hemorrhage, as well as post-operative complications 
are likely to be associated with a significant adverse effect on QOL, an indirect assessment of QOL 
can be made by reviewing the surgical and primary tumor complication rates. A surgical 
intervention with a low complication rate could potentially have a favorable QOL as a result of  
fewer non-resection interventions, lack of primary tumor related complications and better 
tolerance to systemic therapy.  
 
A substantial low quality studies, publications bias and selected reporting were the major 
limitations of the review.  Several studies did not provide baseline characteristics of the groups, 
and others revealed significant imbalance in baseline characteristics of the two groups and did not 
control for them. Furthermore, only few studies provided detail information about the use and type 
of systemic therapy in each group making it difficult to assess the relative contribution of resection 
on outcome. These concerns significantly impact the validity of the observed survival benefit noted 
in our review and may just reflect selection of younger and healthier patients with good 
performance status, and low disease burden.  
 
9.2 Cohort Study 
 
Although several studies previously have shown survival benefit of primary tumor resection, 
validity of survival benefit observed in these studies has been questioned and is believed to be 
biased by the selection of healthier and younger patients for surgery (12-15). Most studies failed 
to adjust for performance status and other important clinical and pathological variables.  To 
overcome some of the limitations discussed above, we conducted this well-designed retrospective 
cohort study. In order to assess the validity of selected studies in the systematic review and meta-
analysis we utilized the Newcastle-Ottawa Quality Assessment Scale comprised of nine items 
grouped in three sections of selection, comparability, and outcome (16). Most were low quality 
studies with a median score of 5 (range: 4-6). In contrast, our cohort study received one point for 
each item and scored 9 out of 9.  
 
In agreement with previous studies we noted significant differences in the baseline characteristics 
between the resection and the control groups. For example, patients who underwent surgery were 
younger with less disease burden compared with the non-surgical group suggesting a selection bias 
for the surgical intervention. Nevertheless, when these variables were included in a multivariate 
model, primary tumor resection remained an important prognostic variable and was associated 
with significant reduction in mortality when adjusted for age, performance status, comorbid 
illnesses, chemotherapy, metastasectomy, combination chemotherapy, disease burden and various 
other important prognostic factors. To our knowledge, the present study is the only study that 
controlled for all the major known clinical variables to minimize selection bias and has 
demonstrated survival benefit with primary tumor resection. 
 
  
149 
 
9.2.1 Benefit of Surgery in Minimally Symptomatic or Asymptomatic Patients 
 
There is a general agreement that patients with evidence of perforation, significant obstruction, or 
uncontrolled bleeding should undergo resection of the symptomatic tumor. However, surgical 
resection of the primary tumor, in patients with asymptomatic or minimally symptomatic disease 
and otherwise unresectable metastases, is not recommended. In the study cohort, about 60% of 
patients were asymptomatic or had minimal symptoms related to the primary tumor. These patients 
had comparable survival benefit with surgical intervention (1-3). Of note, survival differences 
between the two groups (resection versus non-resection), within the study cohort and various 
subgroups, were consistently more than 6 months (ranges: 7.6 to 13.6 months). Moreover, the 
surgical intervention was independently associated with a survival benefit, after controlling for 
other important prognostic variables. In our validation cohort, patients with relatively 
asymptomatic primary tumors who underwent surgery and received chemotherapy had median OS 
of 34 months (95% CI: 24.6-43.4) compared with 21 months (95% CI: 15.6-26.3) if they had 
symptomatic primary tumor (p=0.006) [3]. Notably, patients with symptomatic primary tumor had 
30-day postoperative mortality rates of 8.8% compared with 1.5 % if they had an elective surgery. 
Emergency surgery has consistently been demonstrated to be an important risk factor for inferior 
outcome in colorectal surgery and has been associated with a higher 30-day mortality rate (17). 
We believe that in addition to underlying biology of the disease, the 30-day mortality rate most 
likely accounted for the differences in survival rates noted between the two groups. Stilwell and 
others have shown an improvement in the survival of patients with asymptomatic or minimally 
symptomatic primary tumors, who were treated with palliative resection of primary tumor, with 
an estimated standardized median difference of 6.0 months (6).  
 
9.2.2 Benefit of Surgery in Patients Treated with Combination Chemotherapy and Biologics 
 
Modern chemotherapy regimens incorporating novel cytotoxic and biologic agents have been 
associated with high response rates of 40-50% (18). Although only about 19% of the 1992-2005 
cohorts were treated with modern chemotherapy, the magnitude of benefit of surgical intervention 
was substantially higher in subgroup of patients, who were treated with second-generation and/or 
second-line chemotherapy. 
 
Furthermore, the 2006-2010 cohort study validated benefit of surgery in patients who were treated 
with modern chemotherapy. Overall, 57% patients received systemic therapy, of those 91% were 
treated with combination therapy (FOLFIRI or FOLFOX) and 67% received one or two biological 
agents. Despite the use of more effective chemotherapy, surgery was associated with 56% relative 
reduction in mortality. Recent literature also supports survival benefit of surgery of the primary 
tumor in the era of modern chemotherapy.  A retrospective analysis of CAIRO study that compared 
combination versus sequential chemotherapy demonstrated a significantly better median OS of 
16.7 months in patients who underwent surgery compared  with 11.4 months with no surgery (HR 
0.61, 95%CI:49–0.76) [19]. Likewise, a retrospective analysis of CAIRO II trial that primarily 
assessed the efficacy of combination of chemotherapy and biologics, demonstrated a superior 
survival with surgical resection of the primary tumor. In a subgroup of patients who underwent 
surgical resection of primary tumor, a significantly better median overall survival of 20 months 
was observed compared with survival of 13.4 months in the non-resection group, (P<0.0001; HR 
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0.65, 95% CI 0.52–0.80). Furthermore, a pool analysis of four French phase 3 trials involving 850 
patients indicated survival benefit of surgery (20). More than two third of patients were treated 
with FOLFIRI or FOLFOX and about 12% received bevacizumab. The primary tumor resection 
was an independent predictor of superior survival (HR: 0.63, 95% CI: 0.53-0.75). 
  
In addition, our group’ meta-analysis of fifteen observational studies did not reveal a positive 
interaction between surgery and type of chemotherapy. The HR for survival of the group treated 
with modern chemotherapy was 0.68 (95% CI: 0.56-0.83) favoring the surgical intervention 
compared with HR of 0.73 (95% CI: 0.59-0.90) in the group treated with older regimen. However, 
in this meta-analysis individual patient data regarding type of chemotherapy was not available. 
Overall, evidence supports comparable benefit of resection of primary tumor in patients treated 
with modern regimens. Of note, the tests for interactions between the surgical resection of the 
primary tumor and second-line therapy or disease burden were significant after adjusting for other 
variables, which suggests that patients who received second-line therapy or who had metastasis 
confined to one organ or site tend to get greater benefit from surgical removal of the primary tumor.   
 
9.2.3 Postoperative Morbidities and Mortality and Non-surgical Interventions 
 
In the validation study we also evaluated post-operative complications rates in the resection group 
and non-surgical interventions in the control group. Median duration of hospital stay was 9 days 
(inter-quartile range: 7-13). Overall, about 24% patients developed post-operative complications. 
Of note, majority had symptomatic primary tumors. Furthermore, 7% of patients with 
asymptomatic or minimally symptomatic tumor compared with 15.8% of patients with 
symptomatic primary tumor developed major postoperative complications including venous 
thromboembolism, sepsis, wound dehiscence, anastomotic leakage, post-operative bleeding, 
pelvic abscess and ischemic bowel. The 30-day mortality rate of the group who underwent surgery 
was 5.4%. Yet again, 1.4% of the patients with asymptomatic or minimally symptomatic disease 
died within 30 days of surgery compared with 8.8% of the patients with symptomatic primary 
tumor who underwent urgent or emergent surgeries. 
 
In the non-surgical group 5.2% patients required a stent for their symptoms. In addition, 14.8% 
patients in the non-resection group developed obstructive symptoms and required a stoma 
formation (colostomy or ileostomy). Several relatively smaller studies, most of them were 
designed during the period of modern systemic therapy, assessed the risk of primary tumor 
complications in patients with non-resection management. These studies reported complications 
rates related to an intact primary tumor in the range of 3-14% (21-25). About 18% patients in the 
non-resection group received radiation therapy. No differences were noted in the rates of palliative 
radiation therapy between the two groups.  
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9.2.4 Recent Literature 
 
Since the publication of our meta-analysis, primary tumor resection has become one of the key 
issues in the management of stage IV CRC. Several recent studies have addressed this question in 
patients with symptomatic or minimally symptomatic tumors (26-29). Ishihara and others 
retrospectively  evaluated 1982 patients with metastatic CRC from 1997 to 2007 (26). Among the 
whole patient population, primary tumor resection significantly improved survival (HR: 0.46, 95% 
CI 0.32-0.66).  Gresham and others evaluated 517 patients with stage IV CRC (27). Among them, 
378 (73 %) patients underwent palliative resection of their primary tumor. Palliative resection was 
associated with a longer median OS (17.9 vs. 7.9 months) and more favorable adjusted HR for 
death (0.56, 95 % CI 0.40-0.78). Tarantino and others used the Surveillance, Epidemiology, and 
End Results (SEER) database from 1998 to 2009 and identified 37,793 patients with stage IV CRC. 
Of those, 23,004 (60.9%) underwent palliative primary tumor resection. The 
primary cancer resection was associated with a significantly improved overall survival (HR of 
death 0.40, 95% CI: 0.39-0.42) [28]. Yun and others assessed 416 patients with asymptomatic 
unresectable stage IV CRC from the year 2000 to 2008 (29). Among 416 patients, 218 (52.4%) 
underwent palliative resection of the primary tumor. Their data revealed that 
palliative resection was not associated with a significantly better survival compared with a non-
resection approach. 
 
9.3 Importance of Primary Tumor Pathological Features  
 
The significance of pathological features of primary tumor in patients with stage IV CRC is not 
known. In the cohort of patients who underwent primary tumor resection, we examined the 
importance of primary tumor characteristics including the degree of tumor infiltration through the 
bowel wall (T status), histological grade, number of examined lymph nodes and nodal metastases. 
Our results suggest that lymph node status and the ratio of metastatic to examined lymph node 
(LNR) are not only important prognostic factors in the early-stage CRC but also correlate with 
survival, independent of systemic therapy and other patients- and tumor-related factors, in patients 
with stage IV CRC (30,31). We noted an inverse relationship between the number of positive 
regional lymph nodes or LNR and survival. For example, patients with node-negative disease had 
median OS of 31 months compared with 16 months if they had ≥7 regional node were involved. 
The effect size was larger in patients who were treated with second-generation chemotherapy 
(FOLFIRI and/or FOLFOX with a biologic).  Notably, nodal status and LNR remained important 
prognostic variables in patients who underwent metastasectomy and independently correlated with 
survival.   
 
In addition to the nodal status, the depth of local tumor invasion (T status) was correlated with 
survival. Since majority of the patients with stage IV CRC had T3 or T4, T status was examined 
as a continuous variable. The depth of local tumor invasion is a well-known prognostic factor, both 
in node-positive and node-negative early-stage CRC (32). However, relative to regional lymph 
node status, the association between T status and lymph node was weak.  In addition, in this group 
of patients who underwent surgical resection of the primary tumor, chemotherapy, 
metastasectomy, performance status, stage IVb disease, tumor location, leukocytosis, and 
abnormal alkaline phosphatase, CEA, and bilirubin levels were correlated with survival.   
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The mechanisms underlying the relationship between the regional node status and survival in stage 
IV CRC is not known. Lymph node status is most likely a surrogate marker of the underlying 
tumor biology and host response to the disease. Unlike early-stage CRC, where LNR and nodal 
status reflect accurate tumor staging, more efficacious surgical intervention, and superior quality 
of pathology service and correlate with better survival, other factors may account for difference in 
survival in stage IV CRC. For example, a greater host immune response among patients with a 
larger negative lymph node count, or other unknown underlying molecular/biological 
characteristics of tumor may account for the difference in survival. 
 
9.4 Prognostic Factors in Stage IV Colorectal Cancer 
 
A variety of clinical parameters such as age, performance status, WBC count, hemoglobin, serum 
albumin, alkaline phosphatase, CEA, pathological grading or localization of the primary tumor 
have been identified as prognostic markers in patients with stage IV CRC (33-36). Our data is one 
of the largest data sets that included patients-related factors, tumor-related factors, baseline 
laboratory values and various interventions in multivariate models. Our study revealed that in 
addition to surgery of the primary tumor, systemic therapy, subsequent-line of therapy, 
metastasectomy, elevated alkaline phosphatase, low albumin, Grade 3 tumor, leukocytosis, stage 
IVb disease, and ECOG performance status were correlated with survival in patients with stage IV 
CRC.  
 
Systemic therapy is the most important prognostic variables in stage IV CRC and has been 
associated with significant improvement in the outcomes of patients with metastatic CRC. A 
randomized trial demonstrated that patients who received 5-fluorouracil (5-FU) based 
chemotherapy had median overall survival of 11 months compared with 5 months with best 
supportive care alone (37).With the introduction of 5-FU, a fluoropyrimidine, median overall 
survival of patients with stage IV CRC improved to approximately 10-12 months. For many 
decades, 5-FU remained the sole active agent used in the management of advanced CRC.  In the 
later part of 1980s, the addition of biomodulator leucovorin (LV) to 5-FU resulted in modest 
improvement in response rate and overall survival (38). A decade later both irinotecan and 
oxaliplatin demonstrated efficacy as second-line treatments, and subsequently approved as first-
line therapies for metastatic CRC with improvement in median overall survival to 15-20 months 
(39-42). Biological therapies such as cetuximab and bevacizumab bring average survival lengths 
to approximately 20-30 months (43, 44). With the availability of novel agents in the management 
of advanced CRC, we noted approximately 25% increase in the use of chemotherapy. Patients 
treated with curative intention or underwent resection of primary tumor were more likely to 
received chemotherapy. A Canadian study also demonstrated similar findings (45). Between 2003 
and 2004 (pre-bevacizumab era) and 2006 (bevacizumab era), the proportion of patients treated 
with systemic therapy for stage IV CRC significantly increased from 61.1% to 67.6%.  
 
It is known that survival of patients with stage IV CRC is better if they are exposed to all available 
active therapeutic agents during the course of their disease (46). Effective salvage therapies 
(second- or third-line therapies) have a significant impact on patient outcomes and have been 
associated with improvement in survival (47, 48). Our results showed that the patients who 
received FOLFIRI and FOLFOX in combination with a biologic agent and underwent resection of 
the primary tumor had median survival of 35 months (95% CI: 30-40). Furthermore, patients with 
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KRAS wild tumor who received FOLFIRI & FOLFOX in combination with bevacizumab and 
subsequently were treated with an anti-EGFR monoclonal antibody had a median OS of 39 months 
(95%CI: 25.1-52.9) [3]. Due to presence of multicollinearity between various lines of 
chemotherapy and the type of regimens, these variables were not fitted together in the final model.  
Nevertheless, secondary analyses using chemotherapy regimens and biological agents as opposed 
to the subsequent-line of therapies, underscored their prognostic importance. Both combination of 
chemotherapy (HR: 0.67, 95%CI: 0.52-0.87) and biological agents (HR: 0.60, 95%CI: 0.45-0.78) 
were independently correlated with superior survival. Furthermore, surgery of the primary tumor 
in the model using various systemic therapy regimens was independently correlated with survival.    
 
Although our results suggest that chemotherapy utilization is increasing over time, a substantial 
number of patients for several reasons did not receive chemotherapy. Future research exploring 
the correlation between the use of chemotherapy and biologics and various socio-economic 
determinants is important to improve the outcomes of patients with metastatic CRC. Saskatchewan 
is a geographically large province with a population of about 1.1 million. We plan to validate our 
findings in 2006-10 cohort and explore relationship between the travel distance to the cancer center 
and the use of chemotherapy in patients with stage IV CRC.  
  
In addition to systemic therapy and primary tumor resection, metastasectomy was associated with 
better survival. The presence of systemic metastases is a poor prognostic markers in cancer patients 
with a very short survival in most gastrointestinal malignancies. Nevertheless, limited metastatic 
disease in CRC, involving the liver or lungs, does not mean that long-term remission cannot be 
achieved. Surgical resection is the only potentially curative option for selected patients with 
limited liver or lung metastases. Although randomized trials have not been conducted, long term 
survival of about 30-40% reported in retrospective observational studies have led to the acceptance 
of aggressive metastasectomy in patients with limited lung and/or liver metastases (49-52). The 
liver is the dominant metastatic site in patients with CRC and 80-90% developed unresectable liver 
metastases. With the availability of novel chemotherapy and targeted agents, about 10-20% 
patients with initially unresectable or borderline resectable metastatic liver disease can have 
significant response to treatment and are able to undergo resection of the metastases. Comparable 
to liver metastasectomy, patients who underwent pulmonary metastasectomy along with removal 
of the primary tumor had five- and ten-year survival rates of about 35-55% and 20-30%, 
respectively (53-55).  Since patients who undergo metastasectomy have potential to achieve long 
term survival, a secondary analysis was performed after excluding the patients who underwent 
metastasectomy. Despite the exclusion of patients with good prognosis, in a multivariate analysis, 
removal of the primary tumor was associated with 52% relative reduction in mortality.  
 
Among various prognostic variables, elevated alkaline phosphatase, low albumin, leukocytosis, 
Grade 3 tumors, stage IVb disease, and ECOG performance status were correlated with inferior 
survival in patients with stage IV CRC. Alkaline phosphatase (ALP) comprises a group of enzymes 
that catalyze the hydrolysis of phosphate esters and is mainly derived from the liver, bones, and in 
lesser amounts from intestines, kidneys, and leukocytes (56,57). Serum ALP levels are frequently 
elevated in patients with metastatic CRC (56). Our data revealed that patients who received 
combination of chemotherapy and had elevated ALP had median OS of 17 (14.8-19.2) months 
compared with 27 (22.5-31.5) months if they had normal ALP (<0.001). After adjusting for other 
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important covariates baseline abnormal ALP level was associated with 50% relative increase in 
mortality.  
 
In addition to ALP, baseline low serum albumin correlated with inferior survival. Serum albumin 
provides a simple method of estimating visceral protein function. Malnutrition and inflammation 
suppress albumin synthesis (58).  Low serum albumin is one of the surrogate markers of 
malnutrition in patients with advanced cancer.  Several observational studies have suggested that 
low serum albumin is associated with higher mortality from cancer (58). Malnutrition in patients 
with advanced cancer is not uncommon and results from underlying cancer, the host response to 
the cancer, and anticancer therapies. Malnutrition has been associated with an increased risk of 
chemotherapy-related toxicity, decreased response to treatment, poor quality of life, and an inferior 
survival (58, 59). Likewise, the histologic grade of a tumor provides prognostic information. 
Poorly-differentiated tumors are known to pursue a more aggressive course than their well-
differentiated counterparts (60). Patients with poorly-differentiated stage IV CRC had about 33% 
increased risk of mortality.  
 
Our data also revealed that baseline leukocytosis in patients with stage IV CRC was associated 
with poor prognosis. Leukocytosis has been demonstrated to be associated with increased mortality 
in cancer patients (61-63). For example, Connolly and others have demonstrated that elevated 
WBC has been strongly associated with an increased risk of venous thromboembolism and 
mortality in cancer patients receiving systemic chemotherapy. Leukocytosis may be a marker of 
an underlying process such as more aggressive malignancy, major co-morbidities, inflammation, 
or leukocytes may be actively involved in disease progression and cancer-associated thrombosis 
(64).  It has been shown that tissue factor and VEGF levels in leukocytes from cancer patients is 
many fold higher than in leukocytes from normal controls (64, 65). It is plausible that leukocytes 
may directly contribute to disease progression through release of tissue factor and VEGF. 
Furthermore, cytokines secreted by leukocyte may promote a microenvironment that supports 
thrombus generation, tumor growth, metastasis, and chemotherapy resistance (66, 67). 
 
In agreement with previous observation, patients with more than one metastatic sites or stage IVb 
disease had inferior survival. There is evidence that both the total number of metastases and the 
location of the metastatic disease are associated with prognosis (68, 69). However, among patients 
with a large tumor burden, prognostic significance of anatomic location is relatively less important 
(68). In seventh edition of American Joint Committee on Cancer (AJCC) cancer staging manual, 
metastasis to only one site such as liver, lung, ovary, or non-regional node has been classified as 
M1a disease or stage IVa cancer whereas metastasis to multiple sites or to the peritoneum has been 
classified as M1b or stage IVb cancer (70).  
 
As expected significantly more patients were diagnosed with a rectal or recto-sigmoid tumor, in 
the control group. Despites that, for reason not clear, patients with rectal or recto-sigmoid tumors 
compared with more proximal tumor had better survival. Frerrand and colleagues reported a 
similar observation in their retrospective analysis of FFCD 9601 trial (71).  These differences in 
patient survival were maintained after exclusion of patients with rectal primary.  
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With few exceptions, in most advanced solid tumors, poor performance status correlates with 
inferior survival and in many cases poor response to chemotherapy (72). Hence, there is a general 
agreement that patients with advanced solid tumors with a poor performance status would gain 
little benefit from chemotherapy. Data on patients with advanced CRC and poor performance 
status are scant. Clinical trials often exclude patients with ECOG performance status of ≥2 or with 
limited life expectancy. In our study cohort, patients with poor performance status, who received 
chemotherapy, had significantly lower overall survival compared with patients with good 
performance status. The modification in the chemotherapeutic regimen and dose reduction may 
reduce major complications in patients with borderline performance status.  In addition, treatment 
should be started as soon as possible before the performance status further deteriorates. It is not 
known if access to more effective anti-cancer therapy, better anti-emetics, and growth factors 
support improve outcomes of such patients.  
 
We also evaluated prognostic significance of area level variables including household income, 
family income, age dependency ratio, unemployment rate, aboriginal and minority population, 
high school certificate, single parenthood, and socio-economic Factor Index 2 (SAFEI2) in stage 
IV CRC. For income, unemployment rates and SAFEI2, the STATA software could not calculate 
numerical derivatives. For the other variables relationship was not significant (Appendix 11). We 
believe that absence of relationship is most likely due to small sample resulting in fewer numbers 
of observations in the census subdivisions rather than a true finding.      
 
9.5 Potential Mechanisms of Survival Benefit of Surgery 
 
The underlying mechanisms that resulted in better outcomes of the patients treated with surgery 
remains speculative. A benefit for primary tumor resection in stage IV renal cell cancer has been 
demonstrated in the two randomized controlled trials (73, 74). For example, radical nephrectomy 
prior to systemic therapy was associated with significantly better overall survival of 17 months in 
the surgical group compared with 7 months in the controls (73). Furthermore, observational studies 
support primary tumor resection in women with metastatic breast cancer (75). Non-curative 
resection of the primary tumor in patients with advanced cancer may prevent local tumor 
complications and improve disease control by reducing the tumor bulk and tolerance to systemic 
therapy. Furthermore, there is evidence for the genetic variation between the primary tumors and 
metastases (76). Removal of the primary tumor may result in a decreased burden of chemotactic 
cytokines and tumor-promoting factors which are produced by colorectal cancers, and regulate 
tumor cells growth and metastasis (77, 78). In addition, alteration in immune response following 
surgery, with predominant T helper 1 response than one with a substantial T helper 2 component 
may contribute to a better outcome (79).  
 
It has been shown that resection of the primary tumor may eliminate tumor-induced 
immunosuppression, primary tumor cells homing and seeding to distant sites, and may remove a 
source of potentially chemo-resistant cell lines (80-82).  Tumor-induced immunosuppression is a 
fundamental mechanism, which allows malignant cells to escape immune destruction. Tumor cells 
are known to synthesize and secrete several immunosuppressive factors. For example, 
transforming growth factor β inhibits CD8+ effector T cells and Th1 CD4+ T cells, thereby 
suppressing T-cell-mediated antitumor immunity (80, 83). It is possible that patients with bulky 
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primary tumors are profoundly immunosuppressed and primary tumor removal reverses immune 
suppression even in the presence of extensive metastatic disease. 
 
9.6 Strengths and Weaknesses 
 
There are several potential strengths and weakness of our study which are outlined below.  
 
9.6.1 Strengths 
 
• To our knowledge this is the only large population based cohort study that examined several 
patients-related factors (age, co-morbid illness, performance status, etc.), cancer-related factors 
(site, grade, disease burden, symptoms, etc.), laboratory values (leukocyte, albumin, alkaline 
phosphatase, CEA, etc.), and interventions (chemotherapy, biologics, metastasectomy, 
radiation, etc.)  in a multivariate model and demonstrated survival benefit of primary tumor 
resection independent of the other variables.  
• Individual patients’ data were obtained in all cases. In order to avoid erroneous exclusion of 
eligible patients, more than 10,000 individual records of patients with all stages CRC (stage I-
IV) were retrieved and patients (stage IV adenocarcinoma of colon and rectum) were selected 
based on inclusion and exclusion criteria.   
• Being a population-based study the study cohort was true representative of patients with stage 
IV CRC in the community. All patients had a complete follow-up and no subject was lost to 
follow-up to introduce bias.  
• The study population was heterogeneous and benefit of surgery was demonstrated in all 
patients groups (symptomatic versus asymptomatic or with minimally symptomatic primary 
tumor and patients who were treated with single agent chemotherapy versus those who 
received combination chemotherapy and biologics). Hence, our results are generalizable to the 
other people with stage IV CRC.    
• The study period spanned about twenty years and benefit of surgery was demonstrated both in 
the early and the later time periods.    
 
9.6.2 Limitations 
 
• Due to lack of randomization, imbalance of unknown prognostic variables between resection 
and non-resection groups cannot be eliminated.  
• Data was obtained retrospectively and the medical records were not designed for the study 
purpose.  
• In the study cohort we do not have information about BRAF mutation which has been reported 
in about 5-11% stage IV CRC and is an important prognostic biomarker (84). It is not known 
if differential distributions of BRAF mutation in the study groups have accounted for 
difference in survival.  
• In addition, disease burden was not measured in patients with single versus multiple site 
metastases. Hence, better survival secondary to selection of patients with low disease burden, 
who have better prognosis, cannot be eliminated.  
• Although the prognostic role of area-level variables was assessed in a subgroup of patients, 
our study lacks individual information on social determinants of health. 
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9.7 Future Direction 
 
Cancer is one of the leading causes of death globally.  According to the Canadian Cancer Society, 
40% of males and 45% of females are expected to develop cancer during their lifetime and one in 
four Canadians will die from cancer (85). With recent advancement in cancer management and 
research, the outcomes of cancer patients, specifically in the developed countries have improved. 
However, over the past decade, the cost of cancer care has exponentially gone up (86, 87). For 
example, the drugs associated with cancer care are estimated to cost approximately $40 billion 
USD per year globally (88). In 2010, $14 billion was spent in the United States on management of 
colorectal cancer (89). Monoclonal antibodies are an important component of systemic therapy in 
patients with stage IV CRC. For example, bevacizumab, a monoclonal antibody against the VEGF 
A, is commonly used in combination with chemotherapy in stage IV CRC (90, 91). It costs about 
$4000-5000 USD per dose for an average weight person. Goldstein et al. have estimated that 
bevacizumab provides minimal incremental benefit at high incremental cost per quality-adjusted 
life year (QALY) in stage IV CRC (92). In their economical analyses, bevacizumab in first-line 
therapy provided an additional 0.10 QALYs (0.14 life-years) at a cost of $59,361. The incremental 
cost-effectiveness ratio was $571,240 per QALY.  Likewise, anti-EGFR monoclonal antibodies 
cetuximab or panitumumab have demonstrated efficacy in patients with RAS wild metastatic CRC 
(93, 94). However, these monoclonal antibodies cost about $ 7500 to 10000 USD per dose for an 
average weight person and compared with best supportive care are not found to be cost-effective 
(95,96).   
 
The current study revealed that patients with stage IV CRC with symptomatic or asymptomatic or 
minimally symptomatic primary tumor who underwent surgery had better survival with overall 
50-60% relative reduction in mortality after adjustment for older age, comorbid illness, poor 
performance status, disease burden, chemotherapy, and metastasectomy. A larger benefit of 
surgery was noted in patients with stage IVA disease or who received subsequent lines of therapies. 
The group of patients who underwent surgical resection of primary tumor during the period of 
modern chemotherapy had 30-day postoperative mortality rate of about 5%. However, patients 
who underwent elective surgery and had asymptomatic or minimally symptomatic primary tumors 
had operative mortality rate of only 1.5 % (1-3). The major postoperative complications rate was 
11.8%; 7% in asymptomatic or minimally symptomatic compared with 15.8% in patients with 
symptomatic primary tumor (p=0.01).  
 
Based on the result of ours and others, two randomized controlled trials in Europe have been 
designed to confirm survival benefit of resection of the primary tumor in stage IV CRC (97,98). 
The SYNCHRNOUS trial is comparing primary tumor resection to no surgery in patients with 
colon cancer and synchronous metastases who are not amenable to curative therapy (97). The 
CAIRO 4 trial is evaluating this question in patients with stage IV colon and rectal cancer (98). If 
the magnitude of survival benefits is confirmed in these future randomized studies, surgical 
resection of the primary tumor could potentially be a more cost effective intervention in the 
management of metastatic CRC. 
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9.7.1 The SYNCHRONOUS Trial  
 
The SYNCHRONOUS trial will assess the efficacy and safety of primary tumor resection in 
patients with stage IV CRC (97). The primary objective of the trial is to investigate, if primary 
tumor resection prolongs survival of patients with colon cancer and synchronous metastases, not 
amenable to curative therapy.  
 
It is a multicentre, randomized controlled, superiority trial with a two-group parallel design. Colon 
cancer patients with synchronous unresectable metastases are eligible for inclusion. Exclusion 
criteria include symptomatic primary tumor, inability to tolerate surgery or chemotherapy and 
history of another primary cancer. The SYNCHRONOUS trial will be conducted as an intergroup 
trial of the Study Centre of the German Surgical Society (SDGC), the German Surgical Network 
of Clinical Studies (CHIR-Net) together with the Colorectal Study Group of the 
Arbeitsgemeinschaft Internistische Onkologie (AIO) of the German Cancer Society and the 
Association of Certified Intestinal Centers. Patient will be recruited at more than 60 trial centers 
in Europe.  
 
Patients in the experimental arm will undergo primary tumor resection prior to commencement of 
systemic chemotherapy. Surgery will be performed within 14 days of randomization. Systemic 
therapy will be started within 8 weeks after surgery. Patients in the control arm will receive 
chemotherapy and treatment will start within 14 days of randomization. The choice for the 
chemotherapy will be at discretion of the treating oncologist at each participating 
institution. Patients who become candidates for curative resection may receive further treatment 
with curative intent.  
 
The primary hypothesis is that resection of the primary tumor prolongs survival from 20 to 26 
months compared to systemic therapy without prior tumor resection. To detect a hazard ratio of 
1.3 with a two-sided test for treatment effect at a significance level of 5% within a Cox model 
without covariates with a power of 85%, 694 patients (347 per group) have to be included in the 
analysis, leading to a total number of events of 522. The accrual period is projected to be 24 months 
and the follow-up period will be 36 months.  
 
9.7.2 The CAIRO Trial 
 
The CAIRO trial is a multicenter, randomized phase III Dutch trial which is evaluating the clinical 
benefit of primary tumor resection in patients with synchronous unresectable metastatic colon 
cancer (98). Unlike SYNCHRONOUS trial patients with colon or rectal cancer are included in this 
study. Patients with synchronous metastatic colon cancer with asymptomatic or minimally 
symptomatic primary tumor will be randomized 1:1 between systemic treatment and primary 
tumor resection followed by systemic treatment. 
 
 In order to demonstrate a clinically relevant increase of 6 months of the median overall survival 
in the experimental arm, a total of 218 deaths will be required (80% power, significance level 
0.05). With a recruitment rate of 12 patients per month, an accrual period of 30 months and a 
follow-up period of 8 months, a total of 360 patients will be required in order to detect a difference 
in median overall survival of 13 versus 19 months with a power of 80%.  
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In the control arm first-line fluoropyrimidine-based chemotherapy with bevacizumab will be 
initiated within 4 weeks of randomization, followed by salvage therapy on progression at the 
discretion of the treating investigator. Surgery of primary tumor in this group will be performed 
only when indicated by local signs or symptoms. In the experimental arm surgery will be 
performed within 4 weeks of randomization followed by fluoropyrimidine-based chemotherapy 
with bevacizumab until progression or unacceptable toxicity, followed by salvage therapy on 
progression at the discretion of the local investigator.  
 
9.7.3 Relationship between the Primary Tumor and Host Immune Response  
 
The immune systems of cancer patients are able to recognize cancer specific antigens (99,100). A 
strong and a predominant cytotoxic T lymphocyte, Th1 response against cancer cells may keep the 
disease under control while tumor progression may occur with a predominant Th2 component that 
down-regulates the Th1 response (101,102). This phenomenon has been referred to as Th2-
Skewing Hypothesis of Tumor Escape. Of note, the Th1/Th2 phenotype of an immune response to 
an antigen can be inferred from the relative prevalence of IgG isotypes among the antibodies 
specific for this antigen. A predominant Th1 response correlates with a low IgG1/IgG2 ratio, 
whereas a predominant Th2 response correlates with a high IgG1/IgG2 ratio. This indirect 
assessment of the Th1/Th2 immune response has been referred as the IgG isotype methodology 
(101).  
 
Although host factors are critical in regulating cancer, the role of immune response in advanced 
colorectal cancer (CRC) is less clear. Our research group has developed an ELISA assays for the 
monitoring of immune responses against in patients with metastatic CRC. Our preliminary results 
showed that patients with metastatic CRC had elevated IgG1/IgG2 ratio compared with healthy 
control and the elevated ratios correlated with the disease progression (79). This work could be a 
base for future studies to explore the potential mechanisms of survival benefit of primary tumor 
resection and to determine if host immune responses (Th1 versus Th2) play a role in outcomes 
following primary tumor resection.  
    
9.8 Conclusions 
 
In summary, this well-designed population-based cohort study, with minimal selection and 
information biases, and appropriate follow up supports surgical resection of the primary tumor in 
patients with stage IV CRC, independent of other important prognostic factors. The benefit is 
greater in patients with limited burden of the disease or if they received subsequent line of 
therapies. Patients who are treated with combination therapy or who have minimally symptomatic 
primary tumor experienced comparable benefit.  In surgically treated patients pathological 
characteristic of the primary tumor such as nodal status, lymph node ratio, and tumor depth 
correlate with prognosis.   
 
The results warrant a well-designed randomized clinical trial to confirm survival benefit of 
surgery. Two randomized controlled trials in Europe are currently enrolling patients to confirm 
benefit of surgery (85, 86). We hope that the both trials will complete the planned accrual and will 
be able to answer this important question in the management of stage IV CRC. 
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APPENDIX A: SEARCH STRATEGY 
 
Question to be Answered: 
 
Should palliative resection of the primary tumor be performed in patients with advanced colorectal 
cancer? A Systematic Review 
 
Bibliographic Databases to be Searched:  
 
MEDLINE 
EMBASE 
CENTRAL 
In addition, grey literature (the American Society of Clinical Oncology and the European Society 
of Medical Oncology guidelines, education books, the National Comprehensive Cancer Network 
guideline) was reviewed for relevant studies. 
 
Search Terms for the Major Concepts in the Question:  
 
Advanced colorectal cancer term was divided into “colorectal cancer” AND “advanced” 
Colorectal cancer 
colon cancer/colon carcinoma 
colon tumor/large intestine cancer 
rectal cancer/ rectal neoplasm/rectum cancer  
sigmoid carcinoma/sigmoid neoplasms 
colorectal neoplasm/colorectal cancer/colorectal carcinoma 
colon neoplasm/colonic neoplasms 
sigmoid colon cancer 
cecal cancer/cecum carcinoma 
colorectal neoplasms, hereditary nonpolyposis 
 
Advanced 
stage IV or stage 4 or stage four or metastatic or advanced cancer   
 
Surgery 
general surgery or colon surgery or rectal surgery 
The Boolean operator “AND” was used to combine these headings to maximize precision while 
maintaining high recall. 
 
Terms for Appropriate Study Design (Evidence) 
 
Due to the concern of lack of controlled trials addressing this question, no study design restriction 
was applied. All the following study designs were eligible for review   
• Randomized controlled trial 
• Controlled clinical trial 
• Cohort studies (prospective and retrospective) 
• Case-control studies 
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Restriction to the Search 
 
• Publication status: Full published articles (to avoid studies with limited information) 
• Human studies 
• 1980 to 2012 (The study period was chosen as palliative chemotherapy become available 
in early 80s). 
• English language  
 
Inclusion & Exclusion Criteria 
 
Inclusion Criteria 
 
• Study Population 
o Patients with advanced adenocarcinoma of colon and rectum 
• Intervention  
o Surgical resection of the primary tumor 
• Control group  
o no surgery  
• Outcome of interest 
o Primary outcome of interest: Overall survival 
o Secondary outcomes of interest: Surgical mortality & morbidity, complications of 
primary tumor, nonsurgical intervention in the control group, rate of subsequent 
metastasectomy 
• Research design 
o Randomized controlled trial, cohort study (prospective &retrospective), case 
control 
 
Exclusion Criteria 
 
• Patients with small cell carcinoma, gastrointestinal stromal tumor (GIST), lymphoma, 
melanoma, anal canal cancer, melanoma and sarcoma of colon and rectum. 
• Patients with advanced colorectal cancer who underwent surgery with curative intention 
• Patients who had palliative bypass surgery (colostomy formation) or stent placement with 
an intact primary tumor. 
• Patients who received palliative radiation therapy to the primary tumor and did not have 
surgical resection of the primary tumor 
 
Subgroups 
 
• Patients with minimal or relatively asymptomatic primary tumor 
• Patients who were treated with second- and third-generation chemotherapy 
 
Search Strategy 
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Literature search was conducted by consulting a health science librarian at the U of S. The search 
was performed in three stages. 
In the first stage the MEDLINE, & EMBASE databases were searched for relevant studies. The 
University of Saskatchewan Ovid interface was used for the MEDLINE (1946-current) and 
EMBASE (1947-current).   
• All relevant studies were identified using the first 3 components of the PICO format.  
• Studies comparing survival of patients with stage IV colorectal cancer who underwent 
primary tumor resection (study group) with patients who did not have surgery were 
included.  
• Only studies with histologically documented adenocarcinoma of colon and rectum and 
evidence of metastases were included. Studies involving patients with other histological 
diagnosis including small cell carcinoma, gastrointestinal stromal tumor, lymphoma, 
melanoma, anal canal cancer, melanoma and sarcoma were excluded.  
 
Following concepts were used: 
1. Advanced colorectal  cancer 
2. Surgery 
 
A pilot search was performed and various key words and controlled vocabulary (for different 
concepts) were used utilizing ‘explode’ and ‘focus’ (for controlled vocabulary) in various 
combination. Because the use of ‘explode’ revealed mostly irrelevant articles, after consulting a 
librarian, in the final search ‘explode’ and ‘focus’ were not used. Likewise, when the key word 
“advanced colorectal cancer” with its synonyms was used, only small number of articles were 
retrieved. In order to increase the search sensitivity, the term “Advanced colorectal cancer” was 
broken into to the terms “advanced” AND “colorectal cancer”. 
 
• Following keywords, synonyms, and controlled vocabulary (MESH & EMTREE) were 
used   
o ‘‘colorectal cancer’’ or ‘‘colon cancer’’ or ‘‘rectal cancer’’ or ‘‘ colorectal neoplasm’’ 
or  “colon neoplasm” or “rectal neoplasm” please see the search terms above for detail) 
o  “advanced ” or “stage IV” or “stage 4” or “stage four” or “metastatic:  
o “surgery” or “colorectal surgery” or ‘‘palliative surgery” or “palliative surgery” or 
“surgical removal”  
• The three sets of terms were subsequently join together with the ‘AND’ operator.  
• Studies were selected by using pre-specified criteria with restriction to the publication dates 
from 1980 onward, the English language, and human studies.  
• The title and abstract of the searched articles were reviewed to identify relevant studies. In 
addition, using ‘similar study’ further studies were identified and exported to the Refwork. 
• A hand search was performed and the reference lists of the identified articles were reviewed 
to identify additional articles for assessment. In addition, PubMed search was done to 
eliminate any recent articles using different key words.  
In the second stage, the CENTRAL was searched using the term “colorectal cancer" or "colon 
cancer" or rectal cancer" or “colorectal neoplasms” and “surgery”. In order to increase the 
search sensitivity, the term “advanced” or “stage IV” was avoided.  
170 
 
In the third and final stage of search, the grey literature including the education material from 
scientific proceedings and current practice guidelines for the management of colon and rectal 
cancer by the American Society of Clinical Oncology [ASCO], the European Society of Medical 
Oncology [ESMO]) and the National Comprehensive Cancer Network (NCCN) was reviewed. 
Citation index was used to identify relevant articles in that subject.  
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APPENDIX B: SEARCH TERMS 
 
Database: Ovid MEDLINE(R) <1946 to February Week 4 2012> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1. Colonic Neoplasms/  
2. Colorectal Neoplasms/  
3. Rectal Neoplasms/  
4. cecal neoplasms/ or colonic neoplasms/ or sigmoid neoplasms/ or colorectal neoplasms, 
hereditary nonpolyposis/  
5. Colorectal cancer.mp.  
6. Colon cancer.mp.  
7. Rectal cancer.mp.  
8. 1 or 2 or 3 or 4 or 5 or 6 or 7  
9. Advanced cancer.mp.  
10. advanced.mp.  
11. Stage IV.mp.  
12. Stage four.mp.  
13. metastatic.mp.  
14. 9 or 10 or 11 or 12 or 13  
15. 8 and 14 ( 
16. Colorectal Surgery/  
17. surg.mp.  
18. Exp General Surgery/  
19. 16 or 17 or 18  
20. removal.mp.  
21. 19 or 20  
22. 15 and 21  
23. limit 22 to (English language and humans and yr="1980 -Current")  
24. "Palliative surgery”. Mp.  
25. 21 or 24  
26. 15 and 25  
27. "Palliative resection”. Mp.  
28. 25 or 27  
29. 15 and 28  
30. limit 29 to (English language and humans and yr="1980 -Current")  
31. Find similar to Elective palliative resection of incurable stage IV colorectal cancer: who 
really benefits from it? 
32. Find similar to the role of primary tumour resection in patients with stage IV colorectal 
cancer.  
33. Find similar to Surgery of the primary in stage IV colorectal cancer with unresectable 
metastases.  
34. from 33 keep 9-10  
35. Find similar to Elective bowel resection for incurable stage IV colorectal cancer: prognostic 
variables for asymptomatic patients.  
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Database: Embase Classic+Embase <1947 to 2012 February 05> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1. colon cancer/ or colon tumor/ or large intestine cancer/  
2. colon carcinoma/ or colorectal cancer/ or colorectal carcinoma/ or sigmoid carcinoma/  
3. sigmoid carcinoma/  
4. cecum carcinoma/  
5. rectum cancer/  
6. rectum carcinoma/  
7. 1 or 2 or 3 or 4 or 5 or 6  
8. "Stage IV".mp.  
9. "Stage 4".mp.  
10. advanced cancer/  
11. metastatic.mp.  
12. Stage four.mp.  
13. 8 or 9 or 10 or 11 or 12  
14. 7 and 13  
15. "Palliative surgery”. Mp. 
16. "Palliative resection”. Mp.  
17. colon surgery/ or colorectal surgery/ or rectum surgery/  
18. "Surgical removal”. Mp.  
19. 15 or 16 or 17 or 18  
20. 14 and 19  
21. limit 20 to (human and English language and yr="1980 -Current")  
22. from 21 keep 11,31,35,51,67,114,118,139,146,193,217-218,269,385,439,446  
23. find similar to Elective bowel resection for incurable stage IV colorectal cancer: Prognostic 
variables for asymptomatic patients  
24. Find similar to colorectal cancer with multiple metastases: Is palliative surgery needed?  
25. find similar to Surgery of the primary in stage IV colorectal cancer with unresectable 
metastases  
26. find similar to Intestinal complications after palliative treatment for asymptomatic patients 
with unresectable stage IV colorectal cancer  
27. Find similar to How Aggressive Should We Be in Patients with Stage IV Colorectal Cancer?  
28. Find similar to Is there a survival advantage for elective primary tumor resection in 
asymptomatic patients with incurable stage IV colorectal cancer?  
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APPENDIX C: FULL TEXT SCREENING FORM* 
 
Reviewer:    SA           RKS        
Reference ID:       
Last name of the 
first author:       
Title:       
Journal:       
Date of 
publication         D/M/Y 
 
Criteria for exclusion 
Study design ANY of the following 
   No independent control group (e.g. case report or case series) 
   No comparator group 
   Conference abstract 
   Other type of publication (i.e. not a clinical study or review) 
Population ANY of the following 
  Not patients with colorectal cancer 
   Patients with TNM stage 1, 2, 3 colorectal cancer 
   Patients with colorectal cancer of histopathology other than 
adenocarcinoma (melanoma, GIST, lymphoma, small cell 
carcinoma) 
   Patients  with colorectal cancer who had resection of primary 
tumor with curative intent 
Intervention ANY of the following 
   procedures  other than resection of primary tumor (colostomy 
formation, stent, radiation) 
Comparator   Non resection surgery 
 curative surgery 
 
Criteria for inclusion 
Study design    Randomized controlled trial    non-randomized trial   
   Cohort study                              Case control 
   Review** 
Population    Patients with advanced colorectal adenocarcinoma 
Interventions in 
experimental  group 
ANY of the following 
   Surgical resection of the primary tumor 
 
   TO BE INCLUDED  
   FURTHER ACTION 
REQUIRED 
What action:       
 
   TO BE EXCLUDED           
 
What action:       
 FURTHER ACTION REQUIRED (i.e. duplicate) 
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Additional comments:       
 
* The two coauthors using the PICO format developed a full text screening format. Prior to 
development of form, both authors randomly screened the database searched for the systematic 
review. A previous full text screening form template was used for this purpose. Based on a priori 
knowledge, inclusion and exclusion criteria were developed. Human, the English language, and 
time period (1980- present) restrictions were applied in the search databases.  
** Reviews were included for hand search of citations and identification of other studies. 
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APPENDIX D - DATA ABSTRACTION FORM SURGICAL MANAGEMENT VS. 
CONSERVATIVE TREATMENT 
 
Study Characteristics 
1. Journal:  
 
2. Last name of First Author:  
 
3. Year of publication:  
 
4. Country/countries where study took place: 
 
5. Type of Center:   
Multicenter     Single Center 
 
6. Correspondent Author Affiliation 
 
7. Funding Source:  
a. Non-Industry  
b. Industry sponsored 
c. not reported 
 
8. Study Design:   
a. RCT  
b. Controlled trial  
c. cohort study 
d. Case control study 
e. Prospective study  
f. Retrospective study 
 
9. Date of start of study  
M      Year 
 
10. Date of completion of study  
M      Year  
 
11. Duration of follow up:  
Days      Months   Year  
 
12. Eligibility criteria were:  
Explicit  
Not explicit  
Not reported  
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13. Inclusion Criteria: 
 
14. Exclusion Criteria: 
 
 
 
 
15. If Randomized trial:* 
 
a. Method of randomization is described:   Yes No 
b. If yes describe the method 
c. Concealment of allocation is described:  Yes No 
d. Blinding of patients was done:    Yes No 
e. Blinding of Health care providers was done: Yes No 
f. Blinding of data collectors was done:   Yes No 
g. Blinding of assessors of outcomes was done:  Yes No 
h. Blinding of data analysts was done:   Yes No 
i. Number of patients randomized:  
Control      Intervention 
j. Number of patients not followed:  
Control      Intervention 
k. Number of patients followed but not included:  
Control       Intervention 
l. Number of patients followed but not included in primary analysis:  
Control      Intervention 
m. Intent to treat analysis:     Yes N Not Reported 
 
*If a randomized trial found, blinding, follow-up, and intent to treat analysis will be performed 
separately for each outcome.  
 
16. If observational study 
a. Cohort studies: The Ottawa/Newcastle quality assessment Score (See sub-appendix F1 
for score) 
b. Case control studies: The Ottawa/Newcastle quality assessment Score  (See sub-
appendix F2 for score) 
 
Baseline Characteristics (NR=not reported) 
 
17. Symptomatic  
Asymptomatic  
Both  
Not specified 
 
18. Number of patients 
a. Total  
b. Experimental group  
c. Control 
 
 
177 
 
 
19. Median age 
a. Experimental group  
b. Control 
c. NR 
  
20. Age range  
a. Experimental group  
b. Control  
c. NR 
 
21. Mean age 
a. Experimental group  
b. Control 
c. NR 
 
22. SD of mean age 
a. Experimental group  
b. Control  
c. NR 
 
23. Number of female 
a. Experimental group  
b. Control  
c. NR 
 
24. %  of female 
a. Experimental group  
b. Control  
c. NR 
 
25. Comorbid illnesses (number) 
a. Experimental group  
b. Control  
c. NR 
 
26. Comorbid illnesses (%) 
a. Experimental group  
b. Control  
c. NR 
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27. ECOG  performance status >1  (number) 
a. Experimental group  
b. Control 
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
28. Baseline CEA level (Mean) 
a. Experimental group  
b. Control  
c. NR 
 
29. Baseline CEA (SD) 
a. Experimental group  
b. Control  
c. NR 
 
Primary Tumor 
 
30. Number of patients with rectal tumor 
a. Experimental group  
b. Control 
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
31. Number patients with colon tumor 
a. Experimental group  
b. Control 
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
32. For colon cancer number in experimental group  
a. Right colon     
b. left colon 
c. transverse colon    
d. sigmoid colon  
e. NR 
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33. If number not described % in experiment group 
a. Right colon     
b. left colon 
c. transverse colon    
d. sigmoid colon  
e. NR 
 
34. For colon cancer number in control group  
a. Right colon     
b. left colon 
c. transverse colon    
d. sigmoid colon  
e.  NR 
 
35. For colon cancer in % experimental group  
a. Right colon     
b. left colon 
c. transverse colon   
d. sigmoid colon  
e. NR 
 
Disease Burden 
 
36. Liver disease (number) 
a. Experimental group   
b. Control  
c.  NR 
If number not described % 
a. Experimental group  
b.  Control  
c. NR 
 
37. Liver only disease (number) 
a. Experimental group   
b. Control 
c.  NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
Extrahepatic disease (number) 
c. Experimental group  
d. Control  
e. NR 
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If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
38. Peritoneal disease (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control 
c. NR 
 
39. >25% liver involvement (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
40. Single site metastases (number) 
a. Experimental group 
b. Control 
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
41. Multiple site metastases (number) 
a. Experimental group 
b. Control 
c.  NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
42. Received radiation therapy (number) 
a. Experimental group  
b. Control  
c. NR 
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If number not describe% 
a. Experimental group  
b. Control  
c. NR 
 
Systemic Therapy 
 
43. Received chemotherapy (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control 
c. NR 
 
44. Received 5-FU  (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control 
c. NR 
 
45. Received oxaliplatin  (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
46. Received irinotecan  (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
47. Received bevacizumab (number) 
a. Experimental group  
b. Control  
c. NR 
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If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
48. Received anti-EGFR Mabs [cetuximab or panitumumab]  (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
49. Received first-line therapies (number) 
a. Experimental group  
b. Control  
c. NR 
 If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
50. Received second-line therapies (number) or second-generation therapy 
a. Experimental group  
b. Control 
c. NR 
If number not described %  
a. Experimental group  
b. Control 
c. NR 
 
51. Received third-line therapies (number) or third-generation therapy 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b.  Control  
c. NR 
 
52. Received second- or third-generation therapy 
a. Experimental group  
b. Control  
c. NR 
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If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
Primary Outcome 
 
53. Median overall survival in months 
a. Experimental group  
b. Control  
c. NR 
 
54. Median overall survival range  
a. Experimental group  
b. Control  
c. NR 
 
55. One year survival  (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
56. Two year survival  (number) 
a. Experimental group  
b. Control  
c. NR 
If number not described % 
a. Experimental group  
b. Control 
c. NR 
 
57. Three year  survival (number)  
a. Experimental group  
b. Control 
c. NR 
If number not described % 
a. Experimental group  
b. Control 
c. NR 
 
58. Five year  survival (number)  
a. Experimental group  
b. Control  
c. NR 
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If number not described % 
a. Experimental group  
b. Control  
c. NR 
 
Secondary Outcomes (30 days complications, mortality, rate of metastasectomy) 
 
59. Surgical morbidity in the experimental group (number) 
NR  
a. Infection 
b. anastomotic leakage 
c. non-infection/non-anastomotic leakage (please specify  
d. Overall number of surgical morbidity 
If number not described % 
a. Infection 
b. anastomotic leakage 
c. others (please specify  
d. Overall % of surgical morbidity 
 
60. Surgical mortality in the experimental group (number) 
a. ……………. 
b. NR 
If number not described % 
a. Overall % of surgical mortality 
b. NR 
 
61. Primary tumor complications (number in the experimental group) 
a. Perforation  
b. obstruction  
c. bleeding 
 
62. Primary tumor complications (% in the experimental group) 
a. Perforation  
b. obstruction 
c. Bleeding………………… 
 
63. Primary tumor complications (number in control group) 
a. Perforation  
b. obstruction  
c. bleeding 
 
64. Primary tumor complications (% in control group) 
a. Perforation  
b. obstruction  
c. bleeding 
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65. Rate of metastasectomy % 
a. Experimental group  
b. Control 
c. NR 
 
66. Rate of metastasectomy number 
a. Experimental group  
b. Control  
c. NR 
 
Comparison 
 
67. Unadjusted risk Difference (Please specify units) 
a. variance 
b.  P value 
 
68. Adjusted risk Difference (Please specify units) 
a. variance 
b. P value 
 
69. Unadjusted risk ratio 
a. hazard ratio    95% CI    P value 
b. Odd ratio   95% CI    P value 
c. Risk ratio   95% CI    P value 
d. Other (specify).  variance    P value 
 
70. Adjusted risk ratio 
a. hazard ratio    95% CI    P value 
b. Odd ratio   95% CI    P value 
c. Risk ratio   95% CI    P value 
d. Other    (specify variance)   P value 
 
71. Quality of life score 
a. Experimental group  
b. Control  
c. NR  
d. Scale 
 
72. Final outcome 
a. Favoring experimental arm 
b. Favoring control arm 
c. No difference 
 
186 
 
APPENDIX E: MANUAL OF DATA ABSTRACTION SHEET 
 
This manual has been written to clarify the electronic data abstraction sheet and to reduce the 
disagreement between the data extractors. Please follow the steps for the data extraction. If 
information is not included in the manuscript, please leave that section blank. The 
correspondent authors will be contacted for important missing information.  
For each page, please check off your initials and enter the reference number at the top. Each 
reviewer will complete a form for each study. Consensus will be reached between the two 
reviewers for differences.  Once the differences are resolved by consensus, a final electronic copy 
will be used for the synthesis of the data.   
 
Study Characteristics  
 
1-7: Please fill the journal name, last name of the first author, location of the study (based on first 
author affiliation), type of center (single vs. multicenter), correspondent author affiliation, and 
source of funding.   
 
8: Record the study design if reported and clarify retrospective vs. prospective study (6e and 6f). 
 
8-11: Please record the date of start, date of completion, and the duration of follow-up, if reported.   
 
12-14: Please record if eligibility criteria are explicitly defined, and record the inclusion and 
exclusion criteria. The study should have only patients with advanced adenocarcinoma of colon 
and rectum. If the study population is a subgroup of other population, please specified.  
 
15: (13a-13m). Please documents all the bias related to the study if it is a randomized controlled 
trial. Each outcome will require a separate bias assessment for each outcome specifically for 
blinding, follow-up and ITT analysis. Please contact the PI (SA).  
 
16: (14a & 14b). Most studies are anticipated to be observational studies. The Ottawa-Newcastle 
scale will be used to assess the quality of observational study. A study can be awarded a 
maximum of one point for each numbered item within the Selection and outcome categories.  
A maximum of two points can be given for Comparability. 
 
Sub appendix F1: Ottawa-Newcastle scale for cohort study. Please score 0-4 points for 
Selection, 0-2 points for comparability and 0-3 points for outcome with total score of 0-9 of 
9. 
 
Sub appendix F2: Ottawa-Newcastle scale for case-control study. Please score 0-4 points 
for Selection, 0-2 points for comparability and 0-3 points for outcome with total score of 0-
9 of 9. 
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Baseline Characteristics 
 
17: Please record if study population was symptomatic or asymptomatic, if both check both, 
if it is not clarified please records it.  
 
18-29: Please record total number of study population, median age, age range (mean age 
and standard deviation [SD]), raw number of female patients and percentage of female 
patients, percentage of comorbid illness, percentage of patients with ECOG performance 
status of more than 1 and baseline CEA level (mean and SD). All data must be recorded for 
both groups (the intervention group and the control).  
 
Primary Tumor 
 
30-35: Items 30-35 are dealt with location of the primary tumor. Please record number and percent 
of the rectal tumor and colon tumor in both groups. For colon cancer please record the site of the 
tumor (right, left, transverse, sigmoid) in both groups.    
 
Disease Burden  
 
36-42: Items 36-42 are concerned with the extent of the disease in study population. Please record 
number and percent of patients with liver disease, liver only disease, disease outside the liver, 
peritoneal disease, >25% liver involvement, single site metastases, and multiple site metastases in 
the intervention and control groups. 
 
43: Please record if number and percent of patients in both groups received palliative radiation 
therapy.  
 
Systemic Therapy 
 
44-53: Items 44-53 are related to types of chemotherapy and biologics, and number of lines of 
therapy in the intervention and control groups. Please record number or percent of patients in both 
groups received chemotherapy, 5-FU, oxaliplatin, irinotecan, bevacizumab, anti-EGFR-mabs 
[cetuximab, panitumumab], first-line therapy, second-line therapy, third-line therapy, and second- 
or third-generation therapy. 
 
Primary Outcome (Survival) 
 
54-59: Items 54-59 deal with survival of patients in both groups.  
54-55: Please record median overall survival in months and range of survival.  
56-59: Please record number or percent of patients with 1-year survival, 2-year survival, 3-year 
survival, and 5-year survival in both groups.  
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Secondary outcomes (30 days complications, mortality, rate of metastasectomy) 
  
60-67: Items 60-67 are concerned with the secondary outcomes including post-operative mortality, 
morbidity, and rate of metastasectomy.  
60. Please record surgical morbidity number and percent for the experimental group described in 
a study (Ideally 30 days post-op). Infection is defined as all documented surgical wound and other 
infection related to the surgery and reported.  For 58c”non-infection/non-anastomotic leakage” 
please specify the total number.  
 
61. Please record surgical mortality (number and percent) in the experimental group. 
 
62-65: Please record primary tumor complications (number and percent) in the experimental and 
control group. A primary tumor complication is defined as proportion of bleeding, obstruction, 
and perforation in the control group.  
 
66-67: Please record number and percent of metastasectomy in both groups.   
 
Comparison 
 
68-69: Please record unadjusted and adjusted risk difference between the two groups, with 
reported variance (95% CI), and P-value if it is reported. 
  
70: Please record unadjusted risk ratio (e.g. hazard ratio) between the two groups, with reported 
variance (95% CI), and P-value if it is reported. 
 
71: Please record adjusted risk ratio between the two groups, with reported variance (95% CI), and 
P-value if it is reported. 
 
72: Please record quality of life score and scale used in the two groups.  
 
74: Please record the primary outcome reported in a study comparing surgery vs. nonsurgical 
group, record if there was no difference in mortality, or if the survival of one the groups was 
superior.  
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APPENDIX F1- NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALE:  COHORT 
STUDIES (PRIMARY OUTCOME: MORTALITY) 
 
For cohort study these items are as follow (Appendix 3a). Selection: (1) true representativeness 
of the exposed cohort in the community, (2) non exposed cohort drawn from the same community, 
(3) ascertainment of exposure, and (4) demonstration that outcome of interest was not present at 
start of study. Comparability of cohorts: (5) control for symptoms and (6) control for systemic 
therapy. Outcome: (7) assessment of outcome, (8) follow –up was long enough for outcomes to 
occur and (9) adequacy of follow-up of cohorts.  
 
A study can be awarded a maximum of one star for each numbered item within the Selection 
and Outcome categories.  A maximum of two stars can be given for Comparability  
 
Selection (0-4) 
Comparability (0-2) 
Outcome (0-3) 
 
Total: 0-9 
 
Selection 
 
1. Representativeness of the exposed cohort 
a. True representative of the patients with advanced colorectal cancer in the community*  
b. Somewhat representative of the patients with advanced colorectal cancer in the 
community* 
c. Selected group   
d. No description of the derivation of the cohort 
 
2. Selection of the non-exposed cohort 
a. Drawn from the same community as the exposed cohort* 
b. Drawn from a different source 
c. No description of the derivation of the non-exposed cohort 
 
3. Ascertainment of exposure 
a. Secure record*  
b. Structured interview* 
c. Written self-report 
d. no description 
 
4. Demonstration that outcome of interest was not present at start of study  
a. Yes*  
b. No 
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Comparability 
 
1. Comparability of cohorts on the basis of the design or analysis 
a. Study controls for symptoms*  
b. Study controls for systemic therapy* 
 
Outcome 
 
1. Assessment of outcome 
a. Independent blind assessment*  
b. Record linkage*  
c. Self-report 
d. No description 
 
2. Was follow -up long enough for outcomes to occur 
a. Yes (select an adequate follow up period for outcome of interest)* 
b. No 
 
3. Adequacy of follow-up of cohorts 
a. Complete follow-up - all subjects accounted for* 
b. Subjects lost to follow-up unlikely to introduce bias - small number lost <5% or 
description provided of those lost)* 
c. Follow-up rate <5% and or no description of those lost  
d. No statement 
 
……………….…../4, ………………./2,……………………../3= ………………../9 
Total score 
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APPENDIX F2 - NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALE:  CASE-
CONTROL STUDIES 
 
For case control study these items are as follow. Selection: (1) Case definition, (2) 
representativeness of the cases, (3) selection of controls, and (4) definition of controls. 
Comparability of cohorts: (5) control for symptoms and (6) control for systemic therapy. Exposure: 
(7) assessment of exposure, (8) same method of ascertainment for cases & controls, and (9) non-
response rate 
 
A study can be awarded a maximum of one star for each numbered item within the Selection 
and outcome categories.  A maximum of two stars can be given for Comparability  
 
Selection (0-4) 
Comparability (0-2) 
Outcome (0-3) 
 
Total: 0-9 
 
Selection 
 
1) Is the case definition adequate? 
a) Yes, with independent validation* 
b) Yes, e.g. record linkage or based on self-
reports  
c) No description 
 
2) Representativeness of the cases 
a) Consecutive or obviously representative series of cases* 
b) Potential for selection biases or not stated 
 
3) Selection of Controls 
a) Community controls* 
b) Hospital 
controls c) no 
description 
 
4) Definition of Controls 
a) No history of disease (endpoint)* 
b) No description of source 
 
Comparability 
 
1) Comparability of case and controls on the basis of the design or analysis 
a) Study controls for symptoms*  
b) Study controls for systemic therapy* 
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Exposure 
 
1) Ascertainment of exposure 
a) Secure record*  
b) Structured interview were blind to case/control status*  
c) Written self report or medical record only 
d) No description 
 
2) Same method of ascertainment for cases & controls 
a) Yes* 
b) No 
 
3) Non-Response rate 
a) Same rate for both groups* 
b) Non respondents described 
      c) Rate different and no designation 
 
……………….…../4, ………………./2,……………………../3= ………………../9 
Total score  
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APPENDIX F3- PROTOCOL OF DATA EXTRACTION  
 
Two reviewers will select trials and extract the data using pre-determined forms independently. 
Data will be compared for differences. If there is a difference, it will be resolved by consensus 
• study design 
• population characteristics 
• Intervention 
• outcomes measures 
• results 
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APPENDIX G1 (1992-2005) - COLO-RECTAL CANCER ABSTRACTION SHEET 
 
Date of birth (D/M/Y): _______________  Gender:   M       F 
 
Major Comorbid illness: NA     None     CAD     DM     CRI     COPD    Others -
______________ 
 
Secondary cancer:  Y     N     ECOG PS:      0     1     2     3     4     NA 
 
Current Smoker:  Y     N      NA   EX Smoker: Y      N NA   
 
Baseline:  Na _____ Creatinine _____ BUN _____ Albumin _____ Bilirubin _____ CEA 
______ 
Alk P _____  AST _____ ALT  _____  LDH _____ WBC _____  Hb _____  Plt _____ 
 
Previous diagnosis of early stage colon cancer: Y     N     (if yes exclude) 
 
Date of diagnosis of advanced colorectal cancer (D/M/Y) _______________ 
 
Colon   (RT    T    Lt    Sig) Rectal   Rectosigmoid    Appendix    NOS   Overlap     Code 
_______  
   
 T _____ N_____/_____  Grade  _____ 
 
Obstruction: Y       N       Perforation: Y      N     Heavy Bleeding: Y     N 
 
Mucinous: Y     N 
 
Surgery for primary tumor: Y      N   Surgery for mets: Y      N 
 
Sites of Mets:      Liver        Extra hepatic:      N      Y     (lung   peritoneum   Bone   CNS   
             Others____________________) 
Received chemotherapy: Y     N 
 
Date of start of chemotherapy (D/M/Y)    _______________ 
 
Received 2nd line therapy: Y     N  
 
Received RT: Y      N   Irinotecan/oxaliplatin: Y     N 
 
Date of last contact on which the status of disease was evaluated (D/M/Y) 
________________  
 
Alive      Deceased                 Date of death (D/M/Y)  ___________________ 
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APPENDIX G2 (2006-10) COLO-RECTAL CANCER COHORT 
  
Medical Record Number:  ____________ 
 
Date of Birth (D/M/Y):  ______________ Gender:   M       F Postal Code: __________ 
 
Status at Time of Diagnosis:   Single          Married          Widow         Common-Law        
Unknown 
 
Children:  Y     N     
 
Major Co morbid Illness:    NA       None       CAD        DM        CRI        COPD       
Others____________ 
 
Secondary Cancer: Y     N     ECOG PS:      0     1     2     3     4     NA     NK 
 
Current Smoker: Y     N     NA   EX Smoker: Y     N     NA   
 
Baseline:  
Na______Creatinine_______BUN_______Albumin_______Bilirubin_______CEA________ 
 
     Alk 
P________AST_______ALT_______LDH_______WBC_______Hb_______Plt_______ 
 
Previous Diagnosis of Early Stage Colon Cancer:    Y     N      (IF YES EXCLUDE) 
 
Date of Diagnosis of Advanced Colorectal Cancer (D/M/Y): 
_________________________________ 
 
Colon:       (RT      T      Lt      Sig)      Rectal        Rectosig         Appendix         NOS        
Overlap      
 
Code: ___________   T______ N_____/_______ Grade ________ 
 
Obstruction: Y     N      Perforation: Y     N      Heavy Bleeding: Y      N  
 
Mucinous: Y      N  Moderate to Severe Pain:  Y     N          
 
Surgery for Primary Tumor: Y     N  Date of Surgery of Primary Tumor 
(D/M/Y/):____________ 
 
Non-Surgical Procedure: Y     N  If Yes:      Stent     Ostomy       Other: 
_______________ 
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Surgery for Mets:  Y     N   Date of Start of Surgery of Mets 
(D/M/Y/):_______________ 
 
Sites of Mets:      Liver     Extra hepatic:    N    Y    (lung   peritoneum   Bone   CNS  
Others______________) 
 
Received Chemotherapy:  Y     N 
 
Date of Start of Chemo (D/M/Y): _____________ Date of End of Chemo (D/M/Y): 
______________ 
 
Received 2nd Line Therapy: Y     N  
 
Received 3rd Line Therapy: Y     N  
 
Received Irinotecan:  Y     N  
 
 
Received Oxaliplatin:  Y     N  
 
Received Bevacizumab (Avastin): Y     N  
 
 
Received Cetuximab or Panitumumab: Y     N  
 
Received RT: Y     N  Radical /Palliative 
 
Radiotherapy Start Date (D/M/Y):  ___________Radiotherapy End Date (D/M/Y): 
____________  
 
Date of Last Contact on Which the Status of Disease was E valuated (D/M/Y): 
____________ 
 
Alive      Deceased                  
 
Date of Death (D/M/Y): ______________ 
 
Cause of Death (D/M/Y): _________________________________________________ 
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APPENDIX H: DATA COLLECTION MANUAL (COHORT STUDY) 
 
Medical Record Number clinic chart number of the patient 
 
Date of Birth (D/M/Y)   date of birth of patient 
 
Gender    M=Male        F=Female 
 
Postal Code   postal code at time of diagnosis 
 
Status at Time of Diagnosis single, married, widow, common-law, unknown at time of  
diagnosis 
     
Children any children (Yes/No) do not need to be biological children;  need 
to know if patient has children around for possible support 
 
Major Co Morbid Illness  NA= Not Available         
 None= None 
 CAD= coronary artery disease      
DM=diabetes mellitus       
 CRI= chronic renal insufficiency     
 COPD- chronic obstructive pulmonary disease  
 Other=anything that does not appear above (include angina, 
ischemic, hypertension, MI here) (PI will look through and 
determine if comorbid or not) 
 
Secondary Cancer  Yes     No 
     
Indicates if a patient has had an additional cancer other than the 
colorectal cancer at any time (before or after diagnosis of 
Colorectal); exclude skins (Basal cell & Squamous) but include 
melanomas; exclude benign cases  
 
ECOG PS   Performance status of patient at  first clinic visit. (Use performance 
scale sheet); if unable to figure it out use NA (not available) as per 
PI, if not stated, try to determine using 1 (as ECOG 0 or 1) and 2 
(as ECOG 2 or higher)  
 
Current Smoker   Yes     No     Not Available or NK 
If patient said to be a smoker but not clear whether they still smoke 
= smoker; if patient does snuff/chewing tobacco:  do not include = 
NO 
 
EX Smoker    Yes       No      NA (not indicated in chart) 
Yes = if patient does not currently smoke but did at one time in 
their life  
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Baseline Labs Use lab values from around first clinic visit – Na, Creatinine, BUN 
(Urea), Albumin, Bilirubin, CEA, AlkP (AlkPhos), AST (SGOT), 
ALT(SGPT), LDH ,WBC, Hb, Plt 
 
Previous Diagnosis of Early Yes = Exclude      No 
 
Stage Colon Cancer  previous diagnosis of early stage colon = exclude 
 
Date of Diagnosis of  histological proven date of diagnosis of colorectal or metastasis 
from  
 
Advanced Colorectal Cancer colorectal biopsy date can be used (must have tissues DX to be 
included) 
 
(D/M/Y) 
    
Colon    RT= right (C18.0 cecum), ascending (C18.2) 
    T= transverse (C18.4), hepatic (C18.3), splenic (C18.5) 
    Lt= left, descending (C18.6) 
    Sig= sigmoid (C18.7) 
    Rectal (C20.9) 
    Rectosigmoid (C19.9) 
    Appendix (C18.1) included (email June 15, 2007) 
    NOS (Not Otherwise Specified) (NK) (email Dec 6/06) (C18.9) 
    Overlapping Lesion of Colon (C18.8) 
 
T    Primary Tumor  
    USE AJCC 6th edition to Stage “T” (TX, TO, Tis, T1, T2, T3, T4) 
 
N number of nodes positive and number of nodes examined (3/11= 
three nodes positive out of the eleven nodes examined) - if not 
indicated as to how many involved/examined.  Use “?/#”  
 
Grade    1= Well    4= Undifferentiated 
    2= Moderate   9=Grade Not Determined 
    3= Poor 
         
Obstruction    Yes     No ****************************** 
 
Obstruction is defined as either acute obstruction on presentation 
or obstruction seen on endoscopy or obstruction evident on 
pathologic specimen       
 Can be clinical or pathological 
     Can be complete or partial 
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 Perforation  Yes      No 
Defined as abdominal crisis due to escape of contents of perforated 
viscous into peritoneal cavity 
 Perforation= T4 
 Some T4’s are included and some excluded from study.  
 (See additional “T4” sheet for guide) 
 
Heavy Bleeding   Yes     No 
    Patient anemic = No 
    On presentation and/or surgery 
Surgery in advanced patients is usually not done unless there is 
bleeding (Drop in hemoglobin <20 g/l) 
It is up to treating surgeon if he felt bleeding was significant and 
required palliative surgery than consider heavy bleeding.  It does 
not mean bleeding during surgery. (Email July 2, 2008) 
 
Mucinous   Yes    No 
If stated as 50% or more in the pathological description:  it will be 
“yes”.  It will be “Yes” if stated in final diagnosis of path 
 
Moderate to Severe Pain unpleasant sensation the can range from mild, localized  
discomfort to agony around the time of diagnosis 
 
Surgery for Primary Tumor  Yes     No 
    Did patient have surgery for the primary tumor  
 It is the resection of tumor not biopsy or formation of 
defunctioning colostomy to bypass obstruction (email Feb27/07) 
 Must be a resection to be surgery for primary tumor. 
 
Date of Surgery of Primary  initial date of surgery of the primary tumor:  D/M/Y 
 
Tumor 
 
Non-Surgical Procedure did patient have a stent, ostomy or something else 
 
Surgery for Metastases  Yes     No 
(liver, lung, etc)    did patient have surgery for metastasis of the liver etc. (does not 
need to be complete resection)  
 
Dates of Surgery of Mets initial date of start of surgery of mets:  D/M/Y 
 
Sites of Mets:   Liver (circle if yes) 
 Extrahepatic:  circle Yes or No (lung, peritoneum, Bone, CNS,  
Others) 
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Only at time of diagnosis (based on most recent imaging study 
after diagnosis (email Dec15/06) 
If at time of surgery they had lesions which subsequently turn out 
to be mets; include.  However, for patients with normal presurgical 
imaging studies and no suspicious lesion during surgery we will 
still require 6 weeks eligibility criteria. (Email April 12, 2007) 
 
Received Chemotherapy  Yes     No    
Any time since diagnosis of advanced cancer (make sure it’s not a 
T4 are not eligible if there is direct extension)  
 
Date of Start of Chemo  date patient received cycle 1 of chemo no matter what the regimen 
was 
(D/M/Y)   (5-FU/ Leucovorin, Tomudex, CPT 11 etc.) 
    This is for the very FIRST chemo regimen patient received 
 
Date of End of Chemo End date of chemo D/M/Y 
 
Received 2nd Line Therapy   Yes     No 
If patient received any more than one type of chemo regimens ex. 
5U/Leucovorin, then CPT11:  CPT 11 would be 2nd line therapy  
    
Received 3rd Line Therapy   Yes     No 
 
If patient received any more than two types of chemo regimens ex. 
5-FU/Leucovorin, then CPT11, then Xeloda:  Xeloda  would be 
3rd line therapy  
    
Received Irinotecan   Yes     No 
(CPT-11, Campstosar)  clinical trials are also included  
 
Received Oxaliplatin   Yes     No 
(Eloxatin)   clinical trials are also included 
 
Received Bevacizumab  Yes     No 
(Avastin)   clinical trials are also included 
 
Received Cetuximab   Yes     No 
(Erbitux) or Panitumumab  clinical trials are also included -this is if patient had either one of 
them or  
(Vectibix)   both 
  
Received RT     Yes      No  
(Radical, palliative or adjuvant) (Phone call Dec 22/06) 
    No specific details needed 
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Radical/Palliative  the kind of radiotherapy patient was receiving:   Radical or 
Palliative  
 
Radiotherapy Start Date  date that patient started Radiotherapy 
(D/M/Y)’ 
 
Radiotherapy End Date  date that patient ended Radiotherapy 
 (D/M/Y)  
 
Date of Last Contact on  can use clinic note, family physician note, FBM letter 
Which the Status of Disease use date of death if patient expired 
was Evaluated if Patient was  
alive (D/M/Y) 
    
Alive    patient is alive at the time of data extraction 
 
Deceased         patient is deceased at the time of data extraction      
 
Date of Death (D/M/Y) date of death 
    If exact date is not known use 01/01/9999 
 
Cause of Death  The reason the person died 
    Use the death information in the registry 
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APPENDIX I:  
TABLE I1 CONVERSION OF  KARNOFSKY PERFORMANCE STATUS SCALE  INTO ECOG 
PERFORMANCE STATUS  
 
 
WHO/ECOG Performance Status 
 
 
Karnofsky Performance Status  
 
0 
 
Able to carry out all normal activity 
without restriction  
 
100 Normal no complaints; no evidence of 
disease.  
 
90 Able to carry on normal activity; 
minor signs or symptoms of disease. 
  
1 Restricted in physically strenuous 
activity but ambulatory and able to 
carry out light work  
 
80 Normal activity with effort; some 
signs or symptoms of disease.  
 
70 Cares for self; unable to carry on 
normal activity or to do active work.  
 
2 Ambulatory and capable of all self-
care but unable to carry out any 
work activities. Up and about more 
than 50% of waking hours  
 
60 Requires occasional assistance, but is 
able to care for most of his personal 
needs. 
 
50 Requires considerable assistance and 
frequent medical care.  
 
3 Capable of only limited self-care, 
confined to bed or chair more than 
50% of waking hours  
 
40 Disabled; requires special care and 
assistance. 
  
30 Severely disabled; hospital admission 
is indicated although death not 
imminent.  
 
4 Completely disabled. Cannot carry 
on any self-care. Totally confined 
to bed or chair  
 
20 Very sick; hospital admission 
necessary; active supportive treatment 
necessary.  
 
10 Moribund; fatal processes progressing 
rapidly.  
 
5 Dead 0 Dead 
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APPENDIX J SAMPLE SIZE CALCULATION 
 
Power=90 
Alpha error 0.05 with two tailed  
Ratio 1:2 (q0:q1) 
Hazard reduction=0.80 (20% reduction in mortality) 
Baseline event rate =0.077 
Baseline censor=0.05 
Median survival of control=9 months 
Follow up period=60 months 
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APPENDIX K: RELATIONSHIP BETWEEN AREA LEVEL VARIABLES AND SURVIVAL 
 
Results  
 
The postal code information was obtained for 569 patients who were diagnosed with 
synchronous stage IV CRC. By using the Postal Code Conversion File (PCCF), the postal code 
information was linked to the Census subdivision. The following area level variables were 
examined with respect to their correlation with overall survival. Average household income, 
average family income, age dependency ratio, unemployment rate, labor force participation, 
proportion of aboriginal population, high school certificate rates, single parent, foreign born, 
minority and socio-economic Factor Index 2 (SAFEI2).The mean and median values were 
obtained (Table A11.1).  
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Table K1: Mean and median values of area level variables.   
 
Variables Mean 
SD ± 
Median 
(IQR) 
Average Family Income 70968 ± 11968 CAD 70056 (64096-79852) 
Average House Income 57804 ±10443 CAD 56795 (52207-64254) 
Unemployment Rates 0.058 ±5.37 0.05 (4-6) 
Labor Force Participation   0.81 ±0.13 0.82 (0.80-0.85) 
Aboriginal  Proportion 0.11 ±0.14 0.09 (0.03-0.10) 
Age Dependency Ratio 0.57 ±0.15 0.57 (0.45-0.67) 
Minority Proportion 0.037 ±0.036 0.027 (0.004-0.07) 
No High School Graduation 0.40 ±0.36 0.37 (0.26-0.50) 
Single Parent Household 0.17 ±0.06 0.18 (0.13-0.19) 
Foreign Born 0.05 ±0.03 0.05 (0.03-0.08) 
IQR: inter quartile range 
Using a cut-off of median values, all variables were categorized into two categories. 
Furthermore, using quartile values each variable was categorized into 4 groups (Table A11.2). 
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Table K2: Different quartiles of area-level variables.   
 
Area Level 
Variables 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Household income  52207 CAD 
 
52208-56759 
CAD 
56760-64254 
CAD 
 
64255 and above 
CAD 
Family income   64096 CAD 
 
64097-70056 
CAD 
 
70057-79852 
CAD 
 
79853 and above 
CAD 
 
Age Dependency 
ratio  
 
0.45 
 
0.46-0.57 
 
0.58-0.67 
 
0.68 and above 
 
Unemployment 
rateϮ 
 
4.0 
 
4.1-5.0 
 
5.1-6.0 
 
6.1 and above 
 
Aboriginals 
 
0.031 
 
0.032-0.093 
 
0.094-0.099 
 
0.10 and above 
 
Single Parent* 
 
0.1321 
 
0.1322-0.1800 
 
0.1801-0.1926 
 
0.1927 and 
above 
 
High schools 
certificate§ 
 
0.257 
 
0.258-0.367 
 
0.368-0.500 
 
0.501 and above 
 
SAFEI2ψ -0.2401100 
 
-0.2401099 to -
0.0586400 
 
-0.0586399 to 
0.2218800 
 
0.2218801 and 
above 
 
*Proportion of single-parent families. ϮUnemployment rate for labor force population aged 15 
years and older. §Proportion of population 15 years and older without high school 
graduation.ψSocio-economic Factor Index 2 
 
Kaplan-Meier Survival analysis was performed to compare survival of each category and quartile. 
The log-rank tests were performed and survival curves of different categories and quartiles were 
compared. No significant differences were noted in the survival of individuals from low income, 
high unemployment rate, and lower high school certification areas versus individuals from high 
income, low unemployment rate, and higher high school certification areas, respectively (Table 
A11.3). Furthermore, no significant differences were noted in the survival of individuals from 
different SAFEI2 quartiles (Figure A11.1). 
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Table K3: Survival of individuals from various geographical regions based on several 
socio-economic variables.  
 
Variable Number  
569 
Mean 
95% CI 
Median 
95% CI 
P 
values 
SAFEI2    0.29 
   -0.2401100 or below 145 15.5 (12.6-
18.4) 
11 (6.1-15.9)  
   -0.2401099 to -0.0586400 145 19.0 (15.1-
22.8) 
9 (4.9-13.1)  
   -0.0586399 to 0.2218800 158 19.7 (16.5-
22.9) 
12 (7.4-16.6)  
   0.2218801 and above 119 19.6 (15.3-
23.8) 
11 (7.4-14.6)  
Unemployment Rate     0.80 
<0.05 296 18.1 (15.6-
20.6) 
9 (6.2-11.8)  
≥0.05 273 19.1 (16.5-
21.7) 
12 (8.8-15.20  
Single Parent     0.65 
<0.18 312 18.2 (15.7-
20.8) 
11 (8.4-13.6)  
≥0.18 257 18.7 (16-21.3) 11 (7.4-14.6)  
 Labor Force Participation     0.93 
   ≥0.81 265 18.2 (15.6-
20.1) 
11 (8.3-13.7)  
   <0.81 304 19.1 (16.5-
21.7) 
11 (7.9-14.1)  
No High School Graduation    0.37 
<0.37 276 17.9 (15.3-
20.4) 
 10 (7.3-12.7)  
≥0.37 293 19.0 (16.5-
21.5) 
12 (8.8-15.2)  
Foreign Born    0.52 
   ≥0.05 247 18.8 (16.1-
21.6) 
11 (7.6-14.4)  
   <0.05 322 18.2 (15.8-
20.7) 
11 (8.2-13.8)  
Aboriginal    0.58 
   ≥0.09 298 19.4 (16.6-
22.2) 
10 (6.8-13.2)  
   <0.09 271 17.5 (15.2-
19.9) 
11 (8.0-14.0)  
Average Household income    0.24 
208 
 
   <56795 CAD 285 17.5 (15.1-
20.0) 
11 (7.7-14.3)  
   ≥56795 CAD 284 19.2 (16.6-
21.8) 
11 (8.0-14.0)  
Minority     0.16 
   <0.037 277 19.4 (16.8-
22.0) 
11 (8.1-13.9)  
   ≥0.037 292 17.4 (15.0-
19.8) 
11 (7.7-14.3)  
Age Dependency Ratio    0.91 
    ≥0.57 283 18.1 (15.7-
20.4) 
11 (8.0-14.0)  
   <0.57 286 19.0 (16.2-
21.8) 
11 (8.0-14.0)  
Family income low    0.80 
   <70056 285 18.9 (16.2-
21.6) 
12 (8.8-15.2)  
   ≥70056 284 18.4 (15.9-
20.9) 
10 (7.4-12.6)  
 
Cox models with shared frailty were fitted. The individual clinicopathological variables that 
demonstrated correlation with survival in a multivariate Cox Proportional Hazard model were used 
in the model: chemotherapy, surgical resection of primary tumor,  metastasectomy, second-line 
therapy, third-line therapy, elevated alkaline phosphatase, grade 3 tumor, leukocytosis, stage IVb 
disease, and ECOG performance status of >1. For income, unemployment rates, proportion of 
foreign born and SAFEI2, the STATA software could not calculate numerical derivatives. For the 
other variables, relationships were not significant (Table A11.4).  
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Table K4: Result of Cox models with shared frailty for various area level variables.  
 
Variables Theta P 
Average Family Income  could not calculate numerical derivatives  
Average Household Income could not calculate numerical derivatives  
SAFEI2 could not calculate numerical derivatives  
Unemployment Rate could not calculate numerical derivatives  
Aboriginal population 3.51e-18   4.74e-14 0.5 
Labor Force Participation 2.41e-18   5.57e-14 0.5 
Age Dependency ratio 4.47e-29   2.54e-24 0.5 
Foreign Born could not calculate numerical derivatives  
Minority  3.51e-18   6.18e-14 0.5 
Single Parent 3.51e-18   6.18e-14 0.5 
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Figure K1: Survival of patients with different SAFEI2 scores.  
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APPENDIX N – NEWCASTLE SCORE FOR OBSERVATIONAL STUDIES ANALYZED IN 
META-ANALYSIS 
 
 
Aslam et al  
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 0 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 5 
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Benoist et al  
 
Items Selection 
 
Score 
1       Is the case definition adequate?  
            Yes, eg record linkage or based on self  0 
2       Representativeness of the cases  
            Consecutive or obviously representative series of cases 1 
3     Selection of Controls  
            Hospital controls  0 
4      Definition of Controls  
     No history of disease (endpoint) 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 1 
 Exposure 
 
 
7      Ascertainment of exposure   
           Secure record 1 
8   Same method of ascertainment for cases & controls  
           Yes  1 
9   Non-Response rate   
         rate different and no designation  0 
 Total Score  ………/9 6 
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Chan et al 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Somewhat representative of the patients with advanced colorectal cancer 
in the  
          community  
1 
2       Selection of the non-exposed cohort  
            Drawn from the same community as the exposed cohort  1 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 0 
6      Study controls for systemic therapy 0 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           No (<5 years of study duration) 0 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 5 
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Evan et al 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 0 
6      Study controls for systemic therapy 0 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 4 
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Galizia et al 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known could be from a different source (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 1 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 6 
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Karoui et al 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group  0 
2       Selection of the non-exposed cohort  
            Source not known may be from a different source (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 0 
6      Study controls for systemic therapy 1 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 5 
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Konylian et al  
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known may be from a different source (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 0 
6      Study controls for systemic therapy 1 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 5 
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Michel et al  
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known, may be from a different source (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 0 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           No (<5 years of study duration) 0 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 4 
 
 
 
 
 
 
 
 
 
 
 
  
228 
 
Ruo et al 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 0 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           No (<5 years of study duration) 0 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 4 
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Scoggins et al 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 0 
6      Study controls for systemic therapy 0 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 4 
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Seo et al 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known, may be from a different source (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 1 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 6 
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Tebutt et al  
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Selected group (Single institutional) 0 
2       Selection of the non-exposed cohort  
            Source not known (non-community) 0 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 0 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 5 
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Temple et al 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
            Somewhat representative of the patients with advanced colorectal cancer 
in the  
          community  
1 
2       Selection of the non-exposed cohort  
           Drawn from the same community as the exposed cohort 1 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 0 
6      Study controls for systemic therapy 0 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 6 
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Venderbosch et al (CAIRO)  
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
           Somewhat representative of the patients with advanced colorectal cancer 
in the    
         Community (a subgroup of randomized patients across Netherland) 
1 
2       Selection of the non-exposed cohort  
            Drawn from the same community as the exposed cohort (a subgroup of   
           Randomized patients across Netherland) 
1 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 0 
6      Study controls for systemic therapy 1 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 0 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 6 
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Venderbosch et al (CAIRO II)  
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
           Somewhat representative of the patients with advanced colorectal cancer 
in the    
         Community (a subgroup of randomized patients across Netherland) 
1 
2       Selection of the non-exposed cohort  
            Drawn from the same community as the exposed cohort (a subgroup of   
           Randomized patients across Netherland) 
1 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 0 
6      Study controls for systemic therapy 1 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 0 
9   Adequacy of follow up of cohorts  
         No statement 0 
 Total Score  ………/9 6 
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APPENDIX O – NEWCASTLE SCORE FOR THE AUTHOR’S COHORT STUDIES  
 
Ahmed et al (1992-2005 Cohort) 
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
           True representative of the patients with advanced colorectal cancer in the 
           community   
1 
2       Selection of the non-exposed cohort  
            Drawn from the same community as the exposed cohort  1 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 1 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
        Complete follow up - all subjects accounted for 1 
 Total Score  ………/9 9 
 
 
 
 
 
 
 
 
 
 
  
236 
 
Ahmed et al (2006-2010 Cohort)  
 
Items Selection 
 
Score 
1       Representativeness of the exposed cohort  
           True representative of the patients with advanced colorectal cancer in the 
           community   
1 
2       Selection of the non-exposed cohort  
            Drawn from the same community as the exposed cohort  1 
3     Ascertainment of exposure  
            Secure record 1 
4      Demonstration that outcome of interest was not present at start of  
     Yes 1 
 Comparability 
 
 
5    Study controls for symptoms 1 
6      Study controls for systemic therapy 1 
 Outcome 
 
 
7      Assessment of outcome  
           Record linkage 1 
8   Was follow -up long enough for outcomes to occur  
           Yes (>5 years of study duration) 1 
9   Adequacy of follow up of cohorts  
        Complete follow up - all subjects accounted for 1 
 Total Score  ………/9 9 
 
 
